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1.1 General 
 What are mycotoxins? 
Etymologically the word mycotoxin stems from the Greek word mykes (mould) and the Latin 
word toxicum (poison). Mycotoxins are secondary metabolites that can be produced by 
various types of fungi. Some fungi develop mainly on the crop before harvest whereas other 
fungi usually emerge during storage. Mycotoxins are no primary metabolites for the fungi 
(Bennett, 1983), but they seem to have useful properties for the fungi that produce them. For 
example, the production of aflatoxins is closely related to the presence of reactive oxygen 
species (Reverberi et al., 2008). It is believed that the production of aflatoxins helps to 
manage oxidative stress inside the fungi (Narasaiah et al., 2006). The mycotoxins patulin and 
penicillic acid inhibit the communication between cells of Pseudomonas aeruginosa, a 
potentially dangerous bacterium (Rasmussen et al., 2005). Some parasitic and endophytic 
fungi produce mycotoxins to protect their host against predators such as insects or plant-
eating animals (Vega, 2008). The phytotoxic effects of some mycotoxins, such as ochratoxin 
A (OTA), enables the fungi to invade a plant host by inhibition of plant immunity systems 
resulting in the induction of lesions (Peng et al., 2010) and interference with the hosts’ 
metabolism (Paciolla et al., 2004). In general it is deemed that mycotoxin-producing fungi 
thrive better than fungi which do not (Fox and Howlett, 2008). Currently there are over 400 
chemical entities classified as mycotoxins. The most important in the context of occurrence 
and toxicity, which are also the most relevant in the feed industry, include aflatoxins, 
ochratoxins, trichothecenes, fumonisins and zearalenone (Turner et al., 2009). Besides, 
modified forms produced by either fungi, plants or during processing also exist (Broekaert et 
al., 2015). 
Fungi of the Fusarium genus are considered to be field fungi whereas fungi of the genera 
Aspergillus and Penicillium usually develop during storage, although they may also develop 
in earlier stages of the feed production chain. The growth of fungi is promoted in the presence 
of certain environmental factors. The main factors are temperature, humidity, presence of 
nitrogen and oxygen. Secondary factors include insects (control) and damage to the crops 
(Nelson, 1993). 
1 MYCOTOXINS IN FEED 
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 Risk of mycotoxin contamination 
The risk associated with mycotoxin contamination of crops is determined on the basis of the 
toxicity of the mycotoxin and the exposure. Figure 1 presents the key drivers for the risk and 
how they are related to each other. Toxicity is traditionally approached as an acute 
phenomenon, in which a single exposure to a high dose causes a set of symptoms. An 
important parameter to assess toxicity is the dose at which half of a population is expected to 
die, the lethal dose 50 or LD50. Although LD50-values are known for most toxins in rodents, 
this approach is not suitable to assess the risk of mycotoxins for animal production. Apart 
from the acute toxic effects, ingesting mycotoxins in low doses for a longer period can lead to 
a reduced feed intake, reduced immunity and impaired gut health (Osselaere et al., 2013b; 
Antonissen et al., 2015). Hence, they cause mainly economic damage by reducing the 
zootechnical performance of food producing animals. They also increase the susceptibility to 
infections (Vandenbroucke et al., 2011; Antonissen et al., 2014). The exposure depends on the 
consumption of contaminated feed and the level of contamination. Important for the 
consumption driver is the product mix that is consumed. Both the amount and type of 
consumption (product mix), is subject to the laws of supply and demand for feed, which might 
 
Figure 1: Key drivers of the risk associated with mycotoxin contamination of crops. The 
green arrows connect factors that can reduce the risk of the applicable driver. Adapted 
from (Tirado et al., 2010). 
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be contaminated by mycotoxins. Information about the mycotoxin content can influence the 
demand for certain types of feed and thereby shift the product mix towards a less mycotoxin-
containing mix. On the other hand, legally enforced maximum limits or guidance levels for 
maximum mycotoxin contamination will prevent contaminated batches from entering the 
market. This can be achieved by reducing the supply of heavily contaminated crops and limit 
the concentration in batches that will be consumed by food producing animals. 
1.2 Toxicology of the most important mycotoxins 
 Aflatoxins 
Aflatoxins are produced by Aspergillus fungi, differentiation between the toxicologically most 
relevant types of aflatoxins is based on their fluorescence, namely those reflecting blue light 
are labelled B1 and B2, those reflecting green light are labelled G1 and G2. Aflatoxin B1 
(AFB1) is the most important of the family, it is classified as a class I carcinogen by the 
International Agency for Research on Cancer (IARC) (IARC, 2002) indicating the 
carcinogenic effects are proven for humans. Its structure is presented in Figure 2. AFB1 has a 
difuranocoumarin structure. Sterigmatocystine, also an Aspergillus mycotoxin, is an 
intermediate in the biosynthesis of AFB1. 
 
Figure 2: Skeletal formula of aflatoxin B1 (AFB1). 
The absorption is rapid and complete in most species (Yunus et al., 2011), the main metabolic 
pathway is the phase I bio-activation to the genotoxic AFB1-epoxide and primarily occurs in 
the liver which is the target organ for toxicity. Metabolism to other metabolites can take place, 
including aflatoxicol and aflatoxin M1 (AFM1). Excretion is slower than most other toxins, 
after 7 days about 71% could be recovered (Sawhney et al., 1972). At levels <0.3 mg/kg feed 
for pigs and 1 mg/kg for chickens, weight reduction is the most obvious symptom (Dersjant-
Li et al., 2003). Aflatoxin M1 is categorized as class 2B carcinogen (probably carcinogenic to 
humans) (IARC, 2015).  
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 Ochratoxins 
Ochratoxins are mainly produced by Aspergillus and Penicillum fungi. Ochratoxin A (OTA) 
is the most important mycotoxin in this group. In pigs, OTA (Figure 3) affects primarily the 
liver and kidneys. Ingestions of concentrations up to 1 mg/kg feed for prolonged periods of 
time may cause nephropathy (Krogh et al., 1974). In chickens, OTA also primarily affects the 
kidneys and results in weight loss (Golinski et al., 1983). Higher concentrations of OTA (> 2 
mg/kg) were able to decrease bone density, lower the absorption of carotenoids, cause 
glycogen accumulation in the breast muscle, and increase the number of intestinal ruptures 
(Huff et al., 1983). Synergistic interaction between OTA and other mycotoxins are believed to 
be the main cause of mycotoxin induced porcine/chick nephropathy (MPN/MCN) (Stoev and 
Denev, 2013). The IARC classifies OTA in category 2B (IARC, 2015). 
 
Figure 3: Skeletal formula of ochratoxin A (OTA). 
 Trichothecenes 
Trichothecenes are produced by Fusarium fungi and have a sesquiterpenoid structure (Figure 
4) with an epoxide ring which is responsible for their toxicity. Trichothecenes are powerful 
inhibitors of the protein synthesis through interaction with ribosomes. Therefore, tissues with 
a high regeneration rate are most sensitive. Four types (A, B, C and D) are distinguished by 
substitutions of the 12,13-epoxytrichothec-9-ene (EPT) core structure, which is composed of 
four rings (McCormick et al., 2011). Type A is in general the most toxic group, however type 
B trichothecenes are most common in Europe, therefore, these groups are considered the most 
important classes. Type A trichothecenes include T-2 toxin (T-2), its metabolite HT-2 and 
diacetoxyscirpenol; type B trichothecenes include nivalenol, deoxynivalenol (DON) and 
fusarenon-X. High doses of T-2 cause oral lesions and weight loss in broilers, in lower doses 
systemic effects lead to a reduced bodyweight (BW) gain (Wyatt et al., 1973). Pigs also show 
lesions of the mucosa which come into contact with T-2. It has a pronounced effect on the 
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immune system, thereby affected animals are more sensitive to secondary or opportunistic 
infections (Rafai et al., 1995a; Rafai et al., 1995b). DON is the most abundant trichothecene. 
It differs from nivalenol by the absence of a hydroxyl group at position 4 of the ring structure. 
Chickens are relatively resilient to the exposure to DON because of 1) a low oral 
bioavailability (Dänicke and Brezina, 2013; Osselaere et al., 2013a) and 2) the extensive 
phase II biotransformation capacity to non-toxic sulfate-conjugates (Devreese et al., 2015). 
Pigs on the other hand are very sensitive to DON, it elicits emesis at high concentration levels 
and DON is therefore sometimes named vomitoxin. Feed refusal is the most obvious 
symptom of DON, even at lower contamination levels. The IARC has classified DON and T-2 
toxin as a class 3 carcinogenic substance (not classifiable as to its carcinogenicity to humans) 
(IARC, 2015).  
 
Figure 4: Classification of trichothecene structures: EPT (12,13-epoxytrichothec-9-ene); 
R groups may be H, OH, OAcyl, or variations in the macrolide chain (McCormick et al., 
2011). 
 Fumonisins 
Fumonisins are mainly produced by Fusarium fungi, they have a central carbon chain, two 
tricarballylic acid groups are esterified to this central carbon chain and they also contain 
several hydroxyl groups. Fumonisin B1 (FB1, Figure 5) is the most frequently occurring 
mycotoxin, it differs from B2 and B3 in the position of the hydroxyl groups. Fumonisins 
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interfere with the cell membrane synthesis by inhibiting the ceramide synthase. This enzyme 
plays an important role in the formation of sphingolipids, important components of the cell 
membrane. Because of the inhibition of the ceramide synthase, accumulation of sphinganine 
(Sa) and sphingosine (So) is observed, also the Sa:So ratio will increase and is considered an 
appropriate biomarker of exposure to fumonisins (Riley et al., 1994). Chickens are relatively 
resistant to the effects of fumonisins, yet caution is advised. Elevated liver markers (aspartate 
amino transferase, alkaline phosphatase and lactate dehydrogenase) have been described. Also 
the weight of the liver, gizzard and proventriculus was increased. Finally, the total weight of 
the day-old chicks decreased after administration of 100 mg FB1/kg feed (Ledoux et al., 
1992). Pigs are more susceptible and effects on the respiratory system, liver and 
cardiovascular system are most pronounced. Contaminations of 12 mg/kg feed may cause 
fatal pulmonary oedema (porcine pulmonary oedema, PPE) due to myocard insufficiency 
(Haschek et al., 2001). The IARC categories FB1 as a class 2B toxin (IARC, 2015). 
 
 
Figure 5: Skeletal formula of fumonisin B1 (FB1). 
 Zearalenone 
Zearalenone (ZEN, Figure 6) is also produced by Fusarium fungi. It is a small lipophilic 
molecule which is extensively metabolised (phase I biotransformation) in liver to α- or β-
zearalenol. Both are agonists for the estradiol receptor, ZEN is therefore called a myco-
estrogen. However, α-zearalenol has a 92-times higher affinity for the estradiol receptor 
whereas the affinity of β-zearalenol is 2.5-times lower compared to ZEN (Malekinejad et al., 
2006). Biotransformation to α-zearalenol can thus be considered as activation of ZEN, 
biotransformation to β-zearalenol as deactivation. In chickens, the effects of ZEN are limited 
because of the extensive biotransformation to β-zearalenol. Broiler chickens can tolerate feed 
contamination levels up to 800 mg/kg feed (Allen et al., 1981). Pigs however, are the most 
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sensitive species because they mainly form α-zearalenol, the reproductive organs being the 
primarily affected tissues, especially in females. The main symptoms are related to 
hyperestrogenism and include turgid sex organs (uterotropism), prolapse of the vulva, 
stillbirth, nymphomania, etc. (Kuiper-Goodman et al., 1987). The IARC categorizes ZEN as a 
class 3 toxin (IARC, 2015).  
 
Figure 6: Skeletal formula of zearalenone (ZEN). 
1.3 Prevalence 
Both humans and animals are exposed to mycotoxins through contamination of food and feed 
(Jard et al., 2011). In 2013, a large scale survey was reported in which more than sixty 
thousand feed samples were analysed for the presence of aflatoxins, ZEN, DON, fumonisins 
and ochratoxins (Schatzmayr and Streit, 2013; Streit et al., 2013). Figure 7 and Table 1 show 
the percentage of samples that were positive for each of these mycotoxins. 
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Figure 7: Global mycotoxin prevalence in surveyed regions. Finished feed and maize 
accounted for 27% of the samples each. The pool of samples further comprised wheat 
and wheat bran (9%), barley (8%), silage (8%), soybean meal (4%), distillers dried 
grain with solubles (DDGS; 2%), corn gluten meal (1%), rice and rice bran (1%), straw 
(1%) and other feed ingredients (e.g. cotton seed, sorghum, cassava, peanut, copra, etc.; 
12%). Number of samples analysed for aflatoxins (AF), zearalenone (ZEA), 
deoxynivalenol (DON), fumonisins (FB), ochratoxin A (OTA), respectively: North 
America: 812; 832; 844; 820; 265; South America: 1,521; 784; 768; 1,544; 360; Northern 
Europe (ZEA; DON): 596; 789; others not analysed (NA); Central Europe: 241; 3,632; 
5,521; 206; 235; Southern Europe: 299; 381; 463; 233; 242; Eastern Europe: 59; 106; 
111; 70; 86; Africa: 302; 227; 286; 271; 47; 70; 86; Middle East: 167; 172; 170; 156; 69; 
South Asia: 495; 489; 478; 486; 433; South-East Asia: 2,383; 2,350; 2,237; 2,357; 1,623; 
Oceania: 859; 873; 873; 842; 681; North Asia: 4,723; 4,799; 4,855; 4,365; 3,352. Adopted 
from (Schatzmayr and Streit, 2013). 
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Table 1: Global mycotoxin prevalence in surveyed regions. Finished feed and maize 
accounted for 27% of the samples each. The pool of samples further comprised wheat 
and wheat bran (9%), barley (8%), silage (8%), soybean meal (4%), distillers dried 
grain with solubles (DDGS; 2%), corn gluten meal (1%), rice and rice bran (1%), straw 
(1%) and other feed ingredients (e.g. cotton seed, sorghum, cassava, peanut, copra, etc.; 
12%). For the number of samples analysed per region, see Figure 7 caption. Adopted 
from (Schatzmayr and Streit, 2013). 
 Aflatoxins
1
 Zearalenone Deoxynivalenol Fumonisins
1
 Ochratoxins 
Number of samples 11,967 15,533 17,732 11,439 7,495 
Number of  
positive samples 
3,142 5,797 9,960 6,204 1,902 
% positive samples 26 37 56 54 25 
Average of the 
positive samples 
(μg/kg) 
57 286 1,009 1,647 14 
Median of the 
positive samples 
(μg/kg) 
11 85 453 750 2.6 
1
th
 quartile of the 
positive samples 
(μg/kg) 
3 43 234 332 1.1 
3
rd
 quartile of the 
positive samples 
(μg/kg) 
40 225 972 1,780 6.2 
Maximum of 
positive samples 
(μg/kg) 
6,323 26,728 50,289 77,502 1,589 
Origin sample with 
highest measured 
concentration 
Myanmar Australia Central Europe China China 
Sample type (year) 
with highest 
measured 
concentration 
Other feed 
(2012) 
Silage feed 
(2007) 
Wheat 
(2007) 
Compound 
feed (2011) 
Compound 
feed (2011) 
Results of the analysis of 19,757 samples of feed and feed raw materials sourced globally, specifying the 
number of samples analysed for each of the mycotoxins/mycotoxin groups, the number and percentage of 
samples testing positive for the respective mycotoxin as well as the average, median, maximum, first quartile 
and third quartile of the concentrations detected in positive samples (in µg/kg); regarding maximum values, the 
type and origin of the sample and the year of analysis are given. 
1
Aflatoxins: sum of aflatoxin B1, B2, G1 and G2; Fumonisins: sum of fumonisin B1, B2 and B3. 
The levels are considered relatively low by the authors, the average values are shown in the 
Table 1 accompanying Figure 7. Only 17% of the samples did not meet the European 
legislation for AFB1. It should be noted that levels lower than the permissible values already 
can cause damage, especially if the contaminated feed is fed to the animals for longer periods. 
The simultaneous presence of different mycotoxins can have an additive or synergistic effect 
which can cause significant damage even at low concentrations (Grenier and Oswald, 2011). 
This was the case in 39% of the samples and in 59% of the finished feed samples. 
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1.4 Legislation 
Mandatory limits for maximum mycotoxin content in feed in Europe are limited to levels for 
AFB1. There are however also guidelines for DON, ZEN, OTA and fumonisins. For T2 and 
HT2, action levels are provided. Action levels are concentrations, which, once surpassed, 
require further investigation. Investigation is required regarding the sources of the samples 
and source of contamination. Guidelines and recommendations for complete compound feed 
for pigs and poultry are summarized in Table 2. 
Table 2: Maximum levels, guidance values and indicative levels for mycotoxins in 
complete feed (mg/kg). Values for young animals, if applicable, are presented between 
brackets. 
Mycotoxin Chicken Pig Legislative text 
AFB1 0.02 (0.01) 0.02 (0.01) Directive 2002/32/EC 
DON 5 0.9 Recommendation 2006/576/EC 
ZEN 2 0.25
 
(0.1) Recommendation 2006/576/EC 
OTA 0.1 0.05 Recommendation 2006/576/EC 
T2+HT2 0.25
1
 0.25
1
 Recommendation 2013/165/EC 
FB1+FB2 20 5 Recommendation 2006/576/EC 
AFB1: aflatoxin B1; DON: deoxynivalenol; ZEN: zearalenone; OTA: ochratoxin A; T2: T2-
toxin; HT2: HT2-toxin; FB1: fumonisin B1; FB2: fumonisin B2; 
1
action level: above these 
concentrations further investigation is needed for the sources of the contamination 
In Belgium, the enforcement of these laws is the responsibility of the Federal Agency for the 
Safety of the Food Chain (FASCF). The controls ought to be compliant with regulation 
882/2004/EC (European Commission, 2004). This document states that the authorities, for 
Belgium represented by the FASFC, are obliged to control the feed and feedstuffs. Control 
should be done at regular time points, at all stages of the production and distribution, 
including export and import. The frequency should be appropriate to the risk associated with 
the type of feed, animal species, production process, past record of the compliance, reliability 
of the procedures, etc. In addition, ad hoc controls should be carried out if any information 
might indicate non-compliance. 
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1.5 Risk management 
There are several methods for the prevention of mycotoxins in feed which can be applied 
before and/or after harvest (respectively pre- and/or post-harvest). Although difficult and not 
always sufficient, the best pre-harvest procedure is to minimize the production of mycotoxins 
in the field by applying Good Agricultural Practices (GAP) which comprise cultivar/variety 
choice, crop rotation, crop residue management, fungicide usage, minimizing insect and 
mechanical damage and optimal irrigation (Kabak et al., 2006; Jouany, 2007). These 
measures reduce the development of fungi on the crops.  
To reduce susceptibility of the crop to storage fungi, the method of harvesting can have an 
important impact. As an example, damage to the crops may lead to kernels for fungal 
development. 
After harvesting, crops can also become contaminated with mycotoxins. Either through new 
mycotoxin-producing fungi and/or the fungi already present on crops can continue to produce 
mycotoxins. Finally, fungi already present on the corps may start producing mycotoxins 
triggered by a change in conditions. GAP-guidelines for minimizing mycotoxin contamination 
post harvest include appropriate storage and transport conditions and measures (temperature, 
humidity and pest control) to prevent damage to crops. Furthermore, there are several 
chemical and physical methods available to tackle the mycotoxin problem. The chemical 
methods are based on the principle of transformation of the mycotoxin into less toxic 
products. The efficacy of various chemicals, including acids, bases, oxidizing and reducing 
agents has been described (Kabak et al., 2006; Jard et al., 2011). Only a few are indeed 
effective against mycotoxins, such as ammonia, hydrogen peroxide and hydrochloric acid. 
However, these methods are often time consuming and expensive, they also have a negative 
impact on the nutritional value and organoleptic quality (Kabak et al., 2006), and are therefore 
not allowed in Europe. Examples of physical methods are washing, grinding and heat 
treatment. These are also time-consuming, expensive and their efficiency depends on the 
degree and type of contamination (Kolosova and Stroka, 2011).  
These pre- and post-harvest strategies can prevent many problems, however, they cannot 
always deliver the hoped-for outcome, alternatives are being applied. Nowadays, the mixing 
of mycotoxin detoxifiers in the feed is a frequently used practice (Jard et al., 2011).  
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2.1 Concept and legislation 
Mycotoxin detoxifiers are additives mainly added to compound animal feed. They aim to 
reduce the effects of mycotoxins on the animal, or to prevent damage by lowering the activity 
of mycotoxins in the gastro-intestinal tract (GIT) (Jard et al., 2011; Devreese et al., 2013a). 
The legislation regarding mycotoxin detoxifiers originates from the European Commission, 
and is the jurisdiction of the Directorate General of Agriculture and Rural Development and 
the Directorate General of Health and Food Safety. Policies of both Agriculture and Rural 
Development, and Health and Food Safety, are completely regulated on an European level. 
Mycotoxin detoxifiers belong to the category of technological feed additives and are defined 
by Regulation 386/2009/EC as: ‘substances for reduction of the contamination of feed by 
mycotoxins: substances that can suppress or reduce the absorption, promote the excretion of 
mycotoxins or modify their mode of action’ (European Commission, 2009a). This class of 
feed additives can be divided into two groups: mycotoxin binders and modifiers. The 
mycotoxin binders are non-resorbable materials which aim to adsorb mycotoxins in the GIT. 
Ideally, the non-resorbable complex is then excreted along with the faeces. Mycotoxin binders 
are usually clays, or derivatives of yeast and are discussed in detail in section 2.3. Mycotoxin 
modifiers are enzymes or micro-organisms which are able to transform, or to degrade the 
mycotoxins into less toxic derivatives (Kolosova and Stroka, 2011). To date there are 
mycotoxin modifiers registered for FB1 in pigs (EFSA FEEDAP Panel, 2014) and for DON in 
ruminants, poultry and pigs (EFSA FEEDAP Panel, 2013b; European Commission, 2013a).  
Yeast derived mycotoxin binders are usually registered as feed material. The only registered 
mycotoxin binder is bentonite, a clay of the smectite-type for protection against the effects of 
AFB1 in pigs, poultry and ruminants, this was registered by implementing Regulation 
1060/2013 (European Commission, 2013a). Nevertheless there are many more substances on 
the market that make the claim of mycotoxin binder. They are registered as a different type of 
technological feed additives, namely as an anti-caking agent, or to improve the hardness of 
the pellets in pelleted feed. These products include clays such as zeolite, clinoptilolite, kaolin, 
vermiculite, etc. The feed additives are described in the Regulation 1831/2003/EC (European 
Commission, 2003). In Annex I of this Regulation, a list can be found on the authorized 
additive groups for use in animal nutrition (European Commission, 2015). A summary of the 
legislation is presented below. 
2 MYCOTOXIN DETOXIFIERS 
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 Definitions 
Feed additives are not feed materials, processing aids or veterinary drugs. Feed materials are 
defined as products of vegetable or animal origin with the main purpose to meet the animals 
nutritional requirements and are regulated by EU Regulation 767/2009 (European 
Commission, 2009b). Processing aids are substances not consumed as a feedstuff by itself but 
intentionally used in the production or processing of feed materials in order to fulfil a 
technological purpose. This may result in the unintentional presence of residues of the 
substance in the final product, but provision is made that these residues do not have an 
adverse effect on animal health, human health or the environment and do not have any 
technological effects on the finished feed. An example of a processing aid are extraction 
solvents.  
If single or compounded substances are presented as possessing curative or prophylactic 
properties with respect to a certain disease or condition, e.g. mycotoxicosis; or the substance 
which can be administered to animals to restore, improve or alter physiological functions by 
exerting a pharmacological, immunological or metabolic effect or to make a diagnosis, they 
are considered as a veterinary drug and are subject to the legislation of veterinary drugs, i.e. 
Directive 2001/82/EC (European Commission, 2001).  
Feed additives are substances which are intentionally added to the feed to: 
 improve one or more characteristics of the feed 
 improve the animal production, performance or welfare and the characteristics of 
animal products 
 favourably affect the colours of ornamental fish and birds 
 satisfy the nutritional requirements of the animals 
 favourably affect the environmental impact of animal production 
 have a coccidiostatic or histomonostatic action 
 Classification of feed additives 
Feed additives can be classified into five different categories according to their function: 
technological-, sensory-, nutritional-, zootechnical additives and hygienic condition 
enhancers. 
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The category 'technological additives', which contains most mycotoxin binders, comprises the 
following functional groups. The categories marked with an * are those for which bentonite 
can be registered. 
a) preservatives: substances or micro-organisms which protect feed against deterioration 
caused by micro-organisms or their metabolites 
b) antioxidants: substances prolonging the storage life of feedingstuffs and feed materials 
by protecting them against deterioration caused by oxidation 
c) emulsifiers: substances that make it possible to form or maintain a homogeneous 
mixture of two or more immiscible phases in feedingstuffs 
d) stabilisers: substances which make it possible to maintain the physico-chemical state 
of feedingstuffs 
e) thickeners*: substances which increase the viscosity of feedingstuffs 
f) gelling agents: substances which give a feedingstuff texture through the formation of a 
gel 
g) binders*: substances which increase the tendency of particles of feedingstuffs to 
adhere 
h) substances for control of radionucleide contamination*: substances that suppress 
absorption of radionucleides or promote their excretion 
i) anticaking agents*: substances that reduce the tendency of individual particles of a 
feedingstuff to adhere 
j) acidity regulators: substances which adjust the pH of feedingstuffs 
k) silage additives: substances, including enzymes or micro-organisms, intended to be 
incorporated into feed to improve the production of silage  
l) denaturants: substances which, when used for the manufacture of processed 
feedingstuffs, allow the identification of the origin of specific food or feed materials 
m) substances to reduce the contamination of feed by mycotoxins*: substances that can 
suppress or reduce the absorption, promote the excretion of mycotoxins, or modify 
their mode of action 
*application for bentonite 
Bentonite is registered as a mycotoxin binder for AFB1 for ruminants, poultry and pigs since 
2013 (European Commission, 2013a). However, there are a number of conditions attached to 
the use of bentonite as a mycotoxin binder. A minimum content of smectites (determined by 
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X-ray diffraction (XRD)-analysis) of 70% is required. Furthermore, the levels of feldspar and 
opal should not exceed 10%, and the levels of calcite and quartz cannot exceed 4%. Finally, 
the candidate mycotoxin binder has to be able to bind AFB1 in a well described in vitro setup, 
discussed in section 2.3. The registration is not brand-specific, any substance which fulfils the 
above conditions and the general safety rules for feed additives can make the claim of 
mycotoxin binder for AFB1. Confusion may arise because the same bentonite is also used as a 
thickener (category e), binding agent (g), for control of radionucleide contamination (h), or 
anticaking agent (i). The requirements for this application are less strict than those for 
mycotoxin binders. A content of smectite minerals of ≥50% is required and there are no 
specifications for other minerals. 
The total content of bentonite, regardless of the application for which it is used, can be up to 
20 g/kg of complete feed (2%) (European Commission, 2013a). Most manufacturers of 
mycotoxin binders, however, recommend a lower content, typically between 0.1 and 0.25% 
(m:m) and in some cases 0.5%. Since these clays can be used for different applications, the 
final content can be higher than the amount intended as mycotoxin binder. For example, a 
bentonite can be used in the mixing of different raw materials in order to improve the flowing 
properties, next a different bentonite can be used as a mycotoxin binder, and finally, a third 
bentonite can be used as the pelletizing agent to improve the hardness of the pellets. As the 
various stages can be executed by different parties, the probability that the total content of the 
bentonite approximates to 2% exists, although should not exceed 2%. 
In order to assess the mycotoxin binder producers, an important distinction needs to be made 
for the mycotoxin detoxifier market according to the type of detoxifier, namely mycotoxin 
modifiers and -binders. For mycotoxin modifiers, the value chain up to the wholesale level, 
consists currently of only a few products sold by one company. For the mycotoxin binders, 
the producers of the raw materials include operators of clay mines, especially bentonite mines, 
and producers of yeast (by-products). About 15 producers are members of the association of 
European bentonite producers (Industrial Mineral Association, 2014). On a global level, more 
than 54 countries produce over 20 million ton of bentonite each year (British Geological 
Survey, 2013). Through wholesalers or brokers, the raw materials are provided to the 
manufacturers of feed additives. In Europe, there are about 100 registered members in the 
European Association of Specialty Feed Ingredients and their Mixtures (FEFANA) 
(FEFANA, 2015). The finished additives are sold to compound feed producers, premixers or 
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companies which market the additive as different products, whether or not supplemented with 
other ingredients. 
2.2 Chemical structure of mycotoxin binders 
In order to understand the mechanism of action of the mycotoxin binders, a good 
understanding of the structure of these compounds is necessary. Therefore, an overview will 
be presented here of the molecular structure of clays and mycotoxin binders derived from 
yeasts. 
 Clays 
Clays are finely grinded minerals (≤ 2 µm), which consist mainly of silicate minerals, and 
optionally other materials, so-called associated phases (Guggenheim et al., 2006). The only 
registered clay for mycotoxin binding so far is bentonite which is defined as predominantly (≥ 
70%) composed of montmorillonite (EFSA FEEDAP Panel, 2015). The silicates can be 
subdivided into tectosilicates and phyllosilicates. Zeolites belong to the tectosilicates family 
whereas phyllosilicates include, among other clays, sepiolites, smectites and kaolinites. The 
smectites includes montmorillonite, which can be found in bentonite. Bentonite is defined in 
the applicable legislation as containing at least 70% montmorillonite. An overview of the 
minerals used in the additives can be found in Figure 8. 
The silicates all have in common that their base unit is a tetrahedron composed of a central 
silicon atom (Si
4+
) surrounded by four oxygen atoms, usually in the fully oxydized form O
2-
. 
The residual charge of such a tetrahedron is negative and may be neutralized in various ways. 
In tectosilicates the charge is neutralized by sharing the oxygen atoms of the different 
tetrahedrons, in this way the ratio of oxygen atoms and silicon atoms is reduced, as well as the 
residual charge. The sharing of oxygen atoms results in a porous structure of tetrahedrons 
which are connected to each other at their corner points as shown in Figure 9. 
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Figure 8: Overview of the nomenclature of clays and other minerals used as a feed 
additive, adapted from (Bailey, 1980). 1:1 phyllosilicate sheets are composed of one 
octahedra layer aligned by one tetrahedra layer; 2:1 phyllosilicate sheets are composed 
of one octahedra layer aligned by a tetrahedra layer on each side.   
Silicates 
Phyllosilicates  
1:1 Phyllosilicates 
Serpentines: 
trioctahedral 
Kaolin: 
dioctahedral 
Kaolinite:  ballclay, 
fireclay, flintclay, 
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2:1 Phyllosilicates 
Talc:  
trioctahedral 
Smectites 
Montmorillonite: 
dioctahedral 
Stevensite: 
trioctahedral 
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Muscovit: 
dioctahedral 
Illite:  
dioctahedral 
Biotite: 
 trioctahedral 
2:1 Phyllosilicates 
with inverted 
ribbons 
Sepiolites 
Tectosilicates 
Feldspars 
Albite:  
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SiO2-group Quartz 
Zeolites 
Philipsite 
Clinoptilolite 
Carbonates 
Calcite: 
 CaCO3 
Dolomite: 
CaMg(CO3)2 
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Figure 9: Left and centre: Three-dimensional structure of a tectosilicate (Colville and 
Ribbe, 1968), (Van Ranst, 2013). The tetrahedra represent Si
4+
, surrounded by four O
2-
 
ions (corners of the tetrahedra). The residual negative charge is reduced by sharing O
2-
 
ions and thereby reducing the O
2-
/Si
4+
 ratio. Right: Sheet configuration of tetrahedra 
(Brigatti et al., 2006).  
 
The phyllosilicates (Figure 10) also share oxygen atoms in order to neutralize the residual 
charge, but do so by forming a sheet structure. Typically for the phyllosilicates is the 
formation of octahedra adjacent to the SiO4 tetrahedra. The SiO4 tetrahedra are arranged so 
that three O
2-
 ions of each tetrahedron are shared with three other tetrahedra. The remaining 
oxygen atoms at the top of the tetrahedral sheets are linked to the octahedra sheets.  
Octahedra occur when six oxygen atoms are arranged around a central atom. In octahedral 
sheets, the oxygen atom usually appears as the reduced hydroxide OH
-
, except where they are 
shared with apical oxygens of the tetrahedral sheets. Stereochemical, the OH
-
 form has very 
little consequences because the hydrogen occupies only a small volume compared to the 
oxygen atom. The central void is smaller as in the tetrahedra, therefore the ions that may 
occupy are not the same than in the tetrahedral configuration. In practice, the central void of 
octahedra is mostly occupied by Mg
2+
 of Al
3+
, whereas the configuration around the Si
4+
 is 
always tetrahedral. Substitution of the central octahedral atom might occur, these substitutions 
contribute to the diversity between similar clays. They also have an important impact on the 
residual charge on the phyllosilicate layers, which is also an important feature in 
differentiating different clays.  
The octahedra can be arranged in two different manners, namely dioctahedral and 
trioctahedral, see Figure 10. A trivalent central atom, such as Al
3+
 give rise to a trioctahedral 
configuration. Each oxygen is shared between three octahedra resulting in a ratio of oxygens 
and Al
3+
 of 3 to 1. In case the oxygens are in the reduced OH
- 
form, this configuration as such 
is stable. A divalent central atom, such as Mg
2+
, gives rise to a dioctahedral configuration. In 
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this configuration, each oxygen in the sheet is shared by two octahedra, resulting in a ratio of 
2 oxygens for each Mg
2+
 which is electrochemically stable in case all oxygen atoms are in the 
reduced form.  
 
 
Figure 10: Left: Trioctahedral configuration. Right: Dioctahedral configuration (Wittke 
and Bunch, 2014). 
 
Depending on whether on one side or on both sides the octahedral sheets are linked with 
tetrahedra planes, 1:1 and 2:1 phyllosilicates are formed, respectively. The apical oxygens of 
the tetrahedral sheet are shared with oxygens of the octahedral sheet. The oxygen atoms of the 
octahedral sheet that are not shared, i.e. fall in the cavities formed by the tetrahedral sheet, 
remain in the reduced form OH
-
. By forming a layered sheet structure, not all of the residual 
charges are neutralized. The oxygen atoms at the ends of the sheet structure can be neutralized 
by free hydrogen atoms and thus form pH-sensitive -OH groups. The non-neutralized charges 
inside the sheet structure are neutralized by the so-called exchangeable cations. These atoms 
have a positive charge, they are usually Na
+
, K
+
, Ca
2+
, Mg
2+
 or NH4
+
 and are located between 
the layers, but are not included in the crystal structure of the phyllosilicate. In an aqueous 
environment, these ions attract water because of their high osmotic value, and are responsible 
for the swelling of the clay. In a hydrated clay these ions can be exchanged. When exchanging 
these ions, other molecules may be placed between the sheets but only if they have the 
appropriate stereochemical properties. This has been described for AFB1 (Phillips et al., 
2006; Deng et al., 2010), and is shown graphically in Figure 11. Distinction between the clays 
is based on their molecular and supramolecular structure, dioctahedral or trioctahedral 
octahedron configuration of the sheet, residual charge between the different layers, specific 
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substitutions of the silicon, aluminum or magnesium atoms and type of exchangeable cations. 
Furthermore, different crystal structures may occur within the same crystal, these are called 
‘mixed-layer’ clays. 
 
  
Figure 11: Left: Model of aflatoxin B1 held between smectite layers. The water 
molecules are not shown in the intermediate layer (Deng et al., 2010). Right: Scanning 
Electron Microscopic image of a phyllosilicate clay (Al-ani and Sarapaa, 2008). 
 Yeasts 
Dead yeast cells (Saccharomyces cerevisiae) are readily available as a by-product of the 
bakery and brewery industry. The different parts, including specific proteins and certain 
fractions, up to complete yeast cells are used as a mycotoxin binder. The best known are 
glucomannans and mannan-oligosaccharides (MOS). The yeast cell wall is shown 
schematically in Figure 12. These products are usually registered as feed material. Cell walls 
– or cell wall fractions – offer many different, easily accessible, adsorption sites such as 
polysaccharides, proteins and lipids. Due to the different properties of these adsorption sites, 
adsorption may occur through multiple, sometimes simultaneous, mechanisms such as 
hydrogen bonding, ionic or hydrophobic interactions. These are relatively weak bonds 
compared to covalent or ionic bonds, however, when large in number, these interactions can 
play an important role. Hydrophobic interactions become more important with increasing pH 
(Picollo, 1999; Huwig et al., 2001).  
Of the yeast-derived products used as mycotoxin binders, the MOS products have been best 
studied. These products interact with intestinal flora by binding to the lectin receptor of 
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Salmonella and Escherichia bacteria, a second important effect of MOS is the increase in the 
Ig's A and B in the intestine (Newman, 1994). Further, an increased villus length was 
observed in pigs (Goossens et al., 2012). Other effects such as an altered pH of the ceca, 
altered intestinal microflora (other than Salmonella and Escherichia spp.) and moisture 
content or a modified BW sometimes contradict each other. 
 
 
Figure 12: Left: Schematic representation of a yeast cell wall (Selitrennikoff, 2001). 
Right: In silico simulation of the adsorption of zearalenone (green and red structure) by 
β-D-glucans (yellow structure) of the Saccharomyces cerevisiae cell wall (Yiannikouris et 
al., 2004).  
 Other mycotoxin binders 
In addition to the clay minerals and yeast-derivatives, a number of other substances are also 
used to adsorb mycotoxins. These mycotoxin binders, with the exception of Lactic Acid 
Bacteria (LAB), are not used in feed but only for research purposes. Some examples are: LAB 
(Lahtinen et al., 2004), molecularly imprinted polymers (MIPs) (Lenain et al., 2012), 
cholestyramine and polyvinylpyrrolidone (Kolosova and Stroka, 2011).  
2.3 Adsorption kinetics 
Adsorption processes are interactions between the surface of a non-dissolved solid (= 
adsorbent, e.g. mycotoxin binder), and a solute molecule (= adsorbate, e.g. veterinary drug). 
The forces that are responsible for the adsorption are non-covalent forces, and can be 
classified into hydrophobic interactions (e.g. Van der Waals), hydrogen bonds and 
electrostatic interactions. Multiple bond mechanisms can simultaneously play a role in the 
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adsorption reaction, the number of interactions and stereochemistry are important for bond 
strength. To form a bond between adsorbent and adsorbate, a bond has to be broken in 
between the adsorbent and solvent. Therefore, the matrix in which the adsorption takes place 
will play an important role. Because of the complexity of binding interactions, they are often 
pragmatically approached. For most applications, quantitative information is sufficient instead 
of elucidating the binding mechanism.  
Consider the equilibrium reaction between adsorbent [B] and adsorbate [D]: 
[𝐵] + [𝐷] ↔  [𝐵𝐷] 
Wherein [D] is the free drug concentration (mol/L), [B] is the concentration of unoccupied 
binding sites on the binder (mol/L) and [BD] is the concentration of occupied binding sites 
(mol/L). The latter is equal to the concentration of adsorbed drug. Following statements apply 
to the adsorption reaction: 
𝐾𝐵𝐷 =
[𝐵𝐷]
[𝐵][𝐷]
 
[𝐷0] = [𝐷] + [𝐵𝐷] 
[𝐵0] = [𝐵] + [𝐵𝐷] 
KBD with the equilibrium constant, B0 and D0 are the initial concentration of the drug and 
binding sites on the adsorbent, respectively. In binding experiments [D0] is a priori known. 
In single concentration adsorption experiments, a certain quantity of binder, and a known 
amount of adsorbate in a known volume of a known matrix are exposed to each other. The 
results are expressed as % adsorption or as the distribution coefficient Kd. The Kd value is 
calculated as follows:  
𝐾𝑑 =
𝐶𝑎𝑑𝑠
𝐶𝑎𝑞
=
1
𝐵𝐶50
 
With Cads the adsorbed concentration (amount of drug absorbed per unit weight of B), and Caq 
the free concentration of D in the medium. This parameter can be interpreted as the 
equilibrium constant in case that the ratio between D and B is very small, in other words, 
when there is an excess of binding sites available relative to the amount of D. If Cads is 
expressed in mg substance adsorbed per gram of adsorbent, Kd indicates how much drug can 
be adsorbed by 1 g of binder if in equilibrium with a 1 µg/mL solution. The BC50 is, in this 
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respect, a somewhat more intuitive parameter which indicates the concentration of binder 
required to bind half of the drug. It can be derived that BC50 is equal to the reciprocal of Kd. 
When a higher concentration of adsorbate is exposed to the binder, it is possible that the 
values obtained for Kd are lower than expected. This is because, at first, the most optimal 
binding sites are occupied followed by the more inferior binding sites. This can be visualized 
by plotting Cads against Caq, the slope of the adsorption isotherm curve decreases with 
increasing concentration of the drug (Figure 13). To correct for this deflection, a curve 
described by the Freundlich equation is fitted (Freundlich, 1906): 
𝐶𝑎𝑑𝑠 = 𝐾𝑓 ∗ √𝐶𝑎𝑞
𝑛
 
 
Figure 13: Adsorption isotherm which exhibits non-linear kinetics. In the ordinate, the 
adsorbed amount of the adsorbate Cads (µg/g adsorbent) is shown, and in the abscissa, 
the dissolved concentration of the adsorbate Caq (µg/mL). 
The Freundlich distribution coefficient Kf has similarities with the distribution coefficient Kd, 
but the Caq value is adjusted with the power 1/n. 
If the adsorbate concentration increases even more, the capacity of the adsorbent will be 
reached and saturation occurs (Figure 14). The Freundlich equation is no longer suitable for 
this situation, the Langmuir equation is used instead (Langmuir, 1918) which takes into 
account the saturation concentration Csat: 
𝐶𝑎𝑑𝑠 = 𝐾𝑙 ∗ 𝐶𝑠𝑎𝑡 ∗
𝐶𝑎𝑞
1 + 𝐾𝑙 ∗ 𝐶𝑎𝑞
 
 
Cads 
(µg/g) 
Caq 
(µg/mL) 
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Figure 14: Adsorption isotherm with saturation of the binding sites. In the ordinate, the 
adsorbed amount of the adsorbate Cads (µg/g adsorbent) is shown, and in the abscissa, 
the dissolved concentration of the adsorbate Caq (µg/mL). 
The distribution coefficient, Freundlich and Langmuir isotherms give an idea about the 
quantitative aspects of the adsorption process. Variations on these equations are made and 
may provide a better description of the binding isotherms (Skopp, 2009). It should also be 
mentioned that the equations described above are purely empirical, they provide only limited 
information regarding the structure of the adsorbent and/or the mechanism of the adsorption 
process (Giles et al., 1974). The qualitative part, namely how strong the bond is, can be 
determined through the Van 't Hoff equation (Van 't Hoff, 1884): 
ln 𝐾𝑑,𝑇 = −
∆𝐻0
𝑅
1
𝑇
+
∆𝑆0
𝑅
 
Where R is the ideal gas constant, ΔH0 the bond-dissociation energy and ΔS0 the bond-
entropy. The latter is under laboratory conditions usually negligible. The bond-dissociation 
energy is a measure of the strength of the bond. In order to derive the bond-dissociation 
energy, the distribution coefficient Kd is determined at different temperatures: Kd,40, Kd,30, 
Kd,20, etc. Next, the logarithm is plotted against the reciprocal of the temperature. The slope of 
the curve is a measure of the bond-dissociation energy (Figure 15). 
Cads 
(µg/g) 
Caq 
(µg/mL) 
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Figure 15: Van 't Hoff isotherm to calculate the bond-dissociation energy. In the 
ordinate, Kd,T: the distribution coefficient at a given temperature, shown on a 
logarithmic scale. In the abscissa, the reciprocal of the temperature T. ∆H0: bond- 
dissociation energy; R: ideal gas constant. 
2.4 Efficacy testing 
 In vitro 
In vitro models for assessing adsorption properties of mycotoxins in the context of efficacy 
studies of mycotoxin binders include static and dynamic models. Dynamic models such as the 
TNO-gastro-Intestinal Model (TIM), developed by the Dutch organisation for applied 
scientific research (Toegepast Natuurwetenschappelijk Onderzoek or TNO) (Minekus et al., 
1995; Avantaggiato et al., 2003; Blanquet et al., 2004) or Simulator of the Human Intestinal 
Microbial Ecosystem (SHIME) (Molly et al., 1993; Molly et al., 1994), could be 
representative for the in vivo situation. However, they are time consuming and require many 
resources, hence, they are not best suited for high throughput screening experiments. Static 
models are often cheap and quick and thereby suitable for rapid screening experiments, 
however, they are less representative for the GIT and the results should be interpreted 
carefully. Static models include adsorption-isotherm studies (Ramos and Hernandez, 1996b) 
or single concentration studies (Sabater-Vilar et al., 2007; Vekiru et al., 2007; Devreese et al., 
2013b). For the authorisation of a bentonite for AFB1 binding, efficacy testing needs to be 
carried out using a static adsorption test in a buffered matrix of pH 5.0 with a concentration of 
4 mg AFB1/L buffer and 200 mg feed additive/L buffer (European Commission, 2013a).  
 
1/T 
Ln (Kd,T) 
−
∆𝐻0
𝑅
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 In vivo 
For the assessment of the in vivo efficacy of mycotoxin binders, several approaches are being 
used. The criteria animal performance and incidence of mycotoxin related pathologies, or the 
prevalence of mycotoxins in products intended for human consumption (e.g. AFB1 in milk), 
are used as clinical endpoint. However, the performance and incidence of pathologies related 
to mycotoxins as criteria are non-specific, even controlled clinical studies which assess these 
endpoints can be subject to many confounding factors such as influence on GI microbiota, GI 
morphology, nutritional value of the mycotoxin binder (e.g. containing micro-nutrients), etc. 
Study of the toxicokinetics and residues in (edible) tissues can avoid some of the problems 
described above. This is sometimes difficult to accomplish because the concentrations in 
which the mycotoxins appear in edible tissues can be very low; the analytical performance is 
key for the success of the experiment. In addition, the relation between concentrations in the 
biological matrices and the endpoint should be well understood to allow interpretation of the 
results and the establishment of maximum levels of the mycotoxins in the specified matrix.  
In some cases, surrogate endpoints such as the use of biomarkers, or examination of target 
organs can circumvent some of the problems described with assessing the toxicokinetics or 
residues of mycotoxins. These surrogate endpoints are suitable provided that their relation to 
the clinical endpoints is completely elucidated. Table 3 presents the most relevant endpoints 
for exposure to selected mycotoxins. 
Table 3: Most relevant in vivo endpoints for evaluating the efficacy of mycotoxin 
detoxifiers for selected mycotoxins (EFSA FEEDAP Panel, 2010). 
Mycotoxin Endpoint 
Aflatoxin B1 Aflatoxin M1 in milk/egg yolk 
Deoxynivalenol Deoxynivalenol or its metabolites in blood serum 
Zearalenone 
Zearalenone + α- and β-zearalenol in plasma 
Excretion of zearalenone/metabolites 
Ochratoxin A Ochratoxin A in kidney or blood serum 
Fumonisins B1 + B2 
Sphinganine/Sphingosine ratio in blood, plasma 
or tissues 
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In 2001, Huwig et al. summarized the results of the research carried out so far (Huwig et al., 
2001), while in 2011 Kolosova and Stroka presented a more recent review (Kolosova and 
Stroka, 2011). The most extensively studied is the binding of aflatoxins by Hydrated Sodium 
Calcium Aluminosilicate (HSCAS), which is marketed as Novasil
®
 (Phillips et al., 1988; 
Kubena et al., 1991; Edrington et al., 1996; Bailey et al., 1998; Ledoux et al., 1999). HSCAS 
is a broad term for aluminium silicate minerals, containing sodium and calcium, hence, almost 
the entire family of silicates can be labelled as HSCAS. After the introduction of Novasil
®
, 
other products entered the market labelled containing HSCAS as active ingredient, for 
example Milbond-TX
®
, Ethecal
®
, etc. The inclusion rate used in the studies mentioned is 0.5 
g/kg feed or 1.0 g/kg feed. The species in which most in vivo tests are executed are rats, 
(broiler) chickens, turkeys, lambs, pigs, mink, trout and cows. A reduced growth rate due to 
the administration of aflatoxins in the feed was the most obvious symptom in the test groups, 
in most cases this could be prevented, totally or partially, by the addition of HSCAS. The 
concentration of the biomarker AFM1 in milk was, when included in the study, also 
significantly lower. Similar results were obtained with the use of various types of bentonite 
(Pappas et al., 2014).  
For other mycotoxins, the evidence is limited. If positive effects are observed, they are usually 
non-specific such as effects on inflammatory biomarkers or BW loss due to mycotoxin 
administration (Kolosova and Stroka, 2011). It can be concluded that the efficacy for the 
binding of AFB1 is proven for a number of montmorillonite clays, for other toxins no 
effective mycotoxin binders have been identified yet in scientific literature. 
2.5 Risks of mycotoxin binders 
Binding to mycotoxin binders is deemed to be non-specific. These non-specific interactions 
with other feed ingredients or additives are not explicitly mentioned in the legislation of 
mycotoxin binders, although concerns are communicated regarding this subject (EFSA 
FEEDAP Panel, 2010). The non-specific interactions of interest are interactions with 
nutritional compounds in the feed and interactions with veterinary medicinal products which 
are mixed into the feed or drinking water. 
 Interactions with nutritional compounds 
Reports on the interaction with nutritional compounds are limited to a few studies in which 
the uptake of vitamins was investigated in animals or humans which received a clay-based 
additive (Papaioannou et al., 2002; Pimpukdee et al., 2004; Afriyie-Gyawu et al., 2008). In 
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general, the risk for binding vitamins, or other micronutrients, when administering clay-based 
mycotoxin binders is considered limited (EFSA, 2009). 
 Interactions with orally administered veterinary medicinal products 
Previous studies reported possible interactions of mycotoxin binders and veterinary medicinal 
products which are also mixed in the feed or drinking water. The first report of the potential 
interactions dates from 1992 when the Canadian Bureau of Veterinary Drugs reported a case 
in which lack of efficacy of tylosin (TYL) was seen in cattle fed a bentonite supplemented 
feed (Canadian Bureau of Veterinary Drugs, 1992). In 1994, Shryock et al. investigated the 
efficacy of tilmicosin (TIL) for preventing airsacculitis caused by Mycoplasma gallisepticum 
in broiler chickens. A decrease in the effectiveness of TIL was seen as from an inclusion rate 
of bentonite of 2% in the feed (Shryock et al., 1994). In 1998, the effect of sodium bentonite 
on the performance of chickens whose feed was supplemented with the coccidiostats 
monensin (MON) or salinomycin (SAL) was studied. A reduced growth-promoting effect 
could be seen in the group which also received bentonite together with the coccidiostats, but 
only when the inclusion rate of the coccidiostats was below the recommended dose (Gray et 
al., 1998). In a trial in which chickens were challenged with an Eimeria infection, more severe 
clinical symptoms were seen in the groups which received clinoptilolite – a tectosilicate – 
together with SAL compared to the groups only receiving SAL (Nesic et al., 2003). An 
interaction between lincomycin and a non-specified anti-mycotoxin agent was also observed 
in broilers (Amer, 2005). 
In 2010, the European Food Safety Authority (EFSA) stated that the safety of mycotoxin 
binders with respect to non-specific binding of drugs for veterinary use must be examined 
(EFSA FEEDAP Panel, 2010). Devreese et al. studied the pharmacokinetic (PK) properties of 
TYL in fasted broiler chickens, using an oral bolus model in which TYL or TYL + bentonite 
was administered. The daily dose of bentonite corresponding to an inclusion rate of 1 g/kg 
feed, was administered to fasted broilers before administration of a dose of TYL, which also 
corresponded to the recommended daily dose. The oral bioavailability of TYL was 
significantly reduced in the test group receiving TYL + bentonite, as demonstrated by the 
plasma concentration-time curves in Figure 16 (Devreese et al., 2012).  
To date, the concomitant use of bentonite and macrolide antibiotics is prohibited for all 
species (European Commission, 2013a). For poultry, the use of bentonite with the coccidiostat 
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robenidine should be avoided, for other coccidiostats, the maximum inclusion rate for poultry 
feed is set at 5 g/kg (European Commission, 2013a). 
 
Figure 16: Plasma concentration–time profile of tylosin after a single oral bolus 
administration of tylosin (24 mg/kg) with or without bentonite (1 mg/kg) to broiler 
chickens. Values are presented as means + standard deviation (SD, n = 8) (Devreese et 
al., 2012). 
 Veterinary medicinal products and pharmacokinetics 
Over 200 veterinary drug formulations are available on the Belgian market to apply orally to 
pigs and chickens by mixing in the feed or drinking water. Oral administration is applied in 
91.5% of the treatments with antimicrobials in food producing animals in Europe (% of sales, 
expressed as mg/produced kg meat). For poultry and pig rearing, usually multiple animals are 
treated together by medicating the drinking water or feed, mainly because of practical reasons. 
The categories of antimicrobials that are mostly used for food producing animals are 
tetracyclines (37%), β-lactams (22%), sulfonamides (10%) and macrolides (8%). The 
antimicrobials in these categories are mostly (> 90%) applied orally (European Medicines 
Agency, 2013). An overview ot the registered products is presented in table 4. 
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Table 4: Overview of the chemical entities registered as antimicrobial drugs or 
coccidiostats for pigs and poultry. For the antimicrobial drugs, only following categories 
are included: penicillins, tetracyclines, sulfonamides+trimethoprim and macrolides 
(Belgisch Centrum voor Farmacotherapeutische Informatie; http://www.bcfi-vet.be, 
2016) 
 Antimicrobials of the categories penicillins, 
tetracyclines, potentiated sulfonamides and 
macrolides registered for use in pigs or poultry 
Registered coccidiostats 
(feed additive) for use in 
pigs and poultry 
Pigs 
benzylpenicillin, ampicillin, amoxycillin, 
doxycycline, oxytetracycline, sulfonamides 
(sulfadiazine/ sulfamethoxazole/ sulfadoxine/ 
sulfachlorpyridazine) + trimethoprim, 
gamithromycin, tilmicosin, tildipirosin, 
tulathromycin, tylosin, tylvalosin 
 
Poultry 
fenoxymethylpenicillin, amoxycillin, doxycycline, 
sulfachlorpyridazine/sulfadiazine + trimethoprim, 
tilmycosin, tylosin, tylvalosin 
monensin, decoquinate, 
robenidine, lasalocid, 
halofuginone, narasin, 
salinomycin, maduramicin, 
diclazuril, semduramicin, 
nicarbazin 
 
The antimicrobials are absorbed by the animal in the GIT and distributed to the site of the 
infection, where they hopefully reach concentrations that are sufficiently high, to kill or 
inhibit growth of the target pathogen. This concentration is defined as the Minimal Inhibitory 
Concentration (MIC) of a specific pathogen (Andrews, 2001). The different classes of 
antimicrobials differ with regard to the time and degree their concentration should surpass the 
MIC in order to be effective. This is defined as the pharmacokinetic/pharmacodynamic 
(PK/PD)-indices for antimicrobials, and different classes can be considered: 1) time-
dependent antimicrobials: the period their concentration surpasses the MIC is decisive for 
their efficacy (time/MIC or T/MIC), examples are macrolides and β-lactams; 2) 
concentration-dependent antimicrobials: the efficacy depends upon the extent the maximal 
plasma concentration surpasses the MIC (Cmax/MIC), examples are fluoroquinolones and 
aminoglycosides; and 3) co-dependent antimicrobials: their efficacy is related to both duration 
of exposure and maintained concentration: the PK/PD index is area under the plasma 
concentration-time curve (AUC)/MIC, examples are tetracyclines and azalides (Mouton et al., 
2012). 
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In most cases the drug is indeed intended to exhibit a systemic effect, and the availability at 
the site of action is in most cases related to the blood (plasma) concentration. Therefore, the 
bioavailability of the drug is defined as the rate and extent to which the parent drug substance 
becomes available in the systemic circulation (Rang et al., 2007). Consequently, the 
bioavailability is based on the AUC after extravascular administration divided by the AUC 
after IV administration, and correcting for the dose. The AUC can be measured until the last 
blood sampling time point (AUClast) or extrapolated until infinity (AUCinf). AUCinf is 
preferred to calculate the (oral) bioavailability. Oral bioavailability is applicable when the 
drug is administered orally, and it is the result of surpassing biological membranes and 
possible first-pass degradation and/or biotransformation processes. The extent to which orally 
administered drugs express a high bioavailability depends on a number of physicochemical 
and biological factors. Most important physicochemical factors include pKa and lipophilicity 
of the drug, GIT stability, solubility, dissolution rate of the active ingredient from its 
pharmaceutical formulation and composition/pH of GIT juices. Important biological factors 
are the physiology of the GIT and the presystemic biotransformation of gut and liver (Hu and 
Li, 2011).  
For oral medicinal products with a systemic mode of action, a lower oral bioavailability may 
lead to inefficient therapy, meaning that the peak concentration is not high enough or drug 
concentration cannot remain above the MIC long enough to be efficient. An increase in oral 
bioavailability on the other hand, may lead to residues above Maximum Residue Limit (MRL) 
in animal products intended for human consumption. An increase of oxytetracycline plasma 
concentrations was seen in broilers after three weeks exposure to a clay-based mycotoxin 
binder (Osselaere et al., 2012). In pigs, the plasma concentrations of doxycycline and 
paromomycin were higher after exposure of seven days to a yeast derived mycotoxin binder 
in combination with T-2 or DON (Goossens et al., 2012). 
Coccidiostats are feed additives which inhibit the development of coccidia (e.g. Eimeria spp.) 
and histomona (e.g. Histomonas meleagridis) in the GIT. Although they are registered as feed 
additives, they have many properties in common with medicinal products. They claim 
prevention of coccidiosis, have a well described pharmacological mode of action and their 
registration procedure is quite similar to those of medicinal products. These are described in 
Directive 2001/82 and Regulation 429/2008 (European Commission, 2001, 2008). 
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Many mycotoxin binders are available on the European market and many new products are 
entering the market (EFSA, 2009). Given the multitude of veterinary drugs that can be mixed 
in the feed and drinking water, and coccidiostats that are readily mixed in the feed, the 
number of possible combinations with mycotoxin binder is very high and still increasing. 
Current studies on the possible interactions between mycotoxin binders and medicinal 
products cover only a small fraction of the possible combinations, moreover, these studies are 
limited to date and predominantly apply models that are not specific and sensitive for 
detecting interactions. 
2.6 Safety testing 
Safety of mycotoxin binders comprises testing of the direct and indirect risks. Tests and 
regulation regarding the direct risks are provided in the European Directive 429/2008 for 
registration of (technological) feed additives (European Commission, 2008). For indirect 
risks, such as the adsorption of beneficial chemical entities in the feed, e.g. veterinary 
medicinal products, no specific tests are provided.  
The static, single concentration in vitro models required for the registration of a bentonite are 
designed to assess the efficacy, as described above. When similar models are applied for 
safety testing, they should be adapted to maximize sensitivity. This can be done by reducing 
the total volume or using concentrations of mycotoxin binder and adsorbate that maximise the 
probability of interactions, i.e. mimicking worst case scenarios. These adaptations usually 
mean a decrease in specificity, which could lead to prohibition of suitable therapies. Hence, in 
vitro interactions should be further evaluated in vivo. 
To date, no in vitro models are available that are designed for screening the safety 
(interactions with veterinary medicinal products) rather than efficacy. Sensitive and specific 
in vitro models which allow a quick screening for interactions are urgently needed (EFSA, 
2009).  
For in vivo safety studies which investigate the interactions of mycotoxin binders with oral 
veterinary medicinal products, the endpoints are the clinical outcome of the pharmacological 
treatment and whether or not the beneficial effects of the medicinal product are diminished by 
the concomitant use of mycotoxin binders. Studies which assess the endpoints face the same 
problems as for the efficacy studies. A kinetic approach, i.e. effects of the mycotoxin binders 
on the PK of the veterinary medicinal products, is an approach of interest because it avoids 
confounding factors. Moreover, for most medicinal products, plasma (or tissue) 
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concentrations after administration of the recommended dose are high enough to allow 
accurate quantification, and the relation of plasma or tissue concentrations with the clinical 
outcome is usually well known. Therefore more studies should be executed using the PK 
approach, this was also recommended by the European authorities (EFSA, 2011).  
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Mycotoxin binders are mixed in the feed to counter the deleterious effects of mycotoxins. 
Veterinary medicinal products, such as antimicrobials and coccidiostats, are usually 
administered in the feed of poultry and pigs. Antimicrobials are also administered by mixing 
in the drinking water, hence these veterinary medicinal products can come into contact with 
mycotoxin binders in the gastrointestinal tract. This may compromise their pharmacological 
effect and/or oral bioavailability. There is limited information on the possible interactions 
between mycotoxin binders and oral veterinary medicinal products. The European Food 
Safety Authority (EFSA) stated that the non-specific binding needs to be investigated, using 
unambiguous methods such as pharmacokinetic studies. The general aim of this thesis is to 
investigate the safety of mycotoxin binders regarding the possibility for non-specific 
interactions with oral veterinary medicinal products. Knowledge on the effects of mycotoxin 
binders on the pharmacokinetic properties of these products is needed to safeguard their 
optimal pharmacotherapy. Therefore, the results described in this thesis can support 
competent authorities in the safety assessment of these feed additives.  
The goal of the first chapter of this doctoral thesis is to get a better understanding of the 
composition of mycotoxin binders available on the European market. Characterization 
experiments in chapter 1 aim to map the physicochemical properties of the mycotoxin binders 
and to assess a link with the binding potential. The binding of zearalenone, a Fusarium 
mycotoxin, is chosen as model. These characteristics are also used to select a number of 
binders which are subject to further in vitro and in vivo experiments. 
In the second chapter of this thesis, the binding potential of a number of representative 
mycotoxin binders is studied for the antimicrobial doxycycline using an in vitro model. The 
techniques applied are set up as a screening test using single concentration of drug and binder. 
The in vitro results are compared with the results of an in vivo pharmacokinetic experiment, 
which resembles a worst-case scenario in broiler chickens. 
The third and fourth chapter of this thesis focuses on interactions between selected 
mycotoxin binders and veterinary drugs from a pharmacokinetic perspective. These 
experiments apply models which are closer related to the field situation than the worst-case 
setup used in chapter 2. Several in vivo studies are executed in broiler chickens (chapter 3) 
and pigs (chapter 4). The veterinary medicinal products that are studied are selected 
antimicrobials and coccidiostats.  
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In the fifth chapter, a sensitive and specific in vitro model is presented for screening for 
interactions. Feed is incorporated in the design and this approaches the in vivo situation better 
than the model presented in chapter 1. Furthermore the influence of different inclusion rates 
are tested. Finally, the results are compared with the results of in vivo experiments, presented 
in this thesis and published elsewhere. 
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Adapted from: 
Thomas De Mil, Mathias Devreese, Siegrid De Baere, Eric Van Ranst, Mia Eeckhout, Patrick De 
Backer and Siska Croubels (2015b). Characterization of 27 Mycotoxin Binders and the Relation with 
in vitro Zearalenone Adsorption at a Single Concentration. Toxins, 7, 21-33; 
doi:10.3390/toxins7010021 
Chapter 1: Characterization of 27 mycotoxin binders and the relation with in vitro 
zearalenone adsorption at a single concentration  
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Abstract  
The aim of this study was to characterize 27 feed additives marketed as mycotoxin binders and to 
screen them for their in vitro zearalenone (ZEN) adsorption. Firstly, 27 mycotoxin binders, 
commercially available in Belgium and The Netherlands, were selected and characterized. 
Characterization was comprised of X-ray diffraction (XRD) profiling of the mineral content and d-
spacing, determination of the cation exchange capacity (CEC) and the exchangeable base cations, 
acidity, mineral fraction, relative humidity (RH) and swelling volume. Secondly, an in vitro screening 
experiment was performed to evaluate the adsorption of a single concentration of ZEN in a 
ZEN:binder ratio of 1:20,000. The free concentration of ZEN was measured after 4 h of incubation 
with each of the 27 mycotoxin binders at a pH of 2.5, 6.5 and 8.0. A significant correlation between 
the free concentration of ZEN and both the d-spacing and mineral fraction of the mycotoxin binders 
was seen at the three pH levels. A low free concentration of ZEN was demonstrated using binders 
containing mixed-layered smectites and binders containing humic acids. 
 
Keywords: mycotoxin; binders; characterization; zearalenone; adsorption screening 
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1  Introduction 
The contamination of feed with mycotoxins is a continuing feed safety issue, leading to economic 
losses in animal production (Wu, 2007). Consequently, a variety of methods for the decontamination 
of feed has been developed, but the addition of mycotoxin detoxifiers to the feed is the most 
commonly-used method (Jard et al., 2011; Kolosova and Stroka, 2011). The additives used for this 
purpose can be divided into two groups: binders and modifiers. Mycotoxin binders aim to prevent the 
absorption of the mycotoxins from the intestinal tract of the animal by adsorbing the toxins to their 
surface. Mycotoxin binders are generally clay- (inorganic) or yeast-derived (organic) products 
(Kolosova and Stroka, 2011). Mycotoxin modifiers, on the other hand, aim to alter the chemical 
structure of the mycotoxins and, consequently, reduce their toxicity. Mycotoxin modifiers are usually 
of microbiological origin comprised of whole cultures of bacteria or yeasts, as well as specifically 
extracted components, such as enzymes (Kabak and Dobson, 2009). 
The extensive use of specialized additives to diminish the effects of mycotoxins has led to the 
establishment of a new group of feed additives in Regulation 386/2009: “substances for reduction of 
the contamination of feed by mycotoxins: substances that can suppress or reduce the absorption, 
promote the excretion of mycotoxins or modify their mode of action” (European Commission, 2009a). 
However, most of the mycotoxin detoxifiers are registered as technical additives, feedstuff or 
digestibility enhancers, as those are more easily being registered in comparison to the claim of a 
mycotoxin detoxifier. At the moment, only two products are registered in annex I of Regulation 
1831/2003 as being a mycotoxin detoxifier (European Commission, 2015), whereas a wide variety of 
products indirectly claiming mycotoxin binding or modifying abilities is available. In addition, 
European legislation does not require full transparency with regard to the content of these technical 
additives. 
Although many different types of ingredients are known to be used in additives marketed as mycotoxin 
binders (in brief, binders), no studies are available that provide a comprehensive overview of their 
exact composition. In most reports, the description of the products is limited to the product name and 
an entry of a generic name, such as hydrated sodium calcium aluminosilicate (HSCAS) or bentonite 
(Kolosova and Stroka, 2011). Despite this generic nomenclature of commercially-available binders, 
several physicochemical properties have been identified as having a possible association with 
adsorption of mycotoxins and might therefore be used to categorize the different available products. 
These characteristics originate from soil science and comprise cation exchange capacity (CEC), 
exchangeable K
+
, Na
+
, Mg
++
 and Ca
++
, acidity, linear swelling, mineral fraction and relative humidity 
(Burt, 2011).  
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Exchangeable cations neutralize the interlayer charges in phyllosilicates and are involved in the 
binding mechanism of aflatoxin B1 (Phillips et al., 2008; Deng et al., 2010). The CEC is a measure of 
the amount of exchangeable cations, whereas the different types of exchangeable base cations (K
+
, 
Na
+
, Mg
++
 and Ca
++
) have different properties in terms of their affinity for the clay and osmolarity 
(Fletcher and Sposito, 1989). Although a correlation between the binding properties of mycotoxins and 
CEC values is not documented in the literature, this parameter is cited by manufacturers when 
discussing the binding properties of inorganic mycotoxin binders.  
The pH of the binder can provide insight into the saturation of a clay with exchangeable base cations, 
which results in a pH of seven or higher. An increase in pH can be due to the solvation of the 
exchangeable base cations or the presence of carbonates. A low pH is indicative for exchangeable Al
3+
 
or the presence of acidic functional groups, e.g., humic acids.  
Adsorption to clays is not limited to the surface of the clay particles, but extends also to the interlayer 
space of the clay. This interlayer space, characterized by the d-spacing, can be determined with X-ray 
diffraction (XRD) and is restrictive for the formation of one or more adsorbent layers. This space can 
increase if the clay swells, thereby increasing the number of binding sites (Chang et al., 2009). 
Hydration of the minerals plays an important role in this process, as well, since it is related to the 
osmotic power of the mineral (Vidal and Dubacq, 2009; Morrow et al., 2013) and, hence, the ability to 
hydrate the interlayer space.  
Non-enzymatic organic compounds used as additive in feeds are mostly products derived from yeast 
cell walls or organic mineraloids, such as leonardite and lignite, which are a rich source of humic and 
fulvic acids. Adsorption to these compounds can occur through hydrophobic interactions (Picollo, 
1999). Such interactions were proposed for the binding of the antibiotic, oxytetracycline, to 
montmorillonites in the presence of dissolved organic matter (Kulshrestha et al., 2004). To determine 
the mineral fraction of a sample, the organic compounds are discarded by dry combustion.  
With regard to the adsorption of mycotoxins, zearalenone (ZEN) is a secondary metabolite produced 
by several fungi of the Fusarium genus. It has lipophilic properties and exerts its effects on the 
reproductive system of animals (Kanora and Maes, 2009; Cozzini and Dellafiora, 2012). Sabater-Vilar 
et al. described the ZEN-adsorption of three smectite-based minerals, six humic substances, four yeast-
derived detoxifiers and six commercial products, which include, according to the commercial 
brochures, two yeast products, three mineral binders and a mixture of clay and yeast products. A large 
variation in the adsorption of ZEN is seen in all of the types of binders (Sabater-Vilar et al., 2007). 
Yiannikouris et al. compared the ZEN binding properties of a yeast cell extract and a mineral binder 
and concluded that the yeast-based product had better adsorption properties than the mineral in the 
higher concentration range (Yiannikouris et al., 2013). Avantaggiato et al. studied 19 binders and also 
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found a large variation in ZEN adsorption (Avantaggiato et al., 2005). These results indicate that ZEN 
can be adsorbed, but only by a limited number of binders, and there is a large variation in binding 
percentage. Therefore, ZEN binding can be used as model to evaluate which physicochemical 
properties are related to the binding of rather lipophilic mycotoxins. All of the studies cited above used 
activated carbon or charcoal as the positive control and found binding percentages of over 90%. 
The first aim of this study was to identify the qualitative composition of 27 commercially-available 
feed additives marketed as mycotoxin binders by XRD analysis and to determine the following 
physicochemical properties: CEC, exchangeable K
+
, Na
+
, Mg
++
 and Ca
++
, acidity, swelling, mineral 
fraction, presence of carbonates (HCl effervescence test) and relative humidity. 
The second aim was to discuss the relation between the observed free concentration of ZEN after 
incubation with the mycotoxin binders and the physicochemical properties of these binders.  
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2  Experimental Section 
2.1  Mycotoxin binders, chemical products and reagents 
Feed additives marketed as mycotoxin binders (n = 27) were collected after a market study to identify 
the most relevant products. The suppliers include the international companies, Poortershaven, Sanluc, 
Kemin, Biomin, Alltech, Agrimex, Cenzone tech, Tesgo international, Selko, Clariant, Tolsa, BASF, 
Miavit, Special Nutrients and American Colloid. Acid-washed sea sand, HCl, CaCl2·2H2O, NaCl and 
MgO were supplied by VWR (Leuven, Belgium). Technical ethanol was provided by Fiers (Kuurne, 
Belgium). The ammonium acetate, boric acid, H3PO4, Na2HPO4 and Neβler reagent were provided by 
Merck (Darmstadt, Germany). Sigma Aldrich (Bornem, Belgium) supplied KCl, MgCl2·6H2O and 
glycol. Acros Organics (Geel, Belgium) supplied methyl red, bromocresol green and tert-butyl methyl 
ether (tBME). Water and acetonitrile (ACN) used for the HPLC analysis were of MS-grade and 
provided by Fisher Scientific (Wijnegem, Belgium). ZEN and 
13
C18-ZEN were purchased from 
Fermentek (Jerusalem, Israel) and Romerlabs (Tulln, Austria), respectively. 
2.2  CEC and exchangeable base cations 
A glass burette with a porous bottom was filled with, respectively, 10 g of acid-washed sand, 25 g of 
acid-washed sand that was thoroughly shaken on a horizontal shaker for 30 min with 0.5 g of binder 
and 5 g of acid-washed sand to avoid splattering. After 20 min of equilibration, 150 mL of technical 
ethanol was percolated over the burette for two hours. Next, 150 mL of a 1 mol/L aqueous ammonium 
acetate solution was percolated in the same manner for a total time of 4 h. The ammonium acetate 
percolate was analyzed with inductive coupled plasma-atomic emission spectrometry (ICP-AES), as 
described by Burt et al. (Burt, 2011). The device used was an IRIS Interpid II XSP (Thermofisher, 
Waltham, UK). The characteristic wavelengths used were 317.9 nm for Ca
2+
, 766.4 nm for K
+
, 285.2 
nm for Mg
2+
 and 589.5 nm for Na
+
.  
After the ammonium acetate percolation, the column was rinsed with 150 mL of technical ethanol to 
remove ammonium that was not adsorbed by the sample. This washing step was performed over a 
period of 2 h, respecting 20 min of equilibration. The percolate was tested for the presence of ammonia 
with the Neβler reagent. In case the test was positive, an extra 100 mL of ethanol was used to remove 
all ammonia. Next, 500 mL of KCl 1 mol/L were percolated over 4 h, again respecting 20 min of 
equilibration. Fifty milliliters of the KCl percolate were transferred to a Buchi-tube (Buchi 
labortechnik AG, Flawill, Switzerland), together with about 5 g of MgO. Ammonia was captured in a 
boric acid-containing solution (20 mL, 0.3 M). The boric acid solution was supplemented with 
indicators methyl red and bromocresol green. The formed tetrahydroxyborate was titrated back to boric 
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acid with 0.01 mol/L of HCl, and the titration was considered complete when the red color reappeared. 
The reactions involved and formulas to calculate the CEC value are presented below: 
𝑁𝐻4
+
𝑇↑;𝑀𝑔𝑂
→     𝑁𝐻3(↑) (1) 
𝑁𝐻3 + 𝐵(𝑂𝐻)3 + 𝐻2𝑂 → 𝑁𝐻4
+ + 𝐵(𝑂𝐻)4
− (2) 
𝐵(𝑂𝐻)4
− + 𝐻3𝑂
+ ⇋ 𝐵(𝑂𝐻)3 + 2𝐻2𝑂 (3) 
𝐶𝐸𝐶𝑝𝐻7 =
(𝑉2 − 𝑉0) × 𝑇 × 𝑉 × 100
𝑉1 × 𝐺
 (4) 
with (V2−V0) representing the volume of HCl used, T the titer of HCl (= 0.01 mol/L), V the volume of 
KCl percolate (= 500 mL), V1 the volume of KCl percolate sample (= 50 mL) and G the mass of the 
binder (= 0.5 g). A KCl solution was used as a blank sample for the titration; a pure sand sample was 
included for the percolation. 
2.3  Other characterization tests 
To measure the acidity of the samples, a 1:10 binder:water suspension was shaken for 2 h and was left 
to sediment for another 2 h under closed lid. The pH of the supernatant was measured using a glass-
calomel electrode (Inolab WTW, Weilheim, Germany). 
The presence of carbonates in the samples was tested with a HCl effervescence test: a small amount of 
binder was mixed with a few droplets of concentrated HCl on a glass dish. The reaction in the first 10 
seconds was monitored and scored as follows: −, no reaction; +, moderate reaction; ++, strong 
reaction. 
To determine the relative humidity and the mineral fraction, 10 g of binder were dried in an oven 
(Memmert, Swabach, Germany) at 110 °C overnight. The sample was weighed before and after drying, 
and the moisture content was calculated based on the weight reduction. The mineral fraction was 
assessed by the dry combustion method by heating in a Muffle
®
 furnace (Nabertherm, Lilienthal, 
Germany) to 400 °C for 16 h and then cooled in a desiccator (Burt, 2011). 
The swelling volume was assessed by using an adaptation of the coefficient of linear extensibility 
(COLE) (Marroquin-Cardona et al., 2009; Burt, 2011). An aliquot of the binder (2.5 mL tapped bulk 
volume) was mixed with 15 or 50 mL of water, depending on the extent of swelling. The mixture was 
thoroughly vortexed (15 s) in the volumetric tube, incubated (4 h) and centrifuged (1070× g, 10 min, 4 
°C) before measuring the volume of the sediment. 
XRD patterns, including d-spacing, were obtained with a Philips X'PERT SYSTEM (Phillips, 
Eindhoven, The Netherlands), the diffractometer (type: PW 3710) was equipped with a copper tube 
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anode, a secondary graphite beam monochromator, a proportional xenon filled detector and a 35-
position multiple sample changer. The incident beam was automatically aligned, and the irradiated 
wavelength was 12 mm. The secondary beam side surpassed a 0.1-mm receiving slit, a Soller slit and a 
1° anti-scanner slit. The tube was operated at 40 kV and 30 mA. XRD data were collected in a theta, 2-
theta geometry from 3.00' onwards at a step of 0.020° 2-theta and a counting time of 1 s per step. XRD 
patterns of powder samples, oriented samples and glycol-saturated oriented powder samples were 
recorded. 
2.4  Zearalenone adsorption screening 
A saline solution was made by adding 24.0 g of NaCl, 0.3 g of MgCl2·6H2O, 0.6 g of KCl and 0.4 g of 
CaCl2·2H2O to 3L HPLC-grade water. Next, a phosphate buffer system was added to 1 L of saline 
solution to obtain phosphate buffered saline (PBS). The buffer system consisted of H3PO4 and KH2PO4 
for the acidic (pH 2.5) buffer and of KH2PO4 and Na2HPO4 for the buffers of pH 6.5 and 8.0. Total 
buffer concentration was calculated with the Henderson–Hasselbalch equation and the constraint to 
obtain a total osmolarity of 9.6 mmol/L in each buffer. The pH was measured and adjusted with H3PO4 
or Na2HPO4 to obtain buffers of pH 2.5, 6.5 or 8.0. A 60-mL flask was filled with 20 mg of each of the 
binders and 5 mL of PBS; this was done for each pH, in triplicate. ZEN was added to a final 
concentration of 200 ng/mL. The flask was then shaken for 4 h at 37 °C in an incubator (New 
Brunswick Scientific, Rotselaar, Belgium). Next, samples were centrifuged (10 min, 1070× g, 25°C), 
and 2 mL of the supernatant were transferred to a test tube. Next, 25 µL of the internal standard (IS, 
13
C18-ZEN, 1 µg/mL) were added and vortexed, followed by 4 mL of tBME. The tube was swirled on a 
roller bench (Stuart Scientific, Surrey, UK) for 20 min and centrifuged (10 min, 2,851× g, 4 °C). The 
supernatant was evaporated to dryness under a gentle nitrogen stream (40 ± 5 °C). The dry residue was 
reconstituted in 200 µL of ACN and transferred to a glass vial for LC-MS/MS analysis.  
The HPLC system consisted of a Waters 2690 pump and autosampler system with a Zorbax Eclipse C-
18 HPLC column (3 mm × 100 mm; i.d. 3.5 µm) and a pre-column of the same type (Agilent, Diegem, 
Belgium). The injection volume was 10 µL. The mobile phases were ACN (A) and HPLC-grade water 
supplemented with 0.3% ammonia (B). The gradient elution program was as follows: 0–0.5 min, 50% 
A/50% B; 0.5–1 min, linear gradient to 70% A/30% B; 1–4.5 min, 70% A/30% B; 4.5–5.5 min, linear 
gradient to 50% A/50% B; 5.5–8 min, 50% A/50% B. The flow rate was set at 0.6 mL/min. The 
MS/MS detection system was a Micromass Quattro Ultima (Micromass, Manchester, UK) operated in 
the ESI-negative mode. The m/z transitions for quantification were 335 > 140 (
13
C18-ZEN) and 317 > 
131 (ZEN). The capillary and cone voltages were −3.47 kV and 60 V, respectively, and source 
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temperature was set at 120 °C and desolvation temperature at 200 °C. The cone gas flow and 
desolvation gas flow were set at 848 L/h and 60 L/h, and the optimized collision energy was 30 eV. 
The analytical method was validated for the three pHs independently according to European guidelines 
(2002/657/EC, 2002) and was adapted from the method by De Baere et al. (2012) (De Baere et al., 
2012). The validation included evaluation of linearity, within- and between-run accuracy and 
precision, limit of detection (LOD), limit of quantification (LOQ), specificity and carry-over. The 
correlation coefficients (r) and goodness-of-fit coefficients (g) of the 7-point calibration curves were 
calculated and fell within the limits of specification, ≥0.99 and ≤10%, respectively. For the precision, 
the relative standard deviation (RSD, %) fell within 2/3 of the values calculated according to the 
Horwitz equation,RSDmax = 2
(1−0.5logConc) 
× 2/3, for within-run precision, with a minimum of 10%, and 
within the values calculated according to the Horwitz equation for between-run precision, RSDmax = 
2
(1−0.5logConc)
. The LOQ was determined by analyzing six samples spiked at 3.13 ng/mL, on the same 
day. Detection limits for pH 2.5, 6.5 and 8.0 were respectively 0.70, 1.07 and 0.66 ng/mL.  
2.5  Statistical analysis 
Analysis of variance (ANOVA) was used to compare the free concentration of ZEN for the different 
binders. The free ZEN concentration was correlated with the continuous explanatory variables. p-
values below 0.05 were considered statistically significant. All analyses were conducted using SPSS 
22 (IBM, Chicago, IL, USA), and graphs were obtained with GraphPad Prism
®
 version 5 (La Jolla, 
CA, USA). 
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3  Results and discussion 
3.1  Physicochemical characterization 
The physicochemical properties of the 27 binders are presented in Table 1. These samples represent 
the vast majority of additives marketed as mycotoxin binders in Belgium and The Netherlands and are 
available in most European countries. All binders contain one or more mineral constituent, and some 
products contain organic compounds. Most binders are mixtures of different mineral constituents, and 
most prevalent compounds are smectites, such as montmorillonite. The ratio of exchangeable base 
cations varies widely, even among products with similar compounds. The non-mineral content of a 
binder with a low mineral fraction (i.e., Sample Numbers 5, 12, 15 and 16) was confirmed by 
information provided by the manufacturer of the binder, who labelled these products as containing 
humic acids, leonardite or yeast-derived binders.  
3.2  Zearalenone adsorption screening and correlation with physicochemical characteristics 
The in vitro ZEN adsorption is assessed using a high throughput screening model applied at different 
pHs, which are representative for the gastro-intestinal tract of most monogastric animals. Similar 
models were successfully applied in previous in vitro experiments (Ramos and Hernandez, 1996b; 
Avantaggiato et al., 2005; Sabater-Vilar et al., 2007; Marroquin-Cardona et al., 2009; Joannis-Cassan 
et al., 2011; Yiannikouris et al., 2013; Sasaki et al., 2014). Major differences include the use of other 
buffer systems or media and the construction of adsorption isotherms. The use of other buffers or 
media may influence chemical equilibria, whereas adsorption isotherms may reveal information on the 
binding mechanism, affinity and capacity. This study focused on the determination of the free 
concentration of ZEN in phosphate buffered saline (PBS) after incubation with each of the 27 binders. 
The amount of ZEN and mycotoxin binder used for incubation is in accordance with the ZEN-binder 
ratio of 1:20,000, which is based on the maximum guidance level for ZEN in European piglet feed of 
0.1 mg/kg described in Recommendation 2006/576 (European Commission, 2006) and the 
conventional binder inclusion level of 2 g/kg feed. The individual results of three replicates for the 
different pHs are presented in a ranked manner (Figure 1) to facilitate comparison between the binders. 
One-way analysis of variance (ANOVA) for the different binders indicates significant differences in 
free ZEN concentration (p < 0.05). Next, the free ZEN concentration was correlated with the 
physicochemical characteristics. The correlation matrix of free ZEN concentration and the 
physicochemical properties is presented in Table 2.  
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Figure 1: Free zearalenone (ZEN) concentration after incubation of ZEN with 27 mycotoxin 
binders at three different pHs (Sample Numbers 1–27). Individual results of three replicates are 
shown. AC represents activated carbon, which is included as the positive control. 
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Table 1: Physicochemical characteristics of 27 additives marketed as mycotoxin binders and available in Belgium and The 
Netherlands. Mean values of triplicate analyses are presented. 
Sample 
Number 
XRD Result HCl 
d-spacing 
(10
−10 
m) 
CEC 
(cmolc kg
−1
) 
pH 
Ca
2+
 
(cmolc kg
−1
) 
K
+
 
(cmolc kg
−1
) 
Mg
2+
 
(cmolc kg
−1
) 
Na
+
 
(cmolc kg
−1
) 
Swelling 
(mL) 
MF 
(%) 
RH 
(%) 
1 Zeolite + 9.5 172.9 8.3 16.8 102.4 0.8 24.6 2.1 94.4 4.6 
2 Sepiolite, smectite + 12.4 31.9 7.7 7.3 1.5 9.8 1.3 7.7 96.0 8.7 
3 Clinoptilolite − 10.2 120.3 7.7 8.4 58.7 1.2 10.2 2.5 97.7 4.9 
4 Zeolite − 12.5 413.5 10.3 n.d. 35.4 0.1 363.3 0.0 93.8 7.1 
5 Humic substance, quartz − 26.2 185.9 4.2 7.2 1.5 3.4 19.2 2.5 15.8 10.6 
6 Mixed layer montmorillonite, quartz − 19.1 51.0 7.7 10.0 10.7 3.8 21.8 2.7 78.6 3.4 
7 Montmorillonite ++ 12.8 82.9 9.8 12.5 2.8 4.0 63.8 43.7 97.1 10.1 
8 Montmorillonite − 15.5 100.5 3.7 19.2 1.8 3.0 0.8 2.2 95.9 13.3 
9 Sepiolite, montmorillonite, quartz (t), dolomite (t), albite (t) + 12.1 39.3 8.2 8.2 0.6 10.2 0.6 7.9 96.3 5.4 
10 Montmorillonite, sepiolite, quartz (t), calcite (t) ++ 12.4 56.7 8.5 16.9 0.6 8.0 26.9 9.1 96.9 9.1 
11 Montmorillonite, quartz (t), calcite (t), feldspars (t) ++ 12.6 64.1 9.3 19.6 3.0 6.7 54.3 31.8 98.3 11.9 
12 Humic substance, quartz − 25.9 166.4 4.4 1.3 11.5 0.9 18.4 2.5 6.0 12.4 
13 Sepiolite, montmorillonite, calcite (t), quartz (t) + 12.2 22.1 7.1 17.7 2.2 9.3 4.4 5.9 80.3 6.7 
14 Montmorillonite − 9.2 109.4 5.6 21.7 17.2 1.9 4.2 2.9 92.8 7.2 
15 Calcite, dolomite, organic material ++ 6.9 12.6 5.7 35.5 19.1 4.2 26.0 7.5 38.9 5.1 
16 Thenardite, montmorillonite, quartz, organic material 
 
14.8 7.8 4.1 2.3 26.0 7.0 131.8 4.0 27.3 6.4 
17 Montmorillonite − 12.6 71.8 8.0 9.5 4.0 2.7 49.5 7.6 90.2 9.8 
18 Clinoptilolite − 10.2 176.6 7.4 15.2 44.7 2.0 6.0 2.5 96.3 4.7 
19 Quartz, mica, montmorillonite, kaolin − 14.7 59.7 7.9 18.1 1.9 9.0 0.3 4.3 95.4 7.9 
20 Mica, kaolin, quartz, montmorillonite + 14.7 59.6 7.9 14.4 2.5 8.7 0.6 3.5 97.0 9.0 
21 Mixed layered smectite + 12.4 23.7 9.9 13.3 0.7 19.2 47.7 24.2 97.5 7.5 
22 Mica, calcite, smectite + 15.5 77.9 8.0 33.9 1.8 4.1 0.9 4.3 88.6 11.4 
23 Montmorillonite, sepiolite, calcite (t) ++ 12.4 46.5 7.9 24.2 1.4 4.7 55.2 8.6 92.7 7.3 
24 Montmorillonite, mica, feldspars − 12.3 7.0 6.2 8.1 12.9 3.3 4.9 3.8 94.8 5.2 
25 Calcite, montmorillonite (t) ++ 13.1 26.1 6.6 55.8 10.7 2.4 11.6 3.7 97.0 3.0 
26 Mixed layered montmorillonite, quartz, feldspars − 21.5 27.9 7.7 9.3 1.4 2.6 4.9 2.5 98.0 2.0 
27 Montmorillonite − 12.7 111.7 9.5 8.7 1.3 4.0 69.5 5.7 86.8 13.2 
−, + and ++ indicate minor, moderate and strong reaction in the HCl-effervescence test; n.d., not detectable; CEC, cation exchange capacity; MF, mineral fraction; RH, relative humidity; (t) indicates trace 
amounts. 
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Table 2: Correlation matrix of the free zearalenone (ZEN) concentration and the 
physicochemical properties of the 27 mycotoxin binders. 
Parameters 
Free ZEN  
concentration  
pH 2.5 
Free ZEN  
concentration  
pH 6.5 
Free ZEN  
concentration  
pH 8.0 
Average  
free ZEN 
concentration 
Free ZEN  
concentration 
pH 2.5 
R 1 0.887 ** 0.874 ** 0.948 ** 
Sig. - 0.000 0.000 0.000 
Free ZEN 
concentration  
pH 6.5 
R 0.887 ** 1 0.955 ** 0.979 ** 
Sig. 0.000 - 0.000 0.000 
Free ZEN 
concentration  
pH 8.0 
R 0.874 ** 0.955 ** 1 0.976 ** 
Sig. 0.000 0.000 - 0.000 
Average free ZEN 
concentration 
R 0.948 ** 0.979 ** 0.976 ** 1 
Sig. 0.000 0.000 0.000 - 
d-spacing 
R −0.631 ** −0.632 ** −0.659 ** −0.662 ** 
Sig. 0.000 0.000 0.000 0.000 
Swelling 
R 0.090 0.122 0.182 0.137 
Sig. 0.654 0.545 0.364 0.495 
CEC 
R 0.319 0.237 0.266 0.282 
Sig. 0.104 0.234 0.179 0.153 
pH 
R 0.192 0.285 0.357 0.290 
Sig. 0.339 0.149 0.067 0.142 
Ca
2+
 
R 0.257 0.258 0.256 0.266 
Sig. 0.205 0.204 0.207 0.189 
K
+
 
R 0.394 * 0.379 0.360 0.389 * 
Sig. 0.042 0.051 0.065 0.045 
Mg
2+
 
R −0.399 * −0.316 −0.227 −0.321 
Sig. 0.039 0.108 0.254 0.102 
Na
+
 
R 0.302 0.240 0.267 0.278 
Sig. 0.125 0.227 0.178 0.160 
RH 
R 0.082 −0.006 0.055 0.045 
Sig. 0.684 0.977 0.785 0.824 
MF 
R 0.421 * 0.419 * 0.525 ** 0.472 * 
Sig. 0.029 0.030 0.005 0.013 
R: Pearson correlation coefficient; Sig.: significance level; * significant at the 0.05 level (two-
tailed); ** significant at the 0.01 level (two-tailed); CEC, cation exchange capacity; pH, 
acidity of the samples; Ca
2+
, K
+
, Mg
2+
, Na
+
, exchangeable base cations; RH, relative 
humidity; MF, mineral fraction. 
A large variability in free ZEN concentration was observed, ranging from 200 ng/mL, which 
is indicative for no adsorption, to the limit of quantification, which corresponds with 100% 
adsorption under the given conditions. This is in accordance with previous binding 
experiments, where a large variability was also observed (Avantaggiato et al., 2005; Sabater-
Vilar et al., 2007; Yiannikouris et al., 2013). A significant correlation could be demonstrated 
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between the free ZEN concentration and both the d-spacing and mineral fraction (MF). Figure 
2 presents the two biplots of these parameters with the free ZEN concentration. In the low pH 
range (pH 2.5), exchangeable K
+
 and Mg
2+
 were also significantly correlated. The pH may 
influence the phenolic hydroxyl group of ZEN or the ionization-state of the functional groups 
of the mycotoxin binders and thereby alter the chemical sorption due to ionic interactions. A 
low pH can facilitate degradation of the minerals, but this effect is mostly seen over a longer 
period. Deng et al. (2009) described the binding mechanism for aflatoxin B1 (AFB1) to 
montmorillonite clays, a mechanism involving the exchangeable cations and water (Deng et 
al., 2010). The correlation between the d-spacing and the free ZEN concentration suggests a 
cut off-value between 16 and 19 × 10
−10
 m, as can be seen in the left plot in Figure 2. From 
this cut off-value, a similar mechanism might apply for ZEN as for AFB1, explaining the low 
free ZEN concentration in binders expressing a large d-spacing. However, some aspects need 
to be considered: AFB1 has a rather planar structure, which facilitates interlayer adsorption, 
whereas ZEN has a more spherical molecular geometry. Furthermore, AFB1 is more 
hydrophilic than ZEN (estimated log PAflatoxin B1 = 1.58 vs. estimated log PZEN = ca. 4.37 
(Chemaxon, 2013)). This is important, since the interlayer space is hydrophilic (Sposito et al., 
1999).  
  
Figure 2: Biplots of the average free concentration of zearalenone (ZEN) with the d-
spacing (left) and the mineral fraction (right) of the 27 mycotoxin binders (Numbers 1–
27). 
A low free ZEN concentration over the complete pH range was seen with the mixed-layer 
smectites (Sample Numbers 6, 21 and 26), which was also reported by (Avantaggiato et al., 
2005). The exact mechanism for this remains to be elucidated. XRD and infra-red (IR) 
spectroscopy of the binding complex can be used to study the role of the d-spacing and may 
unravel the binding mechanism.  
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The humic acid-containing binders (Sample Numbers 5, 12 and 13) also presented a low free 
ZEN concentration. Similar results were observed in three out of five humic substance 
samples examined by Sabater-Vilar et al. (Sabater-Vilar et al., 2007). Yeast cell wall-derived 
products also expressed a low free ZEN concentration, which was also observed by (Sabater-
Vilar et al., 2007) and (Yiannikouris et al., 2013), but not by (Avantaggiato et al., 2005). A 
high affinity of organic substances for oxytetracycline and AFB1 was described by (Diaz et 
al., 2003; Kulshrestha et al., 2004). The low free ZEN concentration when incubated with 
organic substances can be explained by the additional binding possibilities that these 
substances offer. The extra binding possibilities are hydrophobic in nature and comprise van 
der Waals, π–π and CH-π bonds (Picollo, 1999). Hydrophobic interactions were also 
suggested for the binding of ZEN to modified Japanese acid clay (Sasaki et al., 2014). In 
addition, hydrated humic substances are more flexible than the ridged minerals; this flexibility 
enables a larger interaction surface with the humic substances. These binding possibilities are 
independent of possible interlayer adsorptions and might be a parallel mechanism for toxin 
binding, as can be seen in the right plot of Figure 2. The zeolites and sepiolites expressed a 
rather high free ZEN concentration and are probably not fit for ZEN adsorption. Zearalenone 
was effectively adsorbed by active carbon, and this was also the case in previously published 
studies (Avantaggiato et al., 2005; Sabater-Vilar et al., 2007; Yiannikouris et al., 2013).  
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4  Conclusions 
Twenty-seven frequently-used feed additives and marketed as mycotoxin binders were 
characterized. A single concentration in vitro adsorption screening of ZEN was executed in 
three different PBS-buffers (pH 2.5, 6.5 and 8.0). A significant correlation between free ZEN 
concentration and both the d-spacing and mineral fraction could be demonstrated. In the low 
pH range (pH 2.5), an additional correlation between the exchangeable K
+
 and Mg
2+
 could be 
demonstrated. Humic acid-containing binders and mixed-layered smectite-containing binders 
achieved the lowest free ZEN concentration. 
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Abstract 
Mycotoxin binders are readily mixed in the feed to prevent uptake of mycotoxins by the 
animal. Concerns were raised for non-specific binding with orally administered veterinary 
drugs by the European Food Safety Authority in 2010. This paper describes the screening for 
in vitro adsorption of doxycycline - a broad spectrum tetracycline antibiotic - to six different 
binders that were able to bind more than 75% of the doxycycline. Next, an in vivo 
pharmacokinetic interaction study of doxycycline with two of the binders, which 
demonstrated significant in vitro binding, was performed in broiler chickens using an oral 
bolus model. It was shown that two montmorillonite-based binders were able to lower the area 
under the plasma concentration-time curve of doxycycline with more than 60% compared to 
the control group. These results may indicate a possible risk for reduced efficacy of 
doxycycline when used concomitantly with montmorillonite-based mycotoxin binders. 
 
Keywords: Doxycycline, mycotoxin binder, montmorillonite, in vitro, in vivo, 
pharmacokinetic, broiler chickens 
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1 Introduction 
Mycotoxins are secondary fungal metabolites and are potentially harmful for animals after 
ingestion. They are often detected in feed (Binder, 2007; Streit et al., 2013) and can be 
responsible for economic losses even at subclinical levels (Binder, 2007). Measures such as 
crop rotation, application of fungicides, heat- or chemical treatment and optimal storage are 
often not sufficient to eliminate the production of and the damage caused by mycotoxins, 
hence other methods are used to counteract the effects of mycotoxins (Jard et al., 2011). 
Mixing specialized additives, i.e. mycotoxin detoxifiers, in the feed is nowadays the most 
commonly used method (Kolosova and Stroka, 2011). The mycotoxin detoxifiers can be 
divided in two groups: mycotoxin modifiers and -binders. The modifiers are of 
microbiological origin and aim to transform the chemical structure of mycotoxins into less- or 
non-toxic compounds. Mycotoxin binders aim to adsorb the toxin to their surface in the 
gastro-intestinal tract of the animal, thereby preventing the systemic uptake of the mycotoxin 
(Devreese et al., 2013a). Compounds used as mycotoxin binders are most of all clays, but also 
yeast cell walls and organic humic and fulvic acids, such as leonardite, are used. In a previous 
study (De Mil et al., 2015b), 27 mycotoxin binders commercially available in Belgium and 
The Netherlands were collected and characterized. The clays were mostly smectite clays, e.g. 
montmorillonites/bentonite, but some also contained sepiolites, zeolites, feldspars and kaolins. 
Indeed, 19 of the 27 samples contained montmorillonites, sepiolites or leonardites (Kolosova 
and Stroka, 2011; De Mil et al., 2015b). Besides, montmorillonites are also used because of 
their pellet binding, anti-caking or coagulant properties (EFSA, 2011; Kolosova and Stroka, 
2011). It has been demonstrated that montmorillonite can effectively adsorb the mycotoxin 
aflatoxin B1 (AFB1) both in vitro and in vivo, which prevents the uptake of this mycotoxin in 
the animal (Desheng et al., 2005). The adsorption mechanism is by means of hydrogen bonds 
with exchangeable cations of the clay (Phillips et al., 2006; Deng et al., 2010). These 
mechanisms are deemed to be non-specific and in 2010 the European Food Safety Authority 
(EFSA) stated that next to efficacy testing of mycotoxin binders, also their safety should be 
investigated (EFSA FEEDAP Panel, 2010). Safety concerns the non-specific adsorption of 
vitamins, nutrients and veterinary medicinal products to these clays. Only few literature 
reports have investigated the adsorption of veterinary medicinal products to clays. Interactions 
were reported for the macrolide antibiotics tilmicosin (TIL) (Shryock et al., 1994) and tylosin 
(TYL) (Canadian Bureau of Veterinary Drugs, 1992; Devreese et al., 2012), and for the 
coccidiostats monensin (MON) and salinomycin (SAL) (Gray et al., 1998).  
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Schryock et al. (1994) (Shryock et al., 1994) studied the effectiveness of TIL for prevention 
of airsacculitis in broiler chickens infected with Mycoplasma gallisepticum. A decrease of the 
protective effect of TIL was seen from an inclusion rate of bentonite of 2% onwards. 
Furthermore, the Canadian Bureau of Veterinary Drugs (1992) (Canadian Bureau of 
Veterinary Drugs, 1992) reported a case of lack of efficacy of TYL when concurrently 
administered with bentonite in cattle. Therefore, the EFSA (2012) discourages the 
simultaneous use of bentonite clay with macrolides, coccidiostats and other medicinal 
products (EFSA, 2011). In 2012, Devreese et al. (Devreese et al., 2012) also described the 
interaction between TYL and bentonite in broiler chickens, using a pharmacokinetic (PK) 
approach with single oral bolus administration of TYL whether or not combined with 
bentonite clay. A significant decrease of the area under the plasma concentration-time curve 
(AUC), maximum plasma concentrations (Cmax) and time when Cmax occurs (Tmax) of TYL 
were observed when combined with an inclusion rate of bentonite of 1 g/kg feed. 
Consequently, a relative oral bioavailability (F) of only 23.3% could be calculated for the 
birds receiving TYL+bentonite, compared to 100% in the TYL group alone.  
Next, Gray et al. (1998) (Gray et al., 1998) studied the efficacy of MON and SAL in the 
presence of sodium bentonite. The authors concluded that sodium bentonite could reduce the 
efficacy of MON and SAL but only at levels below the recommended dosages. 
In vitro or in vivo literature data for other clays and/or other mycotoxin binders and for other 
veterinary medicinal products are not available despite the possible risk of binder-drug 
interactions and consequently the reduced efficacy of the drug. In case of antibiotics, not only 
the lack of efficacy is of concern but also the possible increase of antimicrobial resistance due 
to exposure to sub-therapeutic concentrations (Kobland et al., 1987; Levy, 2002; Phillips et 
al., 2004). These concerns were also incorporated in the EFSA recommendations for this class 
of additives (Wache et al., 2009). Besides macrolides, tetracycline antibiotics are frequently 
used in veterinary medicine, more specifically in feed or drinking water medication in pig and 
poultry farming. Doxycycline (DOX) is a broad spectrum, bacteriostatic tetracycline of the 
second generation. It is mainly used in broiler chickens to treat respiratory and systemic 
infections caused by Mycoplasmata, Ornithobacterium rhinotracheale, Avibacterium 
paragallinarum, Pasteurella multocida and Chlamydia spp. (Butaye et al., 1997; Avrain et al., 
2003; Johansson et al., 2004; Cauwerts et al., 2007) and in pigs for respiratory infections 
caused by Actinobacillus pleuropneumoniae, Pasteurella multocida,, Bordetella 
bronchiseptica, Mycoplasma hyorhinis and Streptococcus suis (Pijpers et al., 1989). 
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Therefore, the aim of present study was to evaluate the in vitro adsorption of DOX to four 
montmorillonite and one sepiolite clay, one leonardite-based binder, and including activated 
carbon (AC) as positive control. Next, to confirm and validate the in vitro model, an in vivo 
pharmacokinetic study was performed using oral bolus dosing of DOX and two of the in vitro 
studied mycotoxin binders in broiler chickens. 
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2 Materials and methods 
2.1 Chemicals, solutions and mycotoxin binders 
Sigma-Aldrich (Bornem, Belgium) supplied doxycycline (DOX) hyclate, 
demethylchlortetracycline (DMCTC, used as internal standard), potassium chloride (KCl) and 
phosphoric acid (H3PO4). Water (H2O), methanol (MeOH) and acetonitrile (ACN) used for 
the high performance liquid chromatography (HPLC) analysis and preparation of stock 
solutions were of HPLC-grade and provided by Fisher Scientific (Wijnegem, Belgium). Stock 
solutions of 10 mg/mL were made for DOX and DMCTC in respectively H2O and 
MeOH/H2O (50/50; v/v). Sodium chloride (NaCl), magnesium chloride (MgCl2·6H2O) and 
calcium chloride (CaCl2·2H2O) were supplied by VWR (Leuven, Belgium). Potassium 
dihydrogen phosphate (KH2PO4), disodiumhydrogenphosphate (Na2HPO4), formic acid 
(HCOOH), trifluoroacetic acid (TFA) and sodium hydroxide (NaOH) were obtained from 
Merck (Darmstadt, Germany). Six mycotoxin binders were evaluated and obtained from 
Sigma-Aldrich, Kemin (Herentals, Belgium) and Poortershaven (Rotterdam, The Netherlands) 
(De Mil et al., 2015b), and were identified as ‘montmorillonite number 1, 2, 3 and 4’, 
‘leonardite’ and ‘sepiolite’. Regarding the composition of the evaluated binders, X-Ray 
Diffraction spectrometry (XRD) analysis of montmorillonite 1 indicated montmorillonite as 
the most prevalent mineral, but also the presence of mica, quartz and kaolin was detected, the 
mineral fraction was 97.0%. XRD analysis of montmorillonite 2 indicated mixed layered 
montmorillonite as the most prevalent mineral, but also trace amounts of quartz were 
detected, the mineral fraction was 78.6%. XRD analysis of montmorillonite 3 indicated pure 
montmorillonite as the only mineral, the mineral fraction was 86.8%. Montmorillonite 4 
contained montmorillonite, sepiolite and trace amount of calcite, the mineral fraction was 
92.7%. XRD analysis of the leonardite indicated the presence of humic substance and small 
amounts of quartz. The mineral fraction was less than 16%. The sepiolite contained small 
amounts of a smectite clay, mineral fraction was 96% (De Mil et al., 2015b). AC (Norit 
Carbomix

), used as positive control, was obtained from Kela (Hoogstraten, Belgium) and 
was of pharmaceutical grade and applied in a granulated form. Doxycycline hyclate (Soludox 
15%
®
) used for the in vivo study was supplied by Dechravet (Heusden-Zolder, Belgium). 
2.2 In vitro binding assay 
The protocol used for the in vitro binding assay was adapted from Sabater-Vilar et al. 
(Sabater-Vilar et al., 2007) The main adaptations were the use of Phosphate Buffered Saline 
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(PBS) buffers of two different pH values instead of adjusting the pH during the conduct of the 
experiment. Also the sample preparation, i.e. centrifugation instead of filtering, and 
chromatographic sample analysis differed. PBS was prepared by adding first 24.0 g NaCl, 0.3 
g MgCl2.6H2O, 0.6 g KCl and 0.4 g CaCl2.2H2O to 3 L of HPLC-grade water. Next, a buffer 
system consisting of H3PO4 and KH2PO4, or KH2PO4 and Na2HPO4 was added to 1 L of salt 
solution to obtain a buffer solution of ± 9.6 mM (Sabater-Vilar et al., 2007). The pH was 
adjusted with H3PO4 or NaOH to obtain buffers of pH 2.5 and 6.5, respectively. Five mL of 
the respective PBS at pH 2.5 or 6.5 were added to a 60 mL flask containing 20 mg of the 
respective binder or AC. Finally, DOX hyclate was added to a concentration of 100 µg 
DOX/mL. All samples were prepared and analyzed in triplicate. The ratio DOX/binder of 
1/40 (w/w) corresponds with a dose of 20 mg DOX/kg BW and a feed intake of 80 g/kg BW 
with inclusion of 1% binder. 
The flask was shaken on a lateral shaker (IKA, Staufen, Germany) for 4 h at 37 °C, 180 rpm 
(New Brunswick Scientific, Rotselaar, Belgium). Next, samples were transferred to a 15 mL 
tube and centrifuged (10 min, 524 x g, 4 °C), 100 µL of the supernatant was transferred to an 
Eppendorf cup, supplemented with 50 µL of a 50 µg/mL aqueous solution of DMCTC and 
diluted with HPLC-grade H2O to a volume of 1 mL. After thorough vortex mixing, 100 µL 
was transferred into an autosampler vial and diluted with ACN:H2O 80:20 (v:v) to a final 
volume of 1 mL for further liquid chromatography-tandem mass spectrometric (LC-MS/MS) 
analysis. Negative control samples were included at 10 µg/mL and 100 µg/mL DOX and were 
submitted to the same treatment as the other samples, but without addition of binder. 
2.3  In vivo oral bolus pharmacokinetic study 
Montmorillonite 2 and 3 were selected for further research since montmorillonites are the 
most frequently used mycotoxin binder and because of the high purity of these two 
montmorillonites. Furthermore, montmorillonite 2 differs from montmorillonite 3 in terms of 
Cation Exchange capacity CEC (51.0 cmolc/kg vs. 111.7 cmolc/kg) (De Mil et al., 2015b), 
type of montmorillonite - i.e. mixed layered and normal layered - and mineral fraction. Thirty-
two 14-day-old broiler chickens (Ross 308, as hatched) were randomly divided in four groups 
of eight birds, namely DOX, DOX+AC, DOX+montmorillonite 2 and DOX+montmorillonite 
3. The animals were housed and treated according to European guidelines for animal 
experiments (Council of Europe, 2009). Each group was housed in floor pens of 2 m² covered 
with wood shavings and equipped with a heating lamp. The animals had ad libitum access to 
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feed and drinking water. Temperature and relative humidity were controlled between 15-25 
°C and 40-80% respectively. After 1 week acclimatization, the animals were weighed and 
fasted 12 h before the onset of the experiment. According to their group, the birds received an 
oral intra-crop bolus (2 mL) of tap water for the animals of the negative control group (DOX), 
AC dispersed in 2 mL tap water for the positive control group (DOX+AC) and 
montmorillonite 2 or montmorillonite 3 also dispersed in 2 mL of tap water for the other two 
groups (DOX+montmorillonite 2 and 3, respectively). The montmorillonite and AC dose was 
equivalent with the expected daily intake when 1% (w/w) is included in the feed. Immediately 
after this bolus administration, an oral Soludox 15%
®
 bolus (1 mL) containing 20 mg 
DOX/kg BW in tap water was administered, followed by 1 mL of tap water to flush the tube. 
The ratio DOX/binder was in respect with the in vitro trial, namely 1/40 (w/w). Next, blood 
samples were taken at 0 min (just before administration), 15, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 
12 and 24 hours post-administration (p.a.) of the binder and DOX. Blood samples were 
collected in heparinized tubes, centrifuged (524 x g, 10 min, 4 °C) and plasma was stored at ≤ 
-15 °C until analysis. This experiment was approved by the local Ethical Committee of the 
Faculty of Veterinary Medicine and Bioscience Engineering of Ghent University (case 
number EC 2014/08).  
2.4 Quantification of doxycycline in buffer (in vitro) and in plasma (in vivo) 
The sample preparation for the in vitro buffer samples is presented in the section 2.2 on the in 
vitro binding assay. Sample preparation for plasma samples was as follows: 100 µL of plasma 
was supplemented with 15 µL of TFA, 50 µL of a 10 µg/mL aqueous DMCTC solution and 
50 µL of HPLC water. The sample was vortex mixed for 30 seconds before centrifuging at 
10800 x g for 10 min at room temperature. The supernatant was diluted 5-fold in HPLC water 
before analysis. The HPLC system for all samples consisted of a Waters 2690 pump and 
autosampler (Waters, Milford, USA). Chromatographic separation was achieved on a 
Hypersil Gold column (100 mm x 2.1 mm, particle size 5 µm) and corresponding guard 
column (Thermo Scientific, Erembodegem, Belgium). The mobile phases were A: 0.1% 
HCOOH in H2O; B: 0.1% HCOOH in ACN. Following gradient elution program for the 
samples derived from the in vitro study was applied: 0-2 min: 98% A, 2% B; 2-5.5 min: 40% 
A, 60% B; 5.5-12 min: 98% A, 2% B. The flow rate was set at 0.30 mL/min, 5 µL of sample 
was injected. For the analysis of plasma samples, following gradient was applied: 0-0.3 min: 
95% A, 5% B, 0.3-3.5 min: 10% A, 90% B, 3.5-8.5 min: 70% A, 30% B, 8.5-15 min: 95% A, 
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5% B. The flow rate was set at 0.45 mL/min, a 5 µL aliquot of the sample extract was 
injected. 
The HPLC effluent was interfaced to a Quattro Ultima tandem mass spectrometer 
(Micromass, Manchester, UK). The capillary- and cone voltage were 3.0 kV and 40 V, 
respectively, the source temperature was set at 120 °C and desolvation temperature at 250 °C. 
Cone gas flow and desolvation gas were respectively 101 L/h and 898 L/h. The positive 
electrospray ionization (ESI+) mode was applied, collision energy was optimized to 25 eV for 
both DOX and DMCTC in plasma samples, and 25 and 20 eV for DOX and DMCTC in the 
samples from the in vitro study, respectively. Following selected reaction monitoring (SRM) 
transitions were monitored and used for quantification: m/z 445.0>428.2 for DOX and 
465.0>448.1 for DMCTC. 
The method was validated for DOX in plasma as well as samples from the in vitro study 
according to a validation protocol previously described (De Baere et al., 2011), using matrix 
matched calibration curves. All parameters met the requirements and were in compliance with 
the recommendations and guidelines defined in Directive 2002/32 and Decision 2002/657 
(European Commission, 2002b, a) and with international criteria described in the literature 
(Knecht and Stork, 1974; Heitzman, 1994; U.S. Department of Health and Human Services, 
2015), except for carry-over of DOX on the instrument. A small interfering peak of 0.4% - 
1% area relative to the area of the highest calibrator was detected when injecting a solvent 
sample directly after the highest calibrator, no peaks were detected when injecting solvents 
after the other calibrators. Since the majority of the samples fell below the concentration 
range in which carry-over was expected, no overestimation was present. The limit of 
quantification (LOQ) was 1 µg/mL for PBS at pH 6.5 and 2.5, and 50 ng/mL for plasma. 
Between-run recovery ± standard deviation (SD, n=6) of the quality control samples prepared 
in PBS at pH 2.5 were 10.9 ± 0.5 µg/mL and 94.2 ± 2.2 µg/mL for blank samples spiked at 10 
and 100 µg/mL, respectively. For pH 6.5 the recoveries were 10.4 ± 0.5 µg/mL and 101.3 ± 
3.9 µg/mL. Within-run recovery (n=6) in PBS at pH 2.5 was 10.7 ± 0.2 µg/mL and 95.3 ± 0.2 
µg/mL, whereas in PBS at pH 6.5 the recoveries were 10.1 ± 0.2 µg/mL and 99.8 ± 1.8 
µg/mL. Validation of the analytical method for the plasma samples included blank plasma 
samples spiked at 250 ng/mL (n=6) and 2500 ng/mL (n=6, both within- and between-run), 
between-run recovery was 242.2 ± 4.6 ng/mL and 2518.2 ± 59.8 ng/mL, respectively. For the 
within-run recovery, values of 243.8 ± 5.6 ng/mL and 2460.4 ± 68.1 ng/mL were obtained. 
2.5 Pharmacokinetic analysis 
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A non-compartmental analysis of the DOX plasma concentration-time data was performed to 
determine the pharmacokinetic (PK) characteristics of DOX using WinNonlin 6.3 (Phoenix 
Pharsight, St. Louis, USA). Following main PK variables were determined for each animal: 
Cmax, Tmax, area under the plasma concentration-time curve from time 0 to infinite and 24 h 
(AUC0-inf and AUC0-24h), elimination rate constant (kel), elimination half-life (T1/2el), volume 
of distribution relative to the absolute oral bioavailability (Vd/F) and clearance relative to the 
absolute oral bioavailability (Cl/F). The relative oral bioavailability (relative F) was 
calculated according to following formula:  
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐹 =
𝐴𝑈𝐶0−𝑖𝑛𝑓.,𝐷𝑂𝑋+𝑡𝑒𝑠𝑡𝑒𝑑 𝑏𝑖𝑛𝑑𝑒𝑟
𝐴𝑈𝐶0−𝑖𝑛𝑓.,𝐷𝑂𝑋 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
∗ 100 
2.6 Statistical analysis 
The free DOX concentrations in the in vitro trial were analyzed using a one-way analysis of 
variance (ANOVA), and executed using the statistical package SPSS for Windows (IBM, 
Brussels, Belgium). The PK values for each group in the in vivo study were compared using a 
one-way ANOVA, p-values below 0.05 were considered as statistical significant.  
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3 Results 
Results of the in vitro binding assay are presented in Figure 1. The concentration of DOX in 
the negative control samples at pH 2.5 were 10.6 ± 0.3 and 91.0 ± 1.8 µg/mL for the samples 
spiked at 10 and 100 µg/mL, respectively. For the samples at pH 6.5 the concentration of 
DOX was 11.0 ± 6.8 and 100.3 ± 4.7 µg/mL, respectively. Low free concentrations of DOX 
after incubation are indicative for high adsorption and are seen in all of the tested binders. No 
significant differences were observed between the binders and AC, however, all of the tested 
binders differed significantly (p<0.001) from the negative control samples.  
 
Figure 1: Doxycycline (DOX, 100 µg/mL) was incubated for 4 h at 37 °C with 20 mg of 
one of following binders in 5 mL PBS buffer at pH 2.5 and pH 6.5: activated carbon 
(positive control), leonardite, sepiolite and 4 different montmorrilonites. The free DOX 
concentration (µg/mL) is presented on the left y-axis as average of 3 independent 
measurements + standard deviation (SD). The % adsorption is presented on the right y-
axis. No significant differences were observed between the binders and activated carbon, 
however, all of the tested binders differed significantly (p<0.001) from the negative 
control samples. 
The plasma concentration-time profiles of DOX after single oral bolus administration of the 
tetracycline whether or not combined with one of the binders are presented in Figure 2. Mean 
plasma concentration of DOX in the negative control group reached a first maximum at about 
2.5 h and a second at 6 h. The area under the plasma concentration-time curves of the test 
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groups are clearly lower compared to the control group, and the curves display only one 
maximum at the same time of the second maximum of the control group (at about 6 h). The 
PK parameters of DOX are presented in Table 1. Significant differences between the negative 
control group and test groups can be seen for the AUC0-inf, AUC0-24h and Cmax (p<0.001). The 
absorption rate constant (ka) was calculated using the curve stripping method as described by 
Gabrielsson and Weiner (Gabrielsson and Weiner, 2000). However, variance on the 
calculated ka values did not allow meaningful comparison, therefore, this parameter was 
omitted from Table 1. 
 
Figure 2: Four groups of eight broiler chickens were given an oral bolus containing 
water (negative control), activated carbon (positive control), montmorillonite 2 or 
montmorillonite 3 directly followed by an oral bolus containing doxycycline (DOX) at 20 
mg/kg bodyweight. Plasma concentration-time profiles of DOX are presented as means 
of 8 observations + standard deviation. 
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Table 1: Four Groups of Eight Broiler Chickens Were Given an Oral Bolus Containing 
Water (Negative Control), Activated Carbon (Positive Control), Montmorillonite 2 or 
Montmorillonite 3 Directly Followed by an Oral Bolus of Doxycycline (DOX) at 20 
mg/kg Bodyweight. The Pharmacokinetic Parameters of DOX for the Different Test 
Groups Are Presented as Mean of the Group ± Standard Deviation. 
Parameter Negative control Activated carbon Mont. 2 Mont. 3 
AUC
b
0-inf 
(h·µg/mL) 
57.58±16.37 7.91±4.86 
‡ a
 23.01±5.82 
‡ a
 20.46±6.22 
‡ a
 
AUC
b
0-24h 
(h·µg/mL) 
54.70±13.96 6.99±4.77 
‡ a
 21.73±5.70 
‡ a
 16.98±4.35 
‡ a
 
Relative F (%) 100.00±28.42 13.74±8.43 
‡ a
 40.0±10.10 
‡ a
 35.52±10.80 
‡ a
 
Tmax
c
 (h) 2.84±2.73 0.88±1.28 4.63±2.55 6.00±0.00 
* a
 
Cmax 
d
 (µg/mL) 5.55±1.40 1.16±0.86 
‡ a
 2.14±0.53 
‡ a
 1.56±0.33 
‡ a
 
kel
e
 (1/h) 0.13±0.02 0.14±0.05 0.13±0.02 0.11±0.03 
T1/2el
f
 (h) 8.22±1.51 7.97±2.64 7.82±1.24 9.82±3.20 
Vd/F
g
 (L/kg) 3.05±0.99 30.50±24.21 
* a
 7.20±2.15 10.01±3.06 
Cl/F
h
 (L/h/kg) 0.38±0.12 3.73±2.48 
‡ a
 0.91±0.20 1.09±0.47 
MRT
i
0-inf (h) 8.87±1.16 8.49±2.17 9.02±1.27 12.35±2.62 
* a
 
a
*, 
†
 and 
‡
 indicate significant difference compared to the control at the 0.05, 0.01 and 0.001 
level respectively; 
b
AUC: Area Under the Curve from time 0 to infinity or 24 h; 
c
Tmax: time of 
maximum concentration; 
d
Cmax: maximum concentration; 
e
kel: elimination rate constant; 
f
T1/2el: 
terminal elimination half-life; 
g
Vd/F: distribution volume relative to the absolute oral 
bioavailability; 
h
Cl/F: clearance relative to the absolute oral bioavailability; 
i
Mean Residence 
Time 
 
  
Chapter 2 
85 
 
4 Discussion 
The aim of this study was to investigate the interactions between DOX and different feed 
additives used as mycotoxin binder. Firstly an in vitro adsorption screening study was 
performed. Therefore an in vitro model as reported by De Mil et al. (2015b) (De Mil et al., 
2015b) and based on the model used by Sabater-Vilar et al. (2007) (Sabater-Vilar et al., 
2007), was applied. This model uses PBS at pH’s 2.5 and 6.5, which represent respectively 
the gastric and duodenal pH conditions of monogastric animals. Less than 25% of the initial 
concentration could be detected as free DOX after 4 h of incubation at 37 °C in all groups, 
indicating that the majority of DOX is adsorbed by the additives. Deng et al. (2010) (Deng et 
al., 2010) described the binding mechanism between AFB1 and montmorillonite clays, the 
adsorption is facilitated by the exchangeable cations which form hydrogen bonds with AFB1. 
Along with the exchangeable cations, AFB1 can then be ‘trapped’ between the silicate sheets 
of the montmorillonite and effectively bound. A similar mechanism might apply here since 
DOX has many sites suitable for hydrogen bonding.  
When used as a mycotoxin binder, most recommendations mention an inclusion rate in the 
feed of 0.1 to 0.5% (w/w), however, when used as pelletizing - or binding agent, inclusion 
rates up to 2% are recommended. The ratio DOX/binder of 1/40 (w/w) is representative for 
the in vivo application of both substances when considering a clay inclusion rate of 1% (w/w), 
this ratio was the same in both the in vitro and the in vivo trial.  
The in vitro models used for the assessment of the efficacy include static (Vekiru et al., 2007; 
Devreese et al., 2013b) and dynamic (Ramos and Hernandez, 1996a; Avantaggiato et al., 
2003) gastro-intestinal (GI)-models, construction of adsorption isotherms (Ramos and 
Hernandez, 1996b) and single concentration studies (Sabater-Vilar et al., 2007). Although the 
simple setup in this study cannot provide the same information as the complex dynamic- and 
isotherm models, by using representative buffers and binder-drug ratio’s, this setup still can 
provide relevant information regarding the safety of the feed additives which can be directly 
extrapolated to the in vivo situation. To verify the latter, in vivo experiments have to be 
carried out. An in vivo oral bolus model was applied to study the interactions from a PK 
perspective (Devreese et al., 2012), this is in accordance with EFSA guidelines for the safety 
testing of these group of additives (EFSA FEEDAP Panel, 2010). Concerning the DOX PK 
parameters in the negative control group, the reported T1/2,el are between 5.69 h (El-Gendi et 
al., 2010) and 7.93 h (Ismail and El-Kattan, 2004) in broiler chickens, whereas this study 
found a T1/2,el of 8.22 h which can be considered to be in the same range. The reported Tmax, 
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Cmax and AUC0-inf values for most references are also in the same range as found for the 
control group in this study, namely between 1.73 h (Laczay et al., 2001) and 2.9 h (Gutierrez 
et al., 2012) for Tmax, between 3.18 µg/mL (El-Gendi et al., 2010) and 7.84 µg/mL (Ismail and 
El-Kattan, 2004) for Cmax and between 39.84 µg·h/mL (El-Gendi et al., 2010) and 97.6 
µg·h/mL (Ismail and El-Kattan, 2004) for AUC0-inf. The appearance of a second maximum in 
the plasma concentration-time profile is likely to be due to an enterohepatic recycling, this 
means excretion of DOX from the blood to the gastro-intestinal lumen by both hepatic/biliary 
or direct passive unionized diffusion from blood to gut, followed by reabsorption. This 
phenomenon, seen for most tetracyclines, has been described for many species such as pigs 
(Riond and Riviere, 1990), humans (Gibaldi, 1967) and sheep (Castro et al., 2009). 
Pharmacokinetic analysis of DOX of the test groups clearly indicates that AUC0-inf and Cmax 
are decreased when AC or the tested montmorillonites are used simultaneously with DOX. 
Table 1 shows a somewhat delayed Tmax of DOX in the montmorillonite test groups. 
However, this Tmax coincides with the second absorption maximum of DOX in the control 
group (Figure 2), which indicates that this shift is rather due to the absence of the first 
maximum than a delayed absorption. Differences in Vd/F and Cl/F can be explained by a 
difference in bioavailability although the latter cannot be calculated with the given data. As 
expected, no differences in elimination kinetics were seen, since kel and T1/2el were similar in 
both control and test groups. The 60% decrease in AUC0-24h in the test groups results in a 
lower AUC/Minimal Inhibitory Concentration (MIC) ratio, which is of major importance for 
the clinical outcome (Hesje et al., 2007). Therefore, a decrease in treatment efficacy can be 
expected since a decrease in oral bioavailability F is linearly correlated to a decrease in AUC 
(Gabrielsson and Weiner, 2006) and therefore also to the AUC/MIC ratio. Antimicrobials for 
which the efficacy depends on the time the plasma concentration is above the MIC, such as 
TYL, might even be more sensitive to a decrease in oral bioavailability since the time above 
MIC decreases in a logaritmic manner in function of F. Moreover, sub-therapeutic 
concentrations of tetracyclines can induce microbial resistance (Phillips et al., 2004). This 
interaction is in line with previously reported interactions of montmorillonite-based feed 
additives with the macrolides TIL (Shryock et al., 1994) and TYL (Devreese et al., 2012) in 
broiler chickens.  
Based on the in vitro adsorption and in vivo pharmacokinetic results, it can be concluded that 
AC and the tested montmorillonite clays can substantially diminish the oral absorption of 
DOX in broiler chickens and this is most likely due to the adsorption of DOX to the clay 
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additives. Therefore, in case DOX is orally administered to chickens that are also fed 
montmorillonite-based feed additives, a possible interaction needs to be carefully considered. 
Further research is needed to investigate the safety of other additives when used 
simultaneously with other veterinary medicinal products. 
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Abstract 
The presence of mycotoxins in broiler feed can have deleterious effects on the wellbeing of 
the animals and their performance. Mycotoxin binders are feed additives which aim to adsorb 
mycotoxins in the intestinal tract and thereby preventing the oral absorption of the mycotoxin. 
Coccidiostats are also feed additives frequently administered to poultry and antimicrobials are 
given as oral mass medication in the poultry industry as well. If the binding of mycotoxin 
binders is non-specific, the simultaneous administration of coccidiostats and/or antimicrobials 
with mycotoxin binders can lead to a reduced oral bioavailability of these veterinary 
medicinal products. This paper describes the influence of four mycotoxin binders on the oral 
bioavailability and pharmacokinetic parameters of the antimicrobials doxycycline and tylosin, 
and the coccidiostats diclazuril and salinomycin. A feeding study was performed which 
evaluates the long-term effects of feeding 2 g mycotoxin binder/kg feed on the possible 
interactions and can therefore be considered as an approximation of the field situation. No 
interactions were observed between any of the mycotoxin binders and the coccidiostats, 
whereas a trend but no significant interactions could be noticed between some mycotoxin 
binders and the antimicrobials doxycycline and tylosin.  
Keywords: Mycotoxin binders, antimicrobials, coccidiostats, broiler chickens, 
pharmacokinetics, oral bioavailability 
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1 Introduction 
Mycotoxins are secondary fungal metabolites frequently contaminating feed which can be 
acute toxic at high doses, whereas chronic exposure to lower contamination levels can result 
in poor animal performance and consequent economical damage (Binder, 2007). It is 
estimated that in the USA Fusarium mycotoxins may cause damage equivalent to 20 million 
US dollars each year (Wu, 2007). Because of a high prevalence of Fusarium mycotoxins in 
cereal based feed, pigs and poultry are frequently exposed to these toxins (Binder et al., 2007; 
Streit et al., 2013). Special feed additives, called mycotoxin detoxifiers, are frequently used in 
the pig and poultry industry to counter the deleterious effects of mycotoxins (EFSA FEEDAP 
Panel, 2010). Based on their mode of action, two categories can be distinguished, namely 
mycotoxin modifiers and mycotoxin binders (Jard et al., 2011). Mycotoxin modifiers aim to 
alter the chemical structure of the mycotoxin into chemical entities that are less or non-toxic. 
To date, all the modifiers available on the market (registered in Annex I of Regulation 
1831/2003) are of microbiological origin and comprise extracted enzymes or whole cultures 
of yeasts or bacteria (European Commission, 2015). Mycotoxin binders aim to form non-
resorbable complexes with mycotoxins in the intestinal tract of the animal, making them 
unavailable for absorption. Most mycotoxin binders contain clay minerals but also yeast based 
products are often used. The clays used as mycotoxin binders are mostly smectites (De Mil et 
al., 2015b), e.g. montmorillonites, which are the main constituents of bentonite. The 
maximum amount of bentonite allowed for aflatoxin B1 detoxification mentioned in 
Reguation 1060/2013 is 20 g/kg complete feed for ruminants, poultry and pigs (European 
Commission, 2013a), however, the inclusion rate that is applied usually varies between 1 and 
2.5 g/kg complete feed. Total amounts of bentonite can reach higher levels than 1-2.5 g/kg 
because bentonite can also be used for other purposes such as pelletizing agents or to improve 
the rheological properties of feed (anticaking agent). The total amount of bentonite in 
complete feed is limited to 20 g/kg, with provision to indicate in the instructions for use that 
the simultaneous oral use with macrolides shall be avoided in any animal species, and that in 
poultry the simultaneous use with robenidine shall be avoided and the simultaneous use with 
other coccidiostats is contraindicated with a level of bentonite above 5 g/kg of complete feed 
(European Commission, 2013a).  
Besides mycotoxin detoxifiers, coccidiostats and antimicrobials can also be mixed in the feed 
of broiler chickens, hence, antimicrobials/coccidiostats and mycotoxin binders may be 
simultaneously present in the intestinal tract and the mycotoxin binders might therefore 
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interact with the oral absorption of antimicrobials/coccidiostats. A number of cases of such 
interactions have been described previously. In 1992, the Canadian Bureau of Veterinary 
Drugs reported a case of lack of efficacy of tylosin (TYL) in cattle fed a bentonite 
supplemented feed (Canadian Bureau of Veterinary Drugs, 1992). Next, a decreased efficacy 
of tilmicosin (TIL) against airsacculitis was demonstrated in chickens when 2% bentonite was 
included in the feed (Shryock et al., 1994). In 1998, Gray et al. demonstrated that bentonite 
reduced the growth-promoting effect of the coccidiostats monensin and salinomycin (SAL) in 
broilers, but only when the coccidiostats were used below the recommended doses (Gray et 
al., 1998). In 2010, the European Food Safety Authority (EFSA) stated that the safety of 
mycotoxin binders regarding non-specific binding of oral veterinary drugs needs to be 
investigated (EFSA FEEDAP Panel, 2010). Devreese et al. (2012) investigated the oral 
bioavailability and pharmacokinetics (PK) of TYL in fasted broilers after a single oral bolus 
administration of TYL or TYL together with bentonite (1 g/kg feed). A relative oral 
bioavailability of 23.3% of TYL was observed in the test group receiving TYL together with 
bentonite (Devreese et al., 2012). In 2015, De Mil et al. performed a similar study using 
doxycycline (DOX) and bentonite clays in fasted broilers (10 g/kg feed) and obtained similar 
results (De Mil et al., 2015a). This indicates that interactions between mycotoxin binders and 
coccidiostats and/or antimicrobials can occur, although further studies on this subject are 
limited. In contrast to a reduced oral absorption, elevated plasma concentrations were seen 
after oral bolus administration of oxytetracycline to broilers that were fed a bentonite 
supplemented diet (1.5 g/kg feed) for 3 weeks (Osselaere et al., 2012). Alterations in the gut 
wall barrier function and surface area might explain the higher absorption of oxytetracycline 
(Osselaere et al., 2013c). Another reason might be the scavenging of bivalent ions by the 
mycotoxin binders which would otherwise form non-resorbable complexes with tetracyclines. 
To the authors knowledge, no studies for other veterinary medicinal products and mycotoxin 
binders in poultry have been published. Moreover, the published PK studies exhibit important 
discrepancies with the field situation such as solely acute or long term exposure to the 
mycotoxin binder, absence of feed or use of different inclusion rates.  
This study aims to describe the influence of several mycotoxin binders on the oral 
bioavailability and PK properties of two antibiotics, TYL and DOX and two coccidiostats, 
diclazuril (DIC) and SAL, in broiler chickens. Mycotoxin binders were mixed in the feed and 
fed for 2 weeks, a setup that relates better to the field situation than previously described 
single bolus administration of binders in fasted broilers.  
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2 Materials and methods 
2.1 Chemicals, mycotoxin binders and reagents 
Activated carbon (Norit Carbomix

, AC) was purchased from Kela Pharma (Herentals, 
Belgium), and three mycotoxin binders were obtained from European wholesalers. The 
mycotoxin binders were labelled as Clay 1, Clay 2 and Yeast 1. Clay 1 contains 
montmorillonite, mica and feldspars, has a d-spacing of 12.3·10
-10
 m, a cation exchange 
capacity (CEC) of 7.0 cmolc/kg, a mineral fraction of 94.8% (m:m) and relative humidity of 
5.2% (m:m). Clay 2 is a mixed layered montmorillonite and quartz, it has a d-spacing of 
19.1·10
-10
 m, a CEC of 51.0 cmolc/kg, a mineral fraction of 78.6% (m:m) and a relative 
humidity of 3.4% (m:m) (De Mil et al., 2015b). Yeast 1 is a modified glucomannan fraction 
of inactivated yeast cells. 
DOX (Soludox 15%
®
, 150 mg doxycycline hyclate/g ) was provided by Dechravet (Heusden-
Zolder, Belgium), TYL (Tylan 100 Granules
®
, 100 mg tylosin phosphate/g) and DIC 
(Vecoxan
®
 2.5 mg diclazuril/mL oral suspension) were purchased from Elanco Animal Health 
(Brussels, Belgium), and SAL (Sacox 120
® 
microGranulate, 120 mg salinomycine sodium/g) 
was kindly donated by Huvepharma (Antwerp, Belgium). Water, methanol (MeOH), and 
acetonitrile (ACN) used for the analytical experiments and preparation of stock solutions were 
of high-performance liquid chromatography (HPLC)-grade and purchased from Fisher 
Scientific (Wijnegem, Belgium). 
Analytical standards of DOX, TYL, DIC, SAL and the internal standards (IS) 
demethylchlortetracycline (DMCTC), valnemulin (VAL), methyldiclazuril (MeDIC) and 
nigericine (NIG), were purchased from Sigma-Aldrich (Bornem, Belgium). Stock solutions of 
10 mg/mL were made in MeOH and stored at ≤ -15 °C. They were appropriately diluted in 
MeOH to obtain working solutions and stored at ≤ -15 °C. Trifluoroacetic acid (TFA) and 
hydrochloric acid (HCl) were purchased from Sigma-Aldrich. 
2.2 Experimental design 
Forty 15-days-old broilers (Ross 308, as hatched) were randomly divided in 5 groups of 8 
animals, namely 1 control group and 4 test groups. They were housed in concrete floor pens 
of 2 m² covered with wood shavings. The animals had ad libitum access to feed and drinking 
water. Temperature and relative humidity were controlled between 15-25 °C and 40-80% 
respectively, the light regime was 6 hours of darkness and 18 hours of light. Housing 
conditions were in accordance to European Directive 2010/63 regarding housing of 
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experimental animals (European Commission, 2010). The feed was wheat based 
commercially available feed, it was finely grinded and contained following ingredients: wheat 
(59.49%), high protein soybean meal (17.70%), corn (8.00%), vegetable oil (5.80%), soy 
beans (5.00%) and premixed supplements (4.01%). The feed was analyzed for mycotoxin 
content using a multi–mycotoxin LC-MS/MS method adapted from Monbaliu et al. 
(Monbaliu et al., 2009), the method included deoxynivalenol (DON) and acetylated forms (3- 
and 15-acetylDON), zearalenone, aflatoxins (aflatoxins B1, B2, G1 and G2), sterigmatocystin, 
fumonisins (B1, B2 and B3), T2-toxin, HT2-toxin, ochratoxin A, fusarenon-X, nivalenol, 
diacetoxyscirpenol, neosolaniol, altenuene, alternariol, alternariol methyl ether, 
fumigaclavine, enniatine B1, paxilline and roquefortine-C. Four test diets were prepared by 
supplementation of the feed with AC, Clay 1, Clay 2 or Yeast 1 at the conventional dose of 2 
kg per ton of feed (0.2%), respectively. This mixing was done manually according to 
geometrical mixing procedure as previously described (Earle and Earle, 1983). The control 
(no binder) and test diets were fed to the control and test groups, respectively, for 15 days. 
Next, both the control and each test group were administered 4 veterinary medicinal products 
consecutively, respecting a wash-out period of 2-3 days between each administration. The 4 
veterinary medicinal products were dosed using a single bolus administration directly in the 
crop, following order was applied: DOX, TYL, DIC and SAL. The night before each 
administration, 10 h of darkness was applied and 1 h before administration of the bolus, lights 
were turned on to ensure that the animals were in a fed state before administration of the 
antimicrobials or coccidiostats. The animals from the test groups also received a bolus 
containing the daily dose of binder, this was calculated using an average of 80 g feed intake 
per kg bodyweight (BW) each day. The animals from the control group received tap water. 
Immediately after the bolus containing the binder or water, a bolus containing the daily dose 
of veterinary medicinal product (DOX or TYL: both 20 mg/kg BW) or coccidiostat (DIC: 80 
µg/kg BW or SAL: 4.8 mg/kg BW) was given to the animals. Blood samples were taken from 
the leg vein (vena metatarsalis plantaris superficialis) at 0 h (just before administering the 
bolus), 1, 2, 3, 4, 6 and 8 h post administration (p.a.) for TYL and DOX. For DIC and SAL, 
samples were taken at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6 and 8 h p.a. Plasma was collected by 
centrifugation and samples were stored at ≤ -15 °C until analysis. A scheme of the actions 
taken is presented in table 1.  
The animals were euthanized after the experiment by intravenously injecting a lethal dose of 
sodium pentobarbital (Kela Pharma), the experiments were approved by the ethical committee 
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of the Faculty of Veterinary Medicine and the Faculty of Bioscience Engineering of Ghent 
University (approval number: EC 2014/166).  
 
Table 1: Scheme listing the different actions taken in the experiment. 
Day (and 
time) of the 
experiment 
Action 
0  Randomly allocate animals to one of the five experimental groups: 
Control, AC, Clay 1, Clay 2, Yeast 1 
0-15  Provide feed supplemented with: nothing (control), AC, Clay 1, Clay 
2 or Yeast 1, ad libitum, inclusion rate of additives: 2 g/kg feed 
15 (18:00h)  Weighing and preparing boli of DOX and binder according to 
bodyweight  
16 (7:00h)  Lights turned on and feed trough refilled  animals gobble on newly 
supplemented feed 
16 (8:00h)  Bolus of DOX and binder was given to each animal of all groups, 
blood samples were taken at regular time points for the next 8 h 
17-19  Recovery 
19 (18:00h)  Weighing and preparing boli of TYL and binder according to 
bodyweight  
20 (7:00h)  Lights turned on and feed trough refilled  animals gobble on newly 
supplemented feed 
20 (8:00h)  Bolus of TYL and binder was given to each animal of all groups, 
blood samples were taken at regular time points for the next 8 h 
21-23  Recovery 
23 (18:00h)  Weighing and preparing boli of DIC and binder according to 
bodyweight  
24 (7:00h)  Lights turned on and feed trough refilled  animals gobble on newly 
supplemented feed 
24 (8:00h)  Bolus of DIC and binder was given to each animal of all groups, 
blood samples were taken at regular time points for the next 8 h 
25-27  Recovery 
2 (18:00h)  Weighing and preparing boli of SAL and binder according to 
bodyweight  
28 (7:00h)  Lights turned on and feed trough refilled  animals gobble on newly 
supplemented feed 
28 (8:00h)  Bolus of SAL and binder was given to each animal of all groups, 
blood samples were taken at regular time points for the next 8 h 
29  Euthanasia of the animals and necropsy 
 
2.3 Analytical methods 
DOX: An aliquot of 100 µL of plasma was supplemented with 50 µL of the IS working 
solution of 10 µg/mL DMCTC and thoroughly vortex mixed. Next, 15 µL of TFA and 50 µL 
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of HPLC-grade water were added and the tube was vortex mixed. The sample was centrifuged 
for 10 min at 10,800 x g (Allegra X-15R centrifuge, Beckman Coulter; Suarlée, Belgium). 
Two hundred µL of the supernatant was transferred to a glass vial and supplemented with 800 
µL of HPLC-grade water, vortex mixed and injected onto the HPLC– tandem mass 
spectrometry (MS/MS) system. The LC system consisted of a Waters 2695 quaternary solvent 
pump and autosampler (Waters, Milford, USA). The effluent was analysed by the Quattro 
Ultima (Waters) MS/MS. The chromatographic conditions are presented in Table 2 and the 
MS parameters are displayed in Table 3.  
TYL: To 100 µL of plasma, 25 µL of a working solution of the IS (25 µg/mL VAL) was 
added. After vortex mixing, 100 µL of ACN was added and the sample was vortex mixed 
again before centrifugation as described above. The supernatant was filtered through a 0.2 µm 
Millex-GN nylon filter (Filter Service, Eupen, Belgium) into an autosampler vial for injection 
onto the LC-MS/MS system. The LC-MS/MS system was the same as described for DOX. 
The chromatographic conditions are presented in Table 2 and the MS parameters are 
displayed in Table 3.  
DIC: An aliquot of 100 µL of plasma was spiked with 50 µL of the IS working solution (1 
µg/mL MeDIC). Next, 100 µL of a 0.5% HCl solution in ACN was added followed by vortex 
mixing. Next, the samples were centrifuged as described above and the supernatant was 
filtered through a Millex-GV PVDF 0.22 µm filter (Filter service) into an autosampler vial. 
The UPLC system consisted of a Acquity binary solvent manager (Waters) and an Acquity 
sample manager (Waters). The detector was a Quattro Premier XE (Waters) tandem MS. The 
chromatographic conditions as presented in Table 2 and the MS parameters are displayed in 
Table 3.  
SAL: An aliquot of 100 µL of plasma was supplemented with 25 µL of an IS working 
solution containing 20 µg/mL NIG. After vortex mixing, 100 µL of ACN was added and the 
sample was vortex mixed again before centrifugation as described above. The supernatant was 
filtered through a 0.2 µm Millex-GN nylon filter (Filter service) into an autosampler vial and 
was injected onto the UPLC-MS/MS system. The UPLC system was the same as described 
for DIC. The chromatographic conditions are presented in Table 2 and the MS parameters are 
displayed in Table 3. 
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Table 2: Chromatographic conditions for the analysis of doxycycline (DOX), tylosin 
(TYL), diclazuril (DIC) and salinomycin (SAL) in broiler plasma. 
Medicinal 
product 
Column 
Inject 
volume 
(µL) 
Mobile phase Gradient 
Flow rate 
(mL/min) 
DOX 
Hypersil Gold
®
, 
Thermo, 100 x 2.1 
mm, 5 µm particle 
size; 
corresponding 
guard column 
 
5 
A: 0.1% 
HCOOH in 
H2O 
B: 0.1% 
HCOOH in 
ACN 
0-0.3 min: isocratic 95% A, 
5% B; 0.3-3.5 min: isocratic 
10% A, 90% B; 3.5-7.5 min: 
isocratic 70% A, 30% B; 
7.5-15 min: isocratic to 95% 
A, 5% B. 
0.45 
TYL 10 
A: 0.01 M 
CH3COONH4 
in H2O, pH 
3.5 using 
glacial acetic 
acid. 
B: ACN. 
0-0.5 min: isocratic 90% A, 
10% B; 0.5-8 min: linear to 
10% A, 90% B; 8-9.5 min: 
isocratic 10% A, 90% B; 9.5 
to 10 min: linear to 90% A, 
10% B; 10-20 min: isocratic 
90% A, 10% B. 
0 to 9.5 min: 
0.20; 9.5 to 9.6 
min: linear to 
0.5; 9.6 to 16.7 
min: 0.5; 16.7 to 
16.8 min: linear 
to 0.2; 16.8 to 
17 min: 0.2 
DIC Acquity UPLC 
BEH C18
®
, 
Waters, 50 mm x 
2.1 mm, 1.7 µm 
particle size; 
corresponding 
guard column 
 
5 
A: ACN 
B: 0.1% 
HCOOH in 
H2O 
0-3 min: 5% A, 95% B, 
linear to 30% A, 70% B; 3-
3.5 min: linear to 90% A, 
10% B; 3.5-4 min: isocratic 
90% A, 10% B; 4-4.1 min: 
linear to 5% A, 95% B; 4.1-
7 min, isocratic 5% A, 95% 
B. 
0.30 
SAL 5 
A: ACN 
B: 0.1% 
HCOOH in 
H2O 
0-0.5 min: isocratic 90% A, 
10% B; 0.5-1.5 min: linear 
to 1% A, 99% B; 1.5-5.0 
min: isocratic 1% A, 99% B; 
5.0- -5.5 min: linear to 10% 
A, 90% B; 5.5-10 min: 
isocratic 90% A, 10% B. 
0 to 1.5 min: 
0.15; 1.5-5.0 
min: 0.3; 5-10 
min: 0.15 
DOX: doxycycline; TYL: tylosin; DIC: diclazuril; SAL: salinomycine; ACN: acetonitrile; HCOOH: formic 
acid; CH3COONH4: ammonium acetate 
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Table 3: Mass spectrometric parameters for the analysis of doxycycline (DOX), tylosin 
(TYL), diclazuril (DIC) and salinomycin (SAL) in broiler plasma. 
Compound 
m/z 
transitions 
for 
quantificatio
n 
ESI 
mode 
Collisio
n 
energy 
(eV) 
Capp. 
Volt. 
(kV) 
Cone 
volt. 
(V) 
Cone 
gas 
flow 
(L/h) 
Desolv. 
gas 
flow 
(L/h) 
DOX 445.0>428.2 + 25 3.0 40 101 895 
DMCTC (IS) 465.0>448.1 + 20 3.0 30 101 895 
TYL 915.9>174.7 + 35 3.0 100 23 838 
VAL (IS) 564.6>263.5 + 20 3.0 100 23 838 
DIC 406.9>335.7 - 20 3.5 60 87 899 
MeDIC (IS) 420.9>322.8 - 26 3.5 50 87 899 
SAL 773.1>431.3 + 50 3.0 55 101 896 
NIG (IS) 747.1>703.5 + 60 3.0 55 101 896 
IS: internal standard; eV: electronvolts; V: volts  
Method validation The analytical methods were validated for both coccidiostats and both 
antimicrobials in plasma according to a validation protocol previously described by De Baere 
et al. using matrix matched calibration curves (De Baere et al., 2011). All parameters met the 
requirements and were in compliance with the recommendations and guidelines defined in 
Directive 2002/657 (European Commission, 2002b) and with international criteria described 
in the literature (Knecht and Stork, 1974; Heitzman, 1994; U.S. Department of Health and 
Human Services, 2015). The results of the validation procedure are presented in Table 4.  
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Table 4: Validation parameters for the analytical methods for doxycycline (DOX), 
tylosin (TYL), salinomycin (SAL) and diclazuril (DIC) in broiler plasma. 
 
Linearity: 
Range (ng/mL) 
Pearson 
correlation 
Goodness of fit 
(%) 
Limit of 
Detection 
(ng/mL) 
Quality 
control 
(ng/mL) 
Accuracy and precision 
within day 
mean ± SD 
(n=6) (ng/mL) 
between day 
mean ± SD 
(n=6) (ng/mL) 
DOX 
(De Mil 
et al., 
2015a) 
50-7500 
>0.99 
3.11% 
10.54 
50 (LOQ) 
51.2 ± 2.4 
(102.4±4.8%) 
/ 
250 
243.8 ± 5.6 
(97.5±2.2%) 
242.2 ± 4.6 
(96.9±1.8%) 
2500 
2460.4 ± 68.1 
(98.4±2.7%) 
2518.2 ± 59.8 
(100.7±2.4%) 
TYL 
25-1000 
>0.99 
3.80% 
1.62 
25 (LOQ) 
25.1 ± 1.3 
(100.4±5.2%) 
/ 
50 
52.0 ± 3.8 
(104.0±7.6%) 
54.5 ± 11.43 
(109.0±22.8%) 
500 
498 ± 43.8 
(99.6±8.8%) 
511 ± 45.7 
(102.2±9.1%) 
DIC 
5-10000 
>0.99 
11.75% 
0.97 
5 (LOQ) 
3.7 ± 0.5 
(74.0±10.0%) 
/ 
100 
95.4 ± 5.7 
(95.4±5.7%) 
102.3 ± 6.6 
(102.3±6.6%) 
2500 
2367.4 ± 220.7 
(94.7±8.8%) 
2519.5 ± 154.8 
(100.7±6.2%) 
SAL 
5-1000 
>0.99 
9.6% 
0.11 
5 (LOQ) 
5.5 ± 0.3 
(110.0±6.0%) 
/ 
50 
54.0 ± 1.4 
(108.0±2.8%) 
51.6 ± 1.8 
(103.2±3.6%) 
500 
518.6 ± 34.3 
(103.7±6.9%) 
467.5 ± 29.1 
(93.5±5.9%) 
LOQ: limit of quantification; SD: standard deviation 
2.4 Pharmacokinetic and statistical analysis 
Non-compartmental PK analysis was performed using WinNonlin
®
 version 6.3 (Phoenix 
Pharsight, St. Louis, USA) and following PK parameters were calculated: area under the 
plasma concentration-time curve from time 0 to last sampling point and to infinity (AUC0-8h 
and AUC0-inf, respectively), maximum plasma concentration (Cmax), time to maximum plasma 
concentration (Tmax), elimination rate constant (kel), elimination half-life (T1/2el), volume of 
distribution scaled for the absolute oral bioavailability (Vd/F), and clearance scaled for the 
absolute oral bioavailability (Cl/F). The relative oral bioavailability of DOX, TYL, DIC and 
SAL (relative F) of the test groups was calculated as follows: 
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𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐹 =  
𝐴𝑈𝐶0−8ℎ,+𝑡𝑒𝑠𝑡𝑒𝑑 𝑏𝑖𝑛𝑑𝑒𝑟
𝐴𝑈𝐶̅̅ ̅̅ ̅̅ 0−8ℎ,𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝
× 100 
The effect of the different mycotoxin binders (AC, Clay 1, Clay 2 and Yeast 1) on the PK 
parameters was assessed using a one-way analysis of variance (ANOVA) using SPSS v22 
(IBM, Brussels, Belgium) with a Bonferroni-corrected LSD post-hoc test. Significance levels 
(p) below 0.05 were considered significant. 
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3 Results 
The feed contained following mycotoxins: nivalenol: 140 µg/kg, deoxynivalenol: 234 µg/kg, 
zearalenone: 327 µg/kg. No other mycotoxins were detected above the limit of detection 
(LOD; as previously described (Monbaliu et al., 2009)). The plasma concentration-time 
profiles of DOX, TYL, DIC and SAL are presented in Figure 1.  
 
Figure 1: Plasma concentration-time profiles of doxycycline (DOX), tylosin (TYL), 
diclazuril (DIC) and salinomycin (SAL). Broiler chickens of the test groups were fed for 
two weeks with feed supplemented with 0.2% of one of the mycotoxin binders: activated 
carbon (AC), clay 1, clay 2 or yeast 1. The control group received no binder. Next, the 
control and test groups received a bolus containing water and the daily dose of 
mycotoxin binder, respectively, immediately followed by a bolus containing the daily 
dose of DOX, TYL, DIC or SAL for both the control group and test groups, at the 
recommended daily dose. Results are presented as mean + or - SD (n=8).  
The PK parameters of all compounds are presented in Table 5. The control group of DOX 
exhibits a mean Cmax and a mean AUC0-inf which are 45% and 70% lower respectively than 
previously reported for fasted broilers (De Mil et al., 2015a). The parameters kel and T1/2el are 
in the same range. The AUC0-inf is significantly lower in the test groups compared to the 
control group, however discrepancy between AUC0-inf and AUC0-8h exceeded 20%, therefore 
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the AUC0-8h was preferred for interpreting bioavailability (Toutain and Bousquet-Melou, 
2004). No differences in other PK parameters nor in oral bioavailability could be noted.  
The control group of TYL also expressed lower plasma concentrations compared to 
previously reported values of TYL administered to fasted animals (Devreese et al., 2012). 
Although the average Cmax and AUC0-inf in the Clay 1, Clay 2 and Yeast 1 group appear lower, 
no significant differences were demonstrated. Significant differences for T1/2el and Vd/F were 
noted for the Yeast 1 group when compared to the control group, Cl/F of the Clay 1 group 
differed significantly from the control group, although large interanimal variability can be 
seen.  
The absorption of DIC was slow, reaching mean levels of 14.57 ± 3.23 ng/mL (mean ± SD, 
n=8) after 6 to 8 h. Only AUC0-8h, Cmax and Tmax could be calculated for DIC. For the 
coccidiostats DIC and SAL, no significant differences could be demonstrated between the test 
groups and the control group. 
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Table 5: Pharmacokinetic parameters of doxycycline (DOX), tylosin (TYL), diclazuril 
(DIC) and salinomycin (SAL). Broiler chickens of the test groups were fed for two weeks 
with feed supplemented with one of the mycotoxin binders: activated carbon (AC), clay 
1, clay 2 or yeast 1. The control group received no binder. Next, the control and test 
groups received a bolus containing water and the daily dose of mycotoxin binder, 
respectively, followed by a bolus containing the daily dose of DOX, TYL, DIC or SAL 
for both the control group and test groups, at the recommended daily dose. Results are 
presented as mean ± SD (n=8). 
 Parameter Control AC Clay 1 Clay 2 Yeast 1 
D
O
X
 
AUC0-8h (h·µg/mL) 16.07 ± 2.12 11.56 ± 4.74 11.20 ± 3.41 13.35 ± 2.99 10.75 ± 4.0 
AUC0-inf (h·µg/mL) 28.64 ± 6.98 
 
17.03 ± 5.71* 17.95 ± 6.02* 18.40 ± 4.87* 17.60 ± 6.42* 
Relative F (%) 100.00 ± 13.18 71.94 ± 29.52 69.71 ± 21.22 83.10 ± 18.63 66.94 ± 24.98 
Tmax (h) 1.75 ± 1.16 1.88 ± 0.83 1.75 ± 0.89 1.75 ± 0.89 2.63 ± 0.74 
Cmax (µg/mL) 3.07 ± 0.70 2.45 ± 1.32 2.07 ± 0.67 2.74 ± 0.89 1.95 ± 0.75 
kel (1/h) 0.12 ± 0.03 0.16 ± 0.05 0.15 ± 0.04 0.18 ± 0.04 0.14 ± 0.04 
T1/2el (h) 9.41 ± 4.76 6.92 ± 1.82 7.33 ± 2.98 5.87 ± 1.28 7.96 ± 3.56 
Vd/F (L/kg) 6.36 ± 1.52 9.25 ± 4.34 8.90 ± 4.20 6.54 ± 1.30 11.04 ± 9.54 
CL/F (L/h/kg) 0.73 ± 0.15 1.32 ± 0.51 1.29 ± 0.62 1.15 ± 0.26 1.29 ± 0.51 
T
Y
L
 
AUC0-8h (h·ng/mL) 377.13 ± 185.57 392.34 ± 385.73 164.62 ± 78.36 161.55 ± 63.35 172.20 ± 90.46 
AUC0-inf (h·ng/mL) 387.55 ± 185.33 501.76 ± 402.80 168.79 ± 80.70 165.53 ± 64.16 237.62 ± 101.43 
Relative F (%) 100.00 ± 49.21 104.03 ± 102.28 43.65 ± 20.78 42.84 ± 16.80 56.31 ± 28.57 
Tmax (h) 3.00 ± 1.41 2.50 ± 0.93 2.50 ± 0.53 2.63 ± 0.52 2.88 ± 0.83 
Cmax(ng/mL) 155.04 ± 100.47 184.06 ± 160.77 82.59 ± 43.60 71.91 ± 43.81 50.50 ± 37.94 
kel (1/h) 0.80 ± 0.42 1.15 ± 0.42 0.92 ± 0.33 0.76 ± 0.30 0.25 ± 0.04 
T1/2el (h) 1.71 ± 0.73 1.29 ± 1.38 1.25 ± 0.58 1.49 ± 0.55 4.05 ± 0.90* 
Vd/F (L/kg) 120.41 ± 95.01 66.34 ± 38.14 167.43 ± 68.34 191.79 ± 67.30 
381.93 ± 
139.92* 
CL/F (L/h/kg) 63.40 ± 30.84 71.04 ± 50.49 156.90 ± 96.26* 135.11 ± 44.87 93.14 ± 25.23 
D
IC
 
AUC0-8h (h·ng/mL) 75.24 ± 12.79 72.39 ± 20.99 61.49 ± 6.90 76.12 ± 22.38 68.33 ± 24.35 
Relative F (%) 100.00 ± 17.00 96.21 ± 27.90 81.73 ± 9.17 101.18 ± 29.75 90.83 ± 32.37 
Tmax (h) 6.57 ± 1.51 7.25 ± 1.49 7.25 ± 1.49 7.00 ± 1.07 7.25 ± 1.04 
Cmax (ng/mL) 14.57 ± 3.23 14.58 ± 4.80 11.91 ± 2.04 14.78 ± 5.63 14.20 ± 4.23 
S
A
L
 
AUC0-8h (h·ng/mL) 694.23 ± 186.28 650.20 ± 156.37 612.51 ± 240.83 663.46 ± 191.65 717.43 ± 165.05 
AUC0-inf (h·ng/mL) 809.57 ± 226.39 722.52 ± 197.18 690.30 ± 277.89 692.83 ± 187.53 799.11 ± 213.93 
Relative F (%) 100.00 ± 46.61 83.97 ± 20.19 79.10 ± 31.10 85.68 ± 24.75 92.65 ± 21.31 
Tmax (h) 0.57 ± 0.43 0.50 ± 0.42 0.46 ± 0.25 0.53 ± 0.31 0.56 ± 0.58 
Cmax (ng/mL) 295.36 ± 138.80 246.10 ± 98.00 201.87 ± 69.71 392.96 ± 206.94 339.90 ± 318.49 
kel (1/h) 0.30 ± 0.10 0.40 ± 0.167 0.37 ± 0.13 0.51 ± 0.25 0.34 ± 0.11 
T1/2el (h) 3.72 ± 1.75 3.05 ± 1.64 3.01 ± 1.07 2.54 ± 1.43 3.22 ± 1.11 
Vd/F (L/kg) 23.36 ± 10.17 20.47 ± 8.34 25.97 ± 18.41 21.93 ± 22.55 19.48 ± 4.62 
CL/F (L/h/kg) 6.50 ± 1.89 7.22 ± 2.26 8.42 ± 4.59 7.64 ± 3.04 6.37 ± 1.49 
AUC: area under the plasma concentration-time curve from time 0 to 8h or 0 to infinity; Tmax: 
time of maximum plasma concentration; Cmax: maximum plasma concentration; kel: 
elimination rate constant; T1/2el: elimination half-life; Vd/F: distribution volume scaled to the 
absolute bioavailability; Cl/F: clearance scaled to the absolute bioavailability; * significant 
differences compared to the control group (p≤0.05). 
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4 Discussion and conclusion 
In previous studies in which interactions were reported with respect to oral bioavailability and 
PK parameters of TYL and DOX (Devreese et al., 2012; De Mil et al., 2015a), an oral bolus 
model with fasted chickens was used. The conditions in those reports can be considered as a 
worst case scenario in which only medicinal product and binders were present in the intestinal 
tract after the boli were administered. Therefore, only the direct binding effect of the 
mycotoxin binders was evaluated without the effect of feed on this interaction. This approach 
is suitable when screening for interactions but shows discrepancies with the field situation 
regarding the duration of exposure to mycotoxin binder and the presence of feed. The setup 
used in this study is similar to the reported bolus studies, however, it includes the long term 
effects of mycotoxin binder and the presence of feed. In field conditions, the amount of feed 
relative to the amount of binder and medicinal product will be higher, hence this model can be 
considered as a more reliable approximation of field conditions for investigating the safety of 
mycotoxin binders. 
For DOX, the Cmax and AUC0-inf of the control group are lower than previously reported 
values in fasted chickens (Laczay et al., 2001; Ismail and El-Kattan, 2004; El-Gendi et al., 
2010; De Mil et al., 2015a). This is mainly attributed to the fed status of the birds in this 
study, as DOX may interact with fibre rich feed or bivalent cations such as Ca
2+
 and Mg
2+
 
(Davis et al., 2006). In the test groups, the relative oral bioavailability ranges from 66.9% up 
to 83.1%, yet the interaction is not as pronounced as reported by De Mil et al. in fasted 
broilers (De Mil et al., 2015a), in which relative oral bioavailabilities of 35.5% to 40.0% are 
reported for bentonite clays. Discrepancies with the latter study include amount of binder 
administered (10 g/kg feed vs. 2 g/kg feed in this study), type of mycotoxin binders nl. Clay 2 
corresponds to montmorillonite 2 in a previously published paper, other mycotoxin binders 
differ (De Mil et al., 2015a), duration of exposure to the mycotoxin binder prior to bolus 
administration of DOX (0 days vs. 14 days in this study) and feed status (fasted vs. non fasted 
in this study). The present study more closely resembles the situation in practice, i.e. lower 
dose of binder, chronic exposure to the binder and presence of feed in the intestinal tract. The 
absence of a strong interaction between mycotoxin binders and DOX might be mainly 
explained by a lower dose, prandial state and other type of mycotoxin binders. The latter is 
partially negated by the results of an in vitro test reported previously (De Mil et al., 2015a), 
which compared the binding potential of seven mycotoxin binders to DOX in an in vitro 
experiment. DOX (100 μg/mL) was incubated for 4 h at 37 °C with 20 mg of one of following 
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binders in 5 mL of phosphate buffered saline solution (PBS) at pH 2.5 and 6.5. All samples 
expressed a binding between 80% and 100% of the added DOX. This indicates the presence 
of feed and the amount of binder relative to the amount of DOX are important variables for 
interaction. In a study in which the effect of mycotoxin binders on the oral bioavailability of 
DOX was studied in pigs, an interaction was seen in the groups who were fasted and received 
a single dose of mycotoxin binder of 10 g/kg feed. The interaction diminished when a lower 
dose of binder was used (2 g/kg feed). No interaction at all was seen when the animals were 
fed and the dose was mixed in the feed at 2 g/kg feed, this is the condition which corresponds 
with field conditions (De Mil et al., 2016b).  
The PK values of TYL of the control group are in accordance with previously reported values 
in non-fasted animals (Lacoste, 2003), but were lower than reported in studies which used 
fasted animals (Devreese et al., 2012; Ji et al., 2014). Although a trend was noticed in the 
average plasma concentrations, no significantly lower relative oral bioavailabilities were 
demonstrated in the groups receiving Clay 1, Clay 2 or Yeast 1. For the derived parameters 
T1/2el, Vd/F and Cl/F differences were noted for Clay 1 and Yeast 1, the reason for these 
differences remains to be elucidated although large interanimal variations were seen. The 
interaction between mycotoxin binders and TYL is not as pronounced as described by 
Devreese et al. (Devreese et al., 2012), in which a relative F of 23.3% was seen compared to a 
relative F of 42.8% and higher in this study. The main differences between the both studies 
are again the feed status of the animals (fasted and non-fasted, respectively), the type of 
mycotoxin binder, dose of mycotoxin binder used (1 g/kg feed and 2 g/kg feed in this study), 
duration of exposure to mycotoxin binder (0 days and 14 days in this study) and salt-form of 
TYL (tartrate and phosphate in this study). The lower plasma concentrations in the control 
group can be partially attributed to the use of the phosphate salt instead of the tartrate salt of 
TYL, which have a different oral F nl. 13.7% for the phosphate salt and 27.0% for the tatrate 
salt (Ji et al., 2014). Again, the main factor that can explain both the lower concentrations in 
the control group and the diminished interaction between the mycotoxin binders and TYL is 
the prandial status.  
The values of the PK parameters of DIC and SAL obtained in this study are consistent with 
the few reports available describing the pharmacokinetics of these coccidiostats in fed birds 
(European commission, 1991; Henri et al., 2012; European Medicines Agency, 2013). For 
DIC and SAL, no differences in AUC0-8h, relative F, Tmax and Cmax were seen between the 
different treatment groups, indicating that the mycotoxin binders have no effect on the 
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absorption of the coccidiostats. To date, EU (Regulation 1060/2013) prohibits the 
simultaneous use of the coccidiostats other than robinidine and bentonite clay when the clay is 
used at an inclusion rate higher or equal to 5 g/kg feed. In our study, 2 g/kg feed was included 
and no interactions were observed, which corresponds well with these EU regulations. For 
robinidine, no bentonite should be used at all (European Commission, 2013a). 
It can be concluded that no significant interactions were observed between any of the 
mycotoxin binders and the coccidiostats, whereas a trend but no significant interactions could 
be noticed between some mycotoxin binders and the antimicrobials doxycycline and tylosin. 
Based on these results and literature, it can be concluded that both the dose as well as prandial 
status are important variables decisive for interaction between mycotoxin binders and oral 
veterinary medicinal products. 
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Abstract 
Mycotoxin binders are feed additives that aim to adsorb mycotoxins in the gastro-intestinal 
tract of animals, making them unavailable for systemic absorption. The antimicrobial drug 
doxycycline (DOX) is often used in pigs and is administered through feed or drinking water, 
hence DOX can come in contact with mycotoxin binders in the gastro-intestinal tract. This 
paper describes the effect of four mycotoxin binders on the absorption of orally administered 
DOX in pigs. Two experiments were conducted, the first used a setup with bolus 
administration to fasted pigs at two different dosages of mycotoxin binder. In the second 
experiment DOX and the binders were mixed in the feed at dosages recommended by the 
manufacturers (=field conditions). Interactions are possible between some of the mycotoxin 
binders dosed at 10 g/kg feed but not at 2 g/kg feed. When applying field conditions, no 
influences were seen on the plasma concentrations of DOX. 
 
Keywords: Doxycycline, mycotoxin binder, interactions, pigs, pharmacokinetics 
  
Chapter 4 
108 
 
1 Introduction 
In 2009, the European Commission introduced a new category of technological feed additives 
titled in Regulation 386/2009: “substances for reduction of the contamination of feed by 
mycotoxins” (European Commission, 2009a). These ‘mycotoxin detoxifiers’ can be divided 
in two sub-categories, namely mycotoxin modifiers and mycotoxin binders. Mycotoxin 
modifiers aim to degrade the toxin into less toxic derivatives, whereas binders aim to adsorb 
mycotoxins to their surface and thereby reducing their toxicological potential (Kolosova and 
Stroka, 2011). The substances most frequently used as mycotoxin binder are clays and yeast 
derived products. The clays mainly belong to the phyllosilicates, such as montmorillonites, 
the main constituent of bentonites (De Mil et al., 2015b). The inclusion rate recommended by 
the manufacturers varies between 1 and 2.5 g/kg complete feed, the maximum amount of 
bentonite is described in Regulation 1060/2013 and is 20 g/kg in complete feed (European 
Commission, 2013a). The total amount of bentonite in compound feed can reach higher levels 
than 1-2.5 g/kg because of intentional/accidental overdosing, the use of bentonites as 
pelletizing agent or to improve the rheological properties.  
In contrast to bentonite, there is no maximum set on the amount of yeast-derived mycotoxin 
binders as these products are usually registered as a feed ingredient. Commercially available 
formulations categorized as mycotoxin modifiers often also contain a substantial fraction of 
mycotoxin binders, i.e. a yeast derived product and/or a clay. In intensively reared livestock, 
administration of antimicrobials and coccidiostats is primarily done through the feed or 
drinking water. Non-specific interactions between mycotoxin binders and these veterinary 
medicinal products and/or nutrients (e.g. vitamins) should therefore be studied (EFSA 
FEEDAP Panel, 2010). Interactions between macrolide antibiotics (tylosin, TYL, and 
tilmicosin) and clay-based mycotoxin binders were previously reported in cattle and broilers 
(Canadian Bureau of Veterinary Drugs, 1992; Shryock et al., 1994). Also lincomycine 
showed an interaction in broilers, although no specifications of the anti-mycotoxin agent were 
presented (Amer, 2005). The efficacy of the coccidiostats monensin and salinomycin may be 
affected by mycotoxin binders in chicken feed (Gray et al., 1998; Nesic et al., 2003). 
Accordingly, Regulation 1060/2013 stated that the simultaneous oral use of bentonite with 
macrolides should be avoided. Moreover, for poultry, the simultaneous use with robenidine 
should be avoided and the use with coccidiostats other than robenidine is contraindicated at a 
level of bentonite above 5 g/kg complete feed (European Commission, 2013a). 
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Previous pharmacokinetic (PK) studies have also reported interactions. In an experiment with 
pigs, the effects of mycotoxins (T-2 toxin or deoxynivalenol) and a yeast derived mycotoxin 
binder on the oral absorption of doxycycline (DOX) and paromomycin were assessed. A 
significant higher area under the plasma concentration-time curve (AUC) was seen for DOX 
in the groups fed mycotoxin-contaminated feed supplemented with mycotoxin binder, 
compared to the control group receiving no mycotoxin nor binder. In contrast, no significant 
differences were seen in the binder group or mycotoxin exposed groups only, when compared 
to the control group (Goossens et al., 2012). In a study with broiler chickens, elevated plasma 
concentrations after bolus administration of oxytetracycline were detected after feeding a 
bentonite-based mycotoxin binder upgraded with a yeast for three weeks (Osselaere et al., 
2012). Although the mechanisms for these observations are still unclear, this might point 
towards an indirect effect of the binder on the intestinal barrier. The latter was demonstrated 
by the observation of longer villi over the entire length of the small intestine after three weeks 
of feeding a clay-based binder (Osselaere et al., 2013c). Devreese et al. studied the PK 
properties of TYL in fasted broiler chickens, using an oral bolus model in which TYL or TYL 
in combination with a bentonite-based mycotoxin binder was administered. The dose of 
bentonite was the daily dose corresponding to an inclusion rate of 1 g/kg feed. A relative oral 
bioavailability of only 23% was found (Devreese et al., 2012). Recently, our group performed 
a similar experiment with DOX and montmorillonite-based mycotoxin binders at an inclusion 
rate of 10 g/kg feed in fasted broiler chickens, and a relative oral bioavailability of 40% was 
noted (De Mil et al., 2015a). These PK experiments included only one dosage of the 
mycotoxin binder and were executed in fasted animals. Although, the parameters dosage and 
prandial state, might be major influencing factors.  
To the authors knowledge, no other studies have been performed in pigs with respect to the 
effects of mycotoxin binders on the absorption of orally administered veterinary drugs. Also, 
studies using field conditions to investigate possible interactions are lacking. Tetracycline 
antibiotics are frequently used in pig production, they comprised 37% and 23% of the total 
use of antimicrobials for food producing animals in Europe in 2012 (European Medicines 
Agency, 2014) and in Belgium in 2014 (Dewulf et al., 2015), respectively. In 97.7% of the 
cases, these drugs are mixed in the feed or drinking water (European Medicines Agency, 
2014), hence, they can come in contact with mycotoxin binders before the main absorption 
site - i.e. small intestine - is reached. DOX is one of the most commonly used tetracycline 
antibiotics in pig rearing, mainly because of its higher oral bioavailability compared to other 
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tetracylines (Bergstrom et al., 2003). DOX is a broad spectrum, semisynthetic tetracycline 
used in pigs for respiratory tract infections caused by susceptible pathogens such as 
Pasteurella multocida, Bordetella bronchiseptica, Mycoplasma hyopneumoniae and 
Actinobacillus pleuropneumoniae (Pijpers et al., 1989).  
The aim of present study was to investigate the interaction between frequently used 
mycotoxin binders and the oral absorption of DOX in pigs, taking into account the inclusion 
rate of binder and prandial state of the animals. 
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2 Materials and methods 
2.1 Chemicals, mycotoxin binders and reagents 
DOX and demethylchlortetracycline (DMCTC, internal standard, IS), used for the analytical 
experiments, were obtained from Sigma-Aldrich (Bornem, Belgium). Water, methanol 
(MeOH), and acetonitrile (ACN) used for the analytical experiments and preparation of stock 
solutions were of high-performance liquid chromatography (HPLC)-grade and purchased 
from Fisher Scientific (Wijnegem, Belgium). Stock solutions of DOX and DMCTC of 10 
mg/mL were made in MeOH and stored at ≤ -15 °C. They were further diluted in MeOH to 
obtain working solutions of appropriate concentration and were also stored at ≤ -15 °C. 
Formic acid (HCOOH) and trifluoroacetic acid (TFA) were obtained from Merck (Darmstadt, 
Germany) and were of HPLC-grade quality. Four mycotoxin binders were obtained from 
several European wholesalers, they are referred to as Clay 1 to 3 and Yeast 1. The physico-
chemical properties of the clay-based mycotoxin binders were described previously (De Mil 
et al., 2015b). Clay 1 contained a mixed layered montmorillonite and quartz, it had a d-
spacing of 19.1·10
-10
 m, a cation exchange capacity (CEC) of 51.0 cmolc/kg, a mineral 
fraction of 78.6% (m:m) and a relative humidity of 3.4% (m:m). Clay 2 contained 
montmorillonite, mica and feldspars, had a d-spacing of 12.3·10
-10
 m, a CEC of 7.0 cmolc/kg, 
a mineral fraction of 94.8% (m:m) and relative humidity of 5.2% (m:m). Clay 3 only 
contained montmorillonite, had a d-spacing of 12.7·10
-10
 m, a CEC of 111.7 cmolc/kg, a 
mineral fraction of 86.8% (m:m) and a relative humidity of 13.2% (m:m). Doxycycline 
hyclate (Doxylin
®
 50% WSP) used for the animal studies was supplied by Dopharma 
(Raamsdonkveer, The Netherlands). 
2.2 Experimental design 
2.2.1 Oral bolus design, fasted animals 
In the bolus experiment, thirty healthy pigs (Belgian Landrace, 10 weeks old, mixed 
male/female, 26.1 ± 3.4 kg average BW ± SD) were randomly allocated in five treatment 
groups (each n=6), one control group and four test groups (Clay 1 to 3 and Yeast 1 group). 
The pigs were housed on a 50/50 concrete floor/grids. Temperature and air humidity were 
climate controlled at 25 ± 3 °C (average ± SD) and 25-60% respectively. Water was supplied 
ad libitum. The feed was a meal-based, commercially available feed (Optipro
®
, Aveve, 
Meigem, Belgium), which contained no mycotoxin binders and no clay- or yeast-based feed 
additives, it was given in two administrations per day. Six samples of the feed were analysed 
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for the presence of mycotoxins according to a multi-mycotoxin LC-MS/MS method adapted 
from Monbaliu et al. (Monbaliu et al., 2009). The feed contained different cereals (maize, 
wheat, barley, cabbage-, rapeseed- and sunflower seeds), animal fat, beet molasses and 
soybeans. It had a raw ashes content of 5.51% (m:m), raw protein content of 16.0% (m:m), 
fatty components of 5.75% (m:m) and a crude fibre content of 4.50% (m:m). After three days 
of acclimatisation all animals were fasted for 12 h. Next, a lubricated rubber tube was inserted 
into the stomach through which a single dose of one of the four mycotoxin binders (Clay 1 – 
3, Yeast 1), dispersed in tap water, was administered. The control group received only tap 
water. Immediately after the mycotoxin binder (or water), a single dose of Doxylin
®
, 
dissolved in tap water, was administered to all groups. The tube was rinsed with 50 mL of tap 
water and 50 mL of air to remove remaining mycotoxin binder or Doxylin
®
. The dose of 
mycotoxin binders corresponded with the daily intake and was estimated using a 2 g/kg 
inclusion rate and a daily feed consumption of 1.6 kg per animal (low exposure, LE). The 
dose of Doxylin
®
 was the daily dose as recommended by the manufacturer, i.e. 10 mg 
DOX/kg BW. Blood samples (ca. 4 mL) were collected by puncturing the jugular vein and 
collected in ethylenediaminetetraacetic acid (EDTA)-containing vacuum tubes (Vacutest 
Kima, Arzergrande, Italy). Blood samples were taken at 0 h (just before onset of the 
experiment), and at 1, 2, 3, 4, 6, 8 and 12 h after administration of the boli (p.a.).  
After a wash-out period of three days, the experiment was repeated with two of the five 
groups, namely the Clay 1 and 3 group. This time, the dose of binder was calculated using an 
inclusion rate of 10 g/kg feed instead of 2 g/kg feed (high exposure, HE). All other procedures 
were the same as described above. 
2.2.2 Steady state design, field conditions 
Thirty other healthy pigs (Belgian Landrace, mixed male/female, 26.4 ± 4.1 kg average BW ± 
SD) were randomly allocated to five treatment groups: one control group and four test groups. 
All groups received feed of the same batch as described for the bolus experiment. For the test 
groups, this feed was supplemented with one of the four mycotoxin binders (Clay 1 – 3, Yeast 
1) at an inclusion rate of 2 g/kg feed, as recommended by the manufacturers. The mixing was 
done according a three-stage mixing procedure (Earle and Earle, 1983), the first stage (up to 5 
kg) was done manually, the second stage (up to 30 kg) in a construction mixer used solely for 
this purpose, and the third stage (up to 250 kg) in a vertical screw feed mixer. The feed of the 
control group contained no mycotoxin binder. This feed regime was maintained for two 
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weeks, and after this period all animals received medicated feed. Doxylin
®
 was mixed in the 
feed of all groups according to instructions of the manufacturer. The dose was 270 mg 
DOX/kg feed, corresponding to a dose of 10 mg DOX/kg BW. It was mixed using a ten-stage 
geometrical mixing procedure (Earle and Earle, 1983). The first six stages (up to 2 kg) were 
done manually, the last four stages (up to 30 kg) were done in a construction mixer. The 
medicated feed was given in two administrations per day, at 8 am and 6 pm, for three 
consecutive days. Blood samples were taken daily at 10 am, 2 pm and 8 pm, corresponding to 
2 h and 6 h after the first administration and 2 h after the second feed administration. The 
blood samples were taken as described for the bolus experiment.  
These animal experiments were approved by the ethical committee of the Faculty of 
Veterinary Medicine and the Faculty of Bioscience Engineering of Ghent University, 
approval number EC 2015/09. 
2.3 LC-MS/MS analysis 
Plasma was collected by centrifuging the blood samples (524 × g, 10 min, 4 °C, New 
Brunswick Scientific, Rotselaar, Belgium) and stored at ≤ -15 °C until analysis. To 250 µL of 
plasma, 50 µL of a 3 µg/mL working solution of IS was added, next, 50 µL of HPLC-grade 
water was added. The samples were vortex mixed for 5 seconds, and supplemented with 25 
µL of TFA, vortex mixed again for 15 seconds and centrifuged (10800 × g, 15 min, 4 °C, 
Kendro technologies, Osterode, Germany). Next, 150 µL of supernatant was mixed with 150 
µL of HPLC-grade water and 5 µL was injected into the LC-MS/MS instrument. 
The LC-MS/MS method was similar to the method described in a previous paper for broiler 
plasma analysis (De Mil et al., 2015a). The method was validated in pig plasma for a range 
between 25 ng/mL (= limit of quantification, LOQ) and 7500 ng/mL. Validation parameters 
were as following: linear calibration curves were weighted 1/x; Pearson correlation was >0.99 
and goodness of fit below 10%. Within-run accuracy and precision was determined using 
blank samples fortified with DOX at 25, 250 and 2500 ng/mL. For each concentration level 
six samples were spiked, recovery rates were 23.9 ± 1.3 ng/mL, 259 ± 13.1 ng/mL and 2640 ± 
86.7 ng/mL respectively. Between-run accuracy and precision was determined on a similar 
manner at 250 and 2500 ng/mL, for three consecutive days a total of nine samples were tested 
for each concentration. Recovery rates were 247 ± 14.1 ng/mL and 2580 ± 123 ng/mL. Limit 
of detection was based on a signal-to-noise ratio of 3/1 of six blank samples spiked with DOX 
at 25 ng/mL (=LOQ) and was found to be 0.96 ng/mL. 
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2.4 Pharmacokinetic and statistical analysis 
The following PK parameters were determined for the bolus experiment for each pig by non-
compartmental analysis using Phoenix WinNonlin
®
 (St. Louis, United States of America): 
area under the plasma concentration-time curve from time 0 to last sampling point and to 
infinity (AUC0-12h and AUC0-inf), maximum plasma concentration (Cmax) and time to 
maximum plasma concentration (Tmax), elimination rate constant (kel), elimination half-life 
(T1/2el), volume of distribution relative to the absolute oral bioavailability (Vd/F), and 
clearance relative to the absolute oral bioavailability (Cl/F). The relative oral bioavailability 
(relative F) of the test groups was calculated as follows: 
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐹 =  
𝐴𝑈𝐶0−𝑖𝑛𝑓,𝐷𝑂𝑋+𝑡𝑒𝑠𝑡𝑒𝑑 𝑏𝑖𝑛𝑑𝑒𝑟
𝐴𝑈𝐶̅̅ ̅̅ ̅̅ 0−𝑖𝑛𝑓,𝐷𝑂𝑋 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝
× 100 
For the steady state experiment, the AUC until the last sampling point (AUC0-58h) was 
calculated using WinNonlin
®
, steady state concentration (Css) was calculated as the average of 
the last six plasma concentrations. Total body clearance (Cl) whether or not corrected for 
absolute oral bioavailability (F) was calculated by: input rate/Css. The input rate was assumed 
to be the daily dose per 24 h. The PK parameters of the different test groups were compared to 
the control group using one-way analysis of variance with a Least Significant Difference 
(LSD) with Bonferroni correction as post-hoc test. Significance levels (p) below 0.05 were 
considered significantly different. 
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3 Results and discussion 
The results of the mycotoxin analysis of the feed samples are shown in supplementary Table 
1. Deoxynivalenol (DON), 3-acetyl-DON, 15-acetyl-DON, HT-2 toxin, fumonisin B1, 
sterigmatocystin and zearalenone could be detected, however all samples complied with the 
recommended maximum levels according to the Directive 2002/32, Recommendation 
2006/576 and Recommendation 2013/165 (European Commission, 2002c, 2006, 2013b). The 
other mycotoxins included in the screening method, aflatoxins (aflatoxins B1, B2, G1 and G2), 
fumonisins (B2 and B3), T-2 toxin, ochratoxin A, fusarenon-X, nivalenol, diacetoxyscirpenol, 
neosolaniol, altenuene, alternariol, alternariol methyl ether and roquefortine-C, were below 
the decision limit and thus also compliant with the European legislation, if available. 
3.1 Oral bolus design (LE and HE) 
The plasma concentration-time profiles of DOX are shown in Figure 1, the PK parameters are 
presented in Table 1 and 2 for LE and HE groups, respectively. In the LE groups no 
significant differences between the test groups and the control group were observed. In 
contrast, in the HE groups, both the Clay 1 and Clay 3 group displayed significantly lower 
plasma concentrations of DOX in comparison to the control group, as reflected by a lower 
values for AUC0-12h, AUC0-inf, relative F, Tmax and Cmax. 
Pigs receiving the high dose of binder (~ 10 g/kg feed) expressed lower plasma concentration 
levels compared to pigs receiving the lower dose (~ 2 g/kg feed). All PK parameters of the 
test groups, except Tmax, kel, T1/2el and Vd/F for Clay 1 HE were significantly different from 
those of the control group. Differences in oral bioavailability might explain the differences 
seen in Vd/F and Cl/F, although this cannot be calculated with the available information. The 
relative F-values in the high exposure groups were about 20%, indicating the systemic 
exposure to DOX is significantly lower in the high exposure groups. These results are 
consistent with the previously reported interactions between DOX and mycotoxin binders in 
broiler chickens (De Mil et al., 2015a), where a relative F of ≤ 40% was seen in fasted 
chickens when a binder at 10 g/kg feed was administered together with DOX. The groups that 
received the lower dose of mycotoxin binder showed no significant difference compared to 
the control group. The control group expressed a mean Cmax of 2.01 µg/mL and a mean AUC0-
inf of 10.56 h·µg/mL, which is similar to previously reported results (Baert et al., 2000). The 
latter authors reported a Cmax of 1.52 µg/mL and an AUC of 13.79 h·µg/mL after oral 
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administration of 10.5 mg/kg BW to fasted piglets. A second maximum in plasma 
concentration was present at about 4 h p.a. and might be due to enterohepatic recycling, a 
phenomenon previously described for DOX in pigs (Riond and Riviere, 1990). 
 
 
Figure 1: Plasma concentration-time profiles of doxycycline (DOX) in pigs. A: each test 
group was fasted and was given a bolus with mycotoxin binder at a dose corresponding 
to an inclusion rate of 2 g/kg feed, the control group received water. Immediately 
thereafter, all groups received a bolus containing Doxylin
®
 (10 mg DOX/kg bodyweight). 
B: Same as A but using an inclusion rate of binder of 10 g/kg feed. The results are 
presented as the mean + or - SD (n = 6). 
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Table 1: Main Pharmacokinetic Parameters Of Doxycycline (DOX) For Fasted Pigs 
Following Bolus Administration of Doxylin
®
 10 mg DOX/kg BW And Mycotoxin Binder 
using an Inclusion Rate Of 2 g/kg Feed (low exposure, LE). Results Are Presented As 
Mean ± SD (n = 6). 
Treatment group Control Clay 1 LE Clay 2 LE Clay 3 LE Yeast 1 LE 
AUC0-12h (h·µg/mL)
a
 9.60 ± 3.49 12.29 ± 4.57 9.73 ± 2.35 6.37 ± 2.63 10.72 ± 5.59 
AUC0-inf (h·µg/mL)
a
 10.56 ± 3.97 12.90 ± 4.84 10.43 ± 2.42 7.54 ± 2.67 11.78 ± 6.04 
Relative F (%) 
100.00 ± 
37.61 
122.31 ± 45.87 98.91 ± 22.95 
71.50 ± 
25.34 
111.69 ± 57.28 
Tmax (h)
b
 2.00 ± 1.10 2.83 ± 1.47 2.50 ± 1.64 2.17 ± 1.47 2.50 ± 1.22 
Cmax (µg/mL)
c
 2.01 ± 0.91 2.46 ± 0.90 2.12 ± 0.77 1.31 ± 0.75 1.93 ± 1.06 
kel (1/h)
d
 0.23 ± 0.08 0.29 ± 0.05 0.22 ± 0.04 0.21 ± 0.13 0.23 ± 0.06 
T1/2el (h)
e
 4.83 ± 1.74 3.57 ± 0.52 4.69 ± 0.87 6.59 ± 3.95 4.60 ± 1.11 
Vd/F (L/kg)
f
 4.77 ± 1.35 3.07 ± 1.12 4.66 ± 1.14 9.26 ± 5.81 5.36 ± 3.92 
Cl/F (L/h/kg)
g
 1.09 ± 0.46 0.88 ± 0.33 1.00 ± 0.23 1.45 ± 0.43 1.15 ± 0.76 
a
 AUC: area under the plasma concentration-time curve from time 0 to 12h or 0 to infinity; 
b
 Tmax: time of 
maximum plasma concentration; 
c
 Cmax: maximum plasma concentration;
 d
 kel: elimination rate constant; 
e
 T1/2: 
elimination half-life; 
f
 Vd/F: distribution volume relative to the absolute bioavailability; 
g
 Cl/F: clearance relative 
to the absolute bioavailability. 
 
 
 
Table 2: Main Pharmacokinetic Parameters Of Doxycycline (DOX) For Fasted Pigs 
Following Bolus Administration of Doxylin
®
 10 mg DOX/kg BW And Mycotoxin Binder 
using an Inclusion Rate Of 10 g/kg Feed (high exposure, HE). Results Are Presented As 
Mean ± SD (n = 6). 
Treatment group Control Clay 1 HE  Clay 3 HE 
AUC0-12h (h·µg/mL)
a
 9.60 ± 3.49 2.26 ± 2.16 *
h
 1.49 ± 0.94 †h 
AUC0-inf (h·µg/mL)
a
 10.56 ± 3.97 2.28 ± 2.55 *
h
 2.07 ± 1.02 *
h
 
Relative F (%) 100.00 ± 37.61 21.62 ± 24.14 *
h
 19.67 ± 9.64 *
h
 
Tmax (h)
b
 2.00 ± 1.10 4.50 ± 2.07 4.50 ± 3.83 
Cmax (µg/mL)
c
 2.01 ± 0.91 0.45 ± 0.40 *
h
 0.32 ± 0.21 *
h
 
kel (1/h)
d
 0.23 ± 0.08 0.33 ± 0.16 0.15 ± 0.06 
T1/2el (h)
e
 4.83 ± 1.74 3.44 ± 1.19 7.44 ± 2.44 
Vd/F (L/kg)
f
 4.77 ± 1.35 26.77 ± 18.28 45.46 ± 32.81 ‡
h
 
Cl/F (L/h/kg)
g
 1.09 ± 0.46 8.16 ± 4.80 ‡
h
 6.11 ± 3.51 ‡h 
a
 AUC: area under the plasma concentration-time curve from time 0 to 12h or 0 to infinity; 
b
 
Tmax: time of maximum plasma concentration; 
c
 Cmax: maximum plasma concentration;
 d
 kel: 
elimination rate constant; 
e
 T1/2: elimination half-life; 
f
 Vd/F: distribution volume relative to 
the absolute bioavailability; 
g
 Cl/F: clearance relative to the absolute bioavailability; 
h
 *, † and 
‡ indicate significant differences compared to the control group, respectively at the 0.05, 0.01 
and 0.001 p-level.  
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3.2 Steady state design, field conditions 
The plasma concentration-time profiles of the steady state experiment are shown in Figure 2. 
The values for the main PK parameters are listed in Table 3. The steady state was reached 
after about 12 h. Following, Css reached values between 100 and 175 ng/mL. No significant 
differences between the test- and the control group were observed. 
 
Figure 2: Plasma concentration-time profile of doxycycline (DOX) in pigs during 
continuous administration of Doxylin
®
 in the feed at the recommended dose of 270 
mg/kg feed, corresponding to a daily dose of 10 mg DOX/kg bodyweight. Mycotoxin 
binders were mixed in the feed of the test groups using an inclusion rate of 2 g/kg feed. 
Results are presented as mean + or - SD (n=6). 
Table 3: Plasma concentration of doxycycline (DOX) at steady state (Css), the area under 
the plasma concentration-time curve (AUC0-58h) and total body clearance (Cl) whether 
or not corrected for absolute oral bioavailability (F) in pigs during continuous 
administration of Doxylin
®
 in the feed at 270 mg/kg feed, corresponding to a daily dose 
of 10 mg DOX/kg bodyweight. Mycotoxin binders were mixed in the feed of the test 
groups using an inclusion rate of 2 g/kg feed. Results are presented as mean ± SD (n=6). 
Treatment Css (ng/mL) 
AUC0-58h 
(h·µg/mL) 
Cl/F 
(L/24h/kg BW) 
Cl (F=21.2%)* 
(L/24h/kg BW) 
Control 143.02 ± 29.48 7.34 ± 1.35 72.60 ± 15.84 3.36 ± 1.37 
Clay 1 144.46 ± 24.32 7.18 ± 1.22 71.03 ± 12.88 2.73  ± 1.11 
Clay 2 121.50 ± 28.53 6.05 ± 1.28 85.51 ± 16.68 3.54 ± 1.44 
Clay 3 127.86 ± 15.89 6.10 ± 1.04 79.22 ± 9.74 2.06 ± 0.84 
Yeast 1 137.23 ± 27.37 6.76 ± 1.60 74.99 ± 12.86 2.73 ± 1.11 
Css: concentration at steady state; AUC0-58h: area under the plasma concentration-time curve; 
Cl: Clearance. No significant differences were observed between the test groups and the 
control group. 
* F was adopted from Baert et al. (2000). 
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The recommended inclusion rate for bentonite-based mycotoxin binders is in the range of 1 
and 2.5 g/kg complete feed. However, higher levels of bentonites in feed might be reached 
due to the simultaneous use of bentonites for other purposes such as pelletizing agent or to 
improve rheological properties. The maximum level of bentonite is set in Regulation 
1060/2013 at 20 g/kg feed (European Commission, 2013a). No differences were seen in the 
DOX plasma concentrations between the test groups and the control group, indicating that 
adding mycotoxin binder to the feed at an inclusion rate of 2 g/kg feed has no influence on the 
oral bioavailability of DOX. Although, the steady state concentrations were lower than 
previously reported values, where a steady state concentration of 1.21 µg/mL (Bousquet et al., 
1998) and 1.06 µg/mL (Pijpers et al., 1991) was measured at 12 h after start of administration 
of comparable doses of DOX in the feed. The discrepancy might be attributed to differences 
in breed, bodyweight, type of feed, spillage, light cycles, formulation of the feed or the 
commercial formulation of DOX.  
3.2 General  
Bolus studies in fasted pigs of the HE groups indicate that an interaction is possible between 
different clay-based mycotoxin binders and DOX. Studies in fasted broiler chickens using a 
similar setup also indicated a potential risk when using mycotoxin binders in combination 
with DOX (De Mil et al., 2015a). The current study indicates that the results obtained in 
fasted animals should be nuanced. The interaction depends upon the inclusion rate of 
mycotoxin binder and the presence of feed in the gastro-intestinal tract, an important factor 
not present in the bolus experiments using fasted pigs in this study and in the cited study with 
DOX in broilers. A lower oral bioavailability of DOX was seen when a clay-based mycotoxin 
binder, in a dose corresponding to 10 g/kg feed, was co-administered with DOX in fasted 
pigs. When applying field conditions, using an inclusion rate of mycotoxin binders of 2 g/kg 
feed and a DOX dose of 270 mg/kg in feed, no influence was seen on the plasma 
concentrations of DOX. This indicates the use of DOX is safe when the feed is supplemented 
with mycotoxin binders at the conditions described above. When using higher inclusion rates 
of DOX and/or binders, either accidental (inhomogeneous mixing) or deliberate, interactions 
cannot be excluded. 
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Supplementary Table 1: Concentration of mycotoxins in the feed, results are presented 
as mean ± SD (n=6)  
Mycotoxin 
Concen- 
tration 
(µg/kg) 
Decision limit 
(CCα) (µg/kg) 
Detection 
capability  
(CCβ) (µg/kg) 
Maximum level 
for pig feed 
(µg/kg)
a
 
Aflatoxin G1 < CCα 1.93 4.19 N.a. 
Aflatoxin G2 < CCα 2.39 4.79 N.a. 
Aflatoxin B1 < CCα 6.75 8.08 20
b
 
Aflatoxin B2 < CCα 1.53 2.57 N.a. 
Ochratoxin A < CCα 3.44 8.93 50 
Sterigmatocystin 5.5 ± 2.0 4.75 8.99 N.a. 
Fumonisin B1 33.1 ± 3.9 31.84 64.34 Σ 5000 
Fumonisin B2 < CCα 24.37 54.69 
Fumonisin B3 < CCα 23.18 42.67 N.a. 
T2-toxin < CCα 9.38 19.47 Σ 250 
HT2-toxin 11 ± 4 9.23 19.58 
Diacetoxyscirpenol < CCα 0.67 1.36 N.a. 
Neosolaniol < CCα 8.60 17.53 N.a. 
Nivalenol < CCα 36.22 71.41 N.a. 
Deoxynivalenol 
(DON) 
554 ± 160 60.61 128.29 900 
3-ADON 16 ± 6 4.90 9.80 N.a. 
15-ADON 53 ± 20 3.07 5.29 N.a. 
Fusarenon-X < CCα 16.58 34.62 N.a. 
Zearalenone 156 ± 50 17.85 35.99 250 or 100
c
 
Roquefortine C < CCα 1.08 2.45 N.a. 
Alternariol < CCα 11.98 23.23 N.a. 
Alternariol 
methylether 
< CCα 17.75 39.00 N.a. 
Altenuene < CCα 4.54 8.89 N.a. 
a
 Guidance for maximum level is provided by the European Commission: Directive 
2002/32/EC, Recommendation 2006/576/EC and Recommendation 2013/165/EU; 
b
 Not 
applicable for young animals; 
c
 250 µg/kg for sows and fattening pigs, 100 µg/kg for piglets 
and gilts; N.a. Not available. 
 
Chapter 4 
121 
 
 
 122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: 
Thomas De Mil, Mathias Devreese, Patrick De Backer and Siska Croubels (2016a). In vitro 
model to assess the adsorption of oral veterinary drugs to mycotoxin binders in a feed-
containing buffered matrix. Submitted to Animal Feed Science and Technology. 
Chapter 5: In vitro model to assess the adsorption of oral veterinary drugs 
to mycotoxin binders in a feed-containing buffered matrix 
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Abstract  
Mycotoxin binders are feed additives which are mixed in the feed to adsorb mycotoxins and 
thereby reducing their toxic effects on animals. Interactions with orally administered 
veterinary medicinal products, such as antimicrobials or coccidiostats, have been reported 
previously. This paper describes an in vitro model to screen for interactions between 
mycotoxin binders and veterinary drugs with respect to the non-specific binding of drugs. It is 
designed as a static setup using single concentration of drug and binder in a feed-containing 
matrix, buffered at different pHs. The model was applied to two frequently used 
antimicrobials in veterinary medicine, doxycycline (DOX) and tylosin (TYL) and four 
mycotoxin binders. Proportions of feed, DOX or TYL and binder are equivalent to the in vivo 
situation for broiler chickens, and pH and volume of the buffer are representative for the 
gastrointestinal tract of chickens as well. Similar results were obtained for DOX and TYL, 
more specifically up to an inclusion rate of 20 g binder/kg feed, no significant binding was 
demonstrated, determined as the free concentration of DOX and TYL. One exception was 
noticed for TYL and a bentonite based mycotoxin binder, for which no significant interaction 
could be demonstrated up to 10 g/kg instead of 20 g/kg. 
 
Keywords: Mycotoxin binder, doxycycline, tylosin, adsorption, in vitro, safety assessment 
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1 Introduction 
Mycotoxin binders are feed additives which are often mixed in feed to counter the harmful 
effects of mycotoxins by adsorbing the toxin to their surface and thereby reducing their 
toxicological potential (European Commission, 2009a). The mechanism was described in 
detail for the binding of aflatoxin B1 (AFB1) to montmorillonite (Deng et al., 2010). To date, 
bentonite, a clay which contains mainly montmorillonite, is the only substance registered in 
the EU to bind AFB1 (European Commission, 2015). Bentonites are usually mixed in the feed 
at a concentration of 1 to 2.5 g/kg, but levels up to 20 g/kg are allowed in complete feed for 
ruminants, poultry and pigs to bind AFB1 (European Commission, 2013a). Besides binding of 
AFB1, bentonites are also used for other purposes such as pelletizing agent or to improve the 
rheological properties of bulk feed (anticaking agent), hence levels higher than 2.5 g/kg can 
be reached. The total amount of bentonite allowed in feed for these other purposes is 20 g/kg 
as well (European Commission, 2013a). For yeast-derived mycotoxin binders no maximum 
level is provided by European legislation because most yeast-based mycotoxin binders are 
registered as a feed ingredient. Concerns about non-specific binding of other feed compounds 
such as vitamins or medicinal products, and thus the safety of binders, were expressed by the 
European Commission in 2009 (EFSA, 2009). The binding of mycotoxins is indeed deemed 
to be non-specific and different in vivo interactions between mycotoxin binders and oral 
veterinary medicinal products have been described (Shryock et al., 1994; Devreese et al., 
2012; De Mil et al., 2015a). Therefore, the European Commission provided to indicate in the 
instructions for use of bentonites that the simultaneous oral use with macrolides shall be 
avoided in any animal species, and that in poultry the simultaneous use with robenidine 
should be avoided and the simultaneous use with coccidiostats other than robenidine is 
contraindicated with a level of bentonite above 5 g/kg of complete feed (European 
Commission, 2013a). 
In vitro models to assess the efficacy of mycotoxin binders to adsorb mycotoxins include 
static and dynamic models. Dynamic models are usually composed of different compartments 
and several parameters can be altered during the experiment, thereby mimicking different 
segments of the gastro-intestinal (GI) tract (Avantaggiato et al., 2003; Blanquet et al., 2004). 
These models are rather time consuming and require many resources, hence, they are not 
suitable for screening experiments. Static models are more cost and labour efficient and 
thereby more suited for screening experiments, however, they are less representative for the 
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GI-tract and the results should be interpreted carefully. Static models include adsorption-
isotherm (Ramos et al., 1996) or single-concentration studies (Sabater-Vilar et al., 2007; 
Vekiru et al., 2007; Devreese et al., 2013b). The European Commission stated that for the 
authorisation of a bentonite as a mycotoxin binder, efficacy testing needs to be carried out 
using a static adsorption test in a buffered matrix of pH 5.0 with a concentration of 4 mg/L for 
AFB1, and 0.02 % (w/v) for the feed additive (European Commission, 2013a).  
In vitro models to assess the safety with respect to binding potential of medicinal products are 
very scarce and they are usually derived from models to assess efficacy (Devreese et al., 
2013b; De Mil et al., 2015a). Furthermore, these models do not include feed, although feed is 
always present in the field situation and can be a major factor influencing the bioavailability 
of a drug (Marasanapalle et al., 2011). Indeed, some drugs may have a lower oral 
bioavailability when administered with feed as the drug can undergo non-specific binding 
with feed compounds. Poorly soluble drugs, i.e. drugs classified as a type II drug according to 
the Biopharmaceutics Classification System (BCS), express a higher bioavailability when 
administered with food. 
To the authors knowledge, no static models with feed are available to assess interactions 
between mycotoxin binders and veterinary drugs with respect to the non-specific binding of 
drugs. Doxycycline (DOX) and tylosin (TYL) are frequently used antimicrobials to treat 
pulmonary and gastro-intestinal infections in poultry and swine and are therefore used in the 
present setup. The aim of this study was to develop a static adsorption model to assess the 
binding of veterinary drugs, with DOX and TYL as model compounds, to various mycotoxin 
binders in a buffered matrix with relevant pH ranges and containing feed. 
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2  Materials and methods  
2.1  Mycotoxin binders and veterinary drugs 
The mycotoxin binders were purchased from Sigma-Aldrich (Bornem, Belgium) or were 
obtained from European wholesalers. The mycotoxin binders were labelled as Clay 1, Clay 2, 
Clay 3 and Yeast 1. Physico-chemical characterisation of the clays is described in a previous 
report, and clay sample numbers 27, 6 and 24 were included in this study (De Mil et al., 
2015b). Yeast 1 is a modified glucomannan fraction of inactivated yeast cells. The feed was 
wheat based, commercially available finely grinded feed for broiler chickens (Aveve, 
Meigem, Belgium), it contained following ingredients: wheat (59.49%), high protein soybean 
meal (17.70%), corn (8.00%), vegetable oil (5.80%), soy beans (5.00%) and premixed 
supplements (4.01%), no mycotoxin binders or clay-based feed additives were present in the 
feed. Analysis according to a previously validated method (Monbaliu et al., 2010) indicated 
the feed contained following mycotoxins: nivalenol: 140 µg/kg, deoxynivalenol: 234 µg/kg, 
zearalenone: 327 µg/kg. No other mycotoxins were detected above the limit of detection, 
hence the feed is compliant to European Directives (European Commission, 2002c), 
Recommendations (European Commission, 2006) and indicative levels (European 
Commission, 2013b) for poultry. Reference standards of DOX, TYL, 
demethylchlortetracycline (DMCTC) and valnemulin (VAL) were purchased from Sigma-
Aldrich. 
2.2  Experimental setup 
Ten gram of feed was supplemented with one of the four mycotoxin binders to a 
concentration of 0, 1.0, 2.5, 5.0, 10, 20, 50 or 100 g/kg feed. Next, 19 mL of phosphate 
buffered salt (PBS) solution and 1 mL of working solution of DOX or TYL were added. To 
obtain the PBS, a salt solution containing 8.0 g/L NaCl (VWR, Leuven, Belgium), 0.1 g/L 
MgCl2·6H2O (Sigma-Aldrich), 0.2 g/L KCl (Sigma-Aldrich) and 0.13 g/L CaCl2·2H2O 
(VWR) was supplemented with a phosphate buffer system to the pH’s of 2.5, 6.5 and 8.0 to 
achieve a total osmolarity of 9.6 mmol/L (De Mil et al., 2015a). 
The working solution of DOX was prepared by mixing Doxylin 50% WSP
®
 (Dopharma, 
Raamsdonkveer, The Netherlands) with HPLC-grade water (Thermo Fisher Scientific, 
Wijnegem, Belgium) to a concentration of 5 mg/mL, this concentration was calculated using a 
daily feed intake of 80 g/kg bodyweight (BW)/day and a DOX dose of 20 mg/kg BW/day. For 
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the working solution of TYL, Tylan Soluble 100%
®
 (Elanco Animal Health, Brussels, 
Belgium) was mixed with HPLC-grade water to a concentration of 3 mg/mL, which 
corresponds to a dose of 24 mg/kg BW/day when 80 g feed/kg BW/day is consumed. 
The volume of 20 mL (PBS + working solution DOX/TYL) relative to the amount of feed (10 
g) corresponds to the water:feed ratio applicable for broilers of 2:1 (Pesti et al., 1985). The 
model includes three different acidity levels of PBS, namely pH 2.5, 6.5 and 8.0, which 
comprise the range of acidity levels in the GI-tract of mammals and poultry in general 
(Maresca, 2013).  
Next, the tubes which contained the feed, buffer and TYL or DOX, were horizontally shaken 
(150 rpm) for 4 h at 37 °C (New Brunswick Scientific, Rotselaar, Belgium). The pH of the 
samples was checked with litmus paper to verify no major changes in Ph occurred during the 
experiment. The samples were centrifuged (3,724 × g, 15 min, 25 °C) and 250 µL of the 
supernatant was transferred to an Eppendorf cup. Three replicates were analysed per inclusion 
rate, per pH, per mycotoxin binder, and per antimicrobial. 
2.3  Analysis of DOX and TYL 
For DOX, 50 µL of a 100 µg/mL working solution of the internal standard, DMCTC in high-
performance liquid chromatography (HPLC)-grade methanol (MeOH, Thermo Fisher 
Scientific), was added followed by 50 µL of MeOH. After vortex mixing, 25 µL of 
trifluoroacetic acid (Sigma-Aldrich) was added and the sample was thoroughly vortex mixed 
again for 30 sec. The sample was centrifuged at 10,800 × g for 15 min at 4 °C and 18 µL of 
the supernatant was supplemented with 282 µL of HPLC-grade water prior to analysis. The 
LC-MS/MS analysis was executed as previously described (De Mil et al., 2015a).  
The samples for TYL were supplemented with 50 µL of a 250 µg/mL working solution of the 
internal standard, VAL in HPLC-grade acetonitrile (ACN, Filter Service, Eupen, Belgium). 
Next, 950 µL of ACN was added, the sample was thoroughly vortexed for 30 seconds and 
centrifuged at 10,800 × g for 15 min at 4 °C. Next, 25 µL of the supernatant was 
supplemented with 275 µL of an aqueous 0.01 M ammonium acetate buffer (Sigma-Aldrich). 
The HPLC equipment consisted of a Waters 2690 pump and autosampler (Waters, Milford, 
USA), chromatographic separation was achieved on a Purospher RP-18 LiChroCART column 
and corresponding guard column (Merck, Darmstadt, Germany). Mobile phase A was ACN 
supplemented with 0.01% HPLC-grade formic acid (Merck), mobile phase B was water 
Chapter 5 
128 
 
supplemented with 0.01% formic acid. The gradient was isocratic 50:50 (A:B, v/v), and the 
flow rate was set at 0.6 mL/min. The HPLC effluent was interfaced to a Quattro Ultima 
tandem mass spectrometer (Waters, Manchester, United Kingdom). For TYL, following 
reaction was monitored for quantification: m/z 915.8>174.2 and a collision energy of 34 eV 
and cone voltage of 35 V were applied. The analysis was adapted from (Devreese et al., 2012) 
and validated as described by De Baere et al. (2011). For VAL, the monitored reaction was 
m/z 564.2>263.1, a collision energy of 23 eV and a cone voltage of 30 V were applied. The 
method was validated for a range between 1 and 150 µg/mL according to a matrix-matched 
validation protocol described by De Baere et al. (2011), which is compliant with European 
guidelines (European Commission, 2002b) and international guidelines (U.S. Department of 
Health and Human Services, 2015). 
2.4  Statistical analysis 
Each inclusion rate was analysed in triplicate per mycotoxin binder; the results were 
compared to the respective control (no binder) using one-way analysis of variance (ANOVA) 
followed by a post hoc, Bonferroni-corrected, LSD-test. Significance levels (p) below 0.05 
were considered significant. 
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3  Results 
The results are presented in figure 1. For DOX, no significant difference could be 
demonstrated with clay binders up to an inclusion rate of 20 g/kg. The results obtained with 
the yeast derived mycotoxin binder did not differ from the control samples throughout the 
entire inclusion range. For DOX, the experiment could not be executed at pH 8.0 because of a 
high variability in the results, which might be caused by a difference in keto-enol tautomerism 
at higher pH-levels (Weng et al., 1993).  
For TYL, similar results were obtained, namely no significant interaction throughout the 
entire inclusion rates tested for the yeast derived binder and for the clay binders up to an 
inclusion rate of 20 g/kg feed. Except for Clay 3, for which the lowest concentration for 
which no significant interaction could be demonstrated is 10 g/kg. The experiment could not 
be executed for pH 2.5 because TYL is not stable below a pH of 4 (Paesen et al., 1995). 
Although, in vivo trials with fasted broiler chickens already demonstrated interactions for 
TYL and DOX with clay based binders at 2 g/kg and 10 g/kg inclusion rate, respectively 
(Devreese et al., 2012; De Mil et al., 2015a). On the other hand, when performing in vivo 
trials in fed broiler chickens, no interactions between TYL and the clay based binders were 
observed after oral administration of TYL and 2 g/kg clay based binder (De Mil et al., 2016c), 
which corresponds with the in vitro results obtained in this study. Therefore, both prandial 
status of the animals and inclusion rate of the binders used must be taken into account in both 
in vitro and in vivo studies. European legislation discourages the simultaneous use of 
macrolides and bentonite clays (European Commission, 2013a), which also corresponds with 
our findings for TYL. 
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Figure 1: Free doxycycline (DOX) (A) and tylosin (TYL) (B) concentrations for different 
inclusion rates of the respective mycotoxin binder at two different pH’s (presented as 
mean + SD). The samples (n = 3 per inclusion rate per mycotoxin binder) were 
incubated for 4 h in 20 mL of phosphate buffered saline solution containing 10 g of 
finely grinded feed supplemented with mycotoxin binder at different inclusion rates. The 
horizontal lines represent the average free concentration ± 1 SD (full line) or ± 2 SD 
(dotted line) of DOX or TYL in the control samples without mycotoxin binder (n = 12). 
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4  Discussion and conclusions 
This model approximates the in vivo situation better than available static single concentration 
models because of the inclusion of feed. Standardized protocols for in vitro models that 
establish fixed values for variables such as buffer choice, duration of the experiment, total 
volumes used, …, are urgently needed to enable comparison and evaluation between results of 
different experiments. This is already the case for the efficacy testing protocol for the binding 
AFB1 by bentonites (European Commission, 2013a), but not for safety testing with regard to 
non-specific interactions. If the analytical method is adjusted properly, this model can also be 
used for screening the interaction with other medicinal products, vitamins or mycotoxins. 
Further refinements may include the use of (simulated) gastric juices to mimic the in vivo 
situations. The model has now been developed using pH values representative for the GIT of 
poultry and with minor adjustments this model can also be appropriate for monogastrica. In 
conclusion, the model presented here may be well suited to evaluate and screen other 
mycotoxin binders for interactions with oral veterinary drugs if the analytical method is 
adjusted accordingly. 
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Mycotoxins are frequent feed contaminants which can impair animal health and performance. 
Both pre- and post-harvest methods are applied to reduce the deleterious effects caused by 
mycotoxins. One of the most commonly used methods is the use of mycotoxin binders. These 
feed additives claim to bind mycotoxins in the gastro-intestinal tract and consequently remove 
them from the animal along with the faeces and thereby reducing their toxicological effects. 
The binding of mycotoxin binders is deemed to be non-specific, a number of literature studies 
report the binding of veterinary medicinal products to these mycotoxin binders when 
administered orally (mixing in the feed or drinking water). To date, the use of mycotoxin 
binders is prohibited when used concomitantly with macrolide antibiotics in all species. Its 
use is restricted when used in poultry with robenidine, a non-ionophoric coccidiostat. 
Information for other categories of veterinary medicinal products is largely lacking, and the 
models used in the available reports, are not always suitable for their intended purpose.  
 
The aim of this thesis was to investigate the safety of mycotoxin binders regarding the 
possibility of non-specific binding of veterinary medicinal products. Therefore, suitable in 
vitro and in vivo models to screen for interactions between veterinary medicinal products and 
mycotoxin binders were developed and applied.  
Although promising attemts are made (e.g. Physiologically Based Pharmacokinetic 
modelling), the pharmacokinetics of a veterinary drug cannot be accurately predicted without 
in vivo experiments. This is because of the complexity of the target organism and 
pharmacokinetic processes, hence no model can yield completely reliable predictions 
regarding the interactions between mycotoxin binders and veterinary drugs. Final 
confirmation of risk assessment should be carried out in the target species whilst applying 
field conditions. Aberrations from field conditions result in less reliable predictions, but are 
sometimes inevitable. In this case, there are too many possible combinations of veterinary 
drugs and mycotoxin binders to test in animals. The main reasons are ethical, practical and 
financial. Therefore, binder-drug combinations are funnelled through different stages, each 
stage reducing the number of combinations to be tested. A first selection is made by selecting 
the veterinary medicinal products to be tested and collecting representative samples of 
mycotoxin binders of which also a selection is made. Next, combinations are tested in vitro 
and in vivo. Figure 1 shows an overview of the progress, methodologies and main results 
obtained in this doctoral thesis. 
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Figure 1: Overview of the methodologies and main results obtained in this doctoral 
thesis. VMP: veterinary medicinal product; relative F: relative oral bioavailability. 
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Veterinary medicinal product selection 
The most commonly used veterinary medicinal products mixed in pig and poultry feed are 
antimicrobials and coccidiostats (European Medicines Agency, 2014). The products of 
interest are those that are exposed to mycotoxin binders before the site of absorption is 
reached. The risk associated with the binding of an antimicrobial by a mycotoxin binder is a 
decline in oral bioavailability. This decreased systemic exposure can be detrimental for the 
therapeutic efficacy and, in the case of antimicrobials, can lead to altered resistance selection. 
In case the use of mycotoxin binders leads to a higher bioavailability, maximum residue limits 
in animal products may be violated. Otherwise, there is a report of elevated oral 
bioavailability after prolonged exposure to a mycotoxin binder (Osselaere et al., 2012). To 
reduce the risk attributed to the combined use of mycotoxin binders and veterinary medicinal 
products, competent authorities restricted or prohibited the use of certain antimicrobials and 
coccidiostats when mycotoxin binders are applied. In turn, setting (too stringent) regulations 
also has detrimental effects: besides the economic losses suffered by the producers of the 
medicinal products and mycotoxin binders, these regulations can be an important constraint in 
the selection of a medicinal therapy for livestock, resulting in less therapies to choose from. 
Also potential beneficial effects of the mycotoxin binders may be discarded by such 
restrictions. 
Characterization and mycotoxin binder selection 
The parameters to characterise the mycotoxin binders (Chapter 1) were chosen pragmatically 
with respect to the adsorption of veterinary drugs. Together with the X-ray diffraction (XRD) 
results, they provide a relatively thorough identification of the mycotoxin binders that are on 
the market. XRD is a technique capable of measuring the distance between layers of 
molecules in a mineral or crystal. Provided correct calibration and adequate reference 
materials, the type of mineral can be identified using this technique. Also mixtures of 
different minerals can be analysed, however, the precision and comprehensiveness of the 
results are often compromised depending on the complexity of the sample. Overall, XRD is 
an essential technique for understanding mineral mycotoxin binders, however, much 
information cannot be elucidated by this technique and it should be complemented by other 
tests.  
The characterization tests were executed to handle the inaudibility originating from both the 
complexity of the minerals and the compounded nature of commercially available mycotoxin 
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binders. They were used in this thesis to justify the selection of the mycotoxin binders used in 
further studies. For further studies, samples were selected based on the (mineral) content, 
physicochemical properties and their relevance in the agricultural sector. Figure 2 illustrates 
the different categories of mycotoxin binders. The groups were obtained by extracting 
principle components out of all of the variables that described the mycotoxin binder samples, 
and subjecting them to cluster analysis. The two most important principle components are 
plotted on the graph along with the different clusters. Each group is represented in the 
samples used in further studies.  
 
Figure 2: Categories of mycotoxin binders obtained by subjecting the characterisation 
and XRD-data to principle component and cluster analysis. PC1 and 2 are the two most 
important principle components, the numbers of the samples correspond with sample 
numbers used in Chapter 1. 
Montmorillonite is the most encountered substance in commercially available mycotoxin 
binders but also many other minerals are found. Bentonite can be registered as mycotoxin 
binder, it is defined in Regulation 1060/2013 as having a montmorillonite (dioctahedral 
smectite) content of at least 70% (w:w) (European Commission, 2013a). However, many 
types of montmorillonite exist, each exerting different physicochemical and binding 
properties (Uddin, 2008). The main differences between different montmorillonites are the 
crystal composition (mixed layers), substitutions of Al
3+
 or Mg
2+
 ions in the silicate sheets, 
surface tension, type of exchangeable cation and degree of saturation. Furthermore, treatments 
using acid and/or heat may alter the physicochemical properties. So, even if the mycotoxin 
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binder is ‘pure’ and defined as a montmorillonite clay, many variations are possible regarding 
their physicochemical properties and perhaps their binding capabilities. 
Organic substances found in mycotoxin binders were of the humic/fulvic acid type or derived 
yeast products. The latter distinction is made based upon the information provided by the 
manufacturer because the XRD and other characterization (mainly mineral fraction) tests only 
indicate the presence of organic material. The nature of the organic substance is even more 
complex as the variety seen in mineral substances, and in this thesis, no further distinction 
was made regarding their physiochemical characteristics. In the context of adsorption of 
veterinary medicinal products, they were considered as a diverse collection of hydrophobic 
and hydrophilic binding sites. 
The binding properties regarding veterinary drugs of the minerals found in mycotoxin binders 
are not known or only poorly investigated (EFSA FEEDAP Panel, 2013a). Studies regarding 
the binding properties of minerals other than montmorillonite were executed in contexts such 
as purification of waste water (Beall, 2003) or mobility of an antibiotic in soil (Kulshrestha et 
al., 2004). The presence of substances, other than montmorillonite, in bentonite registered as 
mycotoxin binder, is permitted up to a level of 30% (w:w), provided they do not violate 
regulations regarding (limits for) undesired substances in feed or feed additives described in 
Regulation 2002/32 (European Commission, 2002c).  
Zearalenone binding 
Determining the physicochemical properties of the mycotoxin binders is not only important 
for selection of representative samples, they are also important for comparing with other 
binders. Certainly when the binding properties ought to be assessed, the physicochemical 
properties are utmost important. The assumption underlying former statement, is that the 
binding is correlated to a certain physicochemical parameter, which might not be the case 
when a very specific stereochemical interaction is needed for binding. The correlation of 
binding and physicochemical properties was assessed for zearalenone (ZEN), a mycotoxin for 
which both high and low binding to mycotoxin binders is described (Bueno et al., 2005). A 
correlation could be demonstrated with the mineral fraction and the d-spacing, a measure for 
the distances between two adjacent silicate layers in a clay. For the smectite-like mycotoxin 
binders, the correlation was not of the linear form but more like a cut-off. Indicating these 
parameters are more related to a restraining factor rather than to the binding mechanism. 
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Remarkable is the absence of correlation with the cation exchange capacity (CEC), a 
parameter that is often cited when discussing the binding properties of mycotoxin binders. 
The reason why this parameter is cited, is the facilitation role of exchangeable cations in the 
adsorption of aflatoxin B1 (AFB1) to smectite clays (Deng et al., 2010). For the mineral 
fraction, an inverse correlation was noted, indicating a correlation between the organic 
fraction and ZEN adsorption. This might be attributed to the hydrophobic binding sites 
organic substances can offer (Picollo, 1999).  
More extensive characterisation might unveil parameters which correlated in a linear manner 
with the adsorption. Candidate parameters include, but are not limited to: specific surface, 
surface tension, chemical composition of clays, intra-layer substitutions, etc. To elucidate the 
binding mechanism completely, samples and ZEN-saturated samples should be subjected to 
infra-red spectrometry. This information would be very useful when searching for an agent to 
bind a specific target (i.e. mycotoxins), however for purpose of safety testing with regard to 
non-specific binding, detailed information on the exact binding mechanism would be 
redundant.  
This experiment does illustrate the potential of this model to compare binding between 
different mycotoxin binders. Furthermore it is fast, cheap and can be executed using basic 
laboratory materials.  
In vitro binding of veterinary medicinal products 
The purpose of the in vitro part of the thesis was to identify a number of combinations which 
have a high potential for exerting an interaction. Apart from an adequate sensitivity and 
specificity, additional requirements include a high throughput, low cost and simple setup so it 
can be executed using basic lab equipment. Such an in vitro model was previously described 
by Sabater-Vilar (Sabater-Vilar et al., 2007). This model is more sophisticated than the model 
required for efficacy testing for AFB1 adsorption, described in Regulation 1060/2013 
(European Commission, 2013a) because of the addition of salts in the matrix and the use of 
different acidity levels. It was slightly adapted and applied to ZEN (Chapter 1) and to 
doxycycline (Chapter 2). Besides doxycycline, also other veterinary drugs (sulfadiazine, 
trimethoprim and tylosin) and coccidiostats (diclazuril, lasalocid and salinomycin) were tested 
with this setup, only the method of analysis of the drug differed. The results are presented in 
Figure 3. 
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Figure 3: In vitro binding of selected veterinary medicinal products according to the 
protocol described in Chapters 1 and 2. Concentrations that were used are (in µg/mL): 
diclazuril: 2, lasalocid: 50, salinomycin: 150, sulfadiazine: 100, trimethoprim: 50, tylosin 
A: 2200.  
There are many factors that can alter the outcome and can be set arbitrary. An overview of the 
factors that determine the outcome are presented in Figure 4. The factors that depend on the 
setup include total volume in which the reaction takes place, amount of drug and mycotoxin 
binder used, temperature, stir/shake, duration of the experiment, matrix: solvents, other 
components (feed, salts, toxins, …), pH (buffer), etc. Some of them (e.g. temperature, pH, 
ratio drug/binder, …) can be set according to physiological analogies. The use of (simulated) 
gastric fluids might improve similarity with the in vivo situation. Others factors, such as total 
volume, duration of the experiment, etc., are difficult to decide upon and can have significant 
impact. There is an urgent need to standardize these parameters in order to correlate in 
vitro results to one another. Because of the lack of standardization, the binding of the 
different veterinary medicinal products can only be compared between combinations in the 
same experimental setup. Regarding the results obtained in this thesis, doxycycline and 
trimethoprim are adsorbed better than salinomycin, sulfadiazine and tylosin A, which are, in 
general, poorly adsorbed by the tested mycotoxin binders. It is remarkable that activated 
carbon is not a good adsorbent for all veterinary medicinal products. It is also remarkable that 
tylosin A was only poorly adsorbed, whereas previously reported in vivo results with the same 
mycotoxin binder indicate a strong interaction (Devreese et al., 2012). Overall, the results 
indicate that interactions are possible between the tested mycotoxin binders and some 
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veterinary drugs in vitro and that further in vivo studies are needed to investigate the potential 
interactions. 
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Figure 4: Factors determining the outcome of a static, in vitro adsorption screening experiment. Top: adsorption process presented as a 
chemical reaction. Factors in green: controlled for by the experimental setup: total volume, amount of drug and mycotoxin binder used, 
temperature, stir/shake, matrix: solvents, other components (feed, salts, toxins, …), pH (buffer), etc. Factors in red: depend on the 
binder and veterinary medicinal product to be tested, cannot be controlled. VMP: veterinary medicinal product; Bi: mycotoxin binder. 
∆G0: Gibbs free energy of the binding reaction; ∆H0: bond-dissociation energy; ∆S0: entropy of the binding reaction 
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In vivo experiments and refinement of the in vitro model 
The pharmacokinetic (PK) approach for studying the effects of mycotoxin binders on the 
absorption of orally administered veterinary medicinal products is the method of choice, 
mainly because the objectivity of the method, i.e. not based on subjective scoring of clinical 
symptoms to assess the efficacy of pharmacological therapy. It is also the method 
recommended by the European Food Safety Authority, EFSA (EFSA FEEDAP Panel, 2010), 
which states oral bioavailability of the drug should be determined, preferably by monitoring 
the plasma concentration (EFSA FEEDAP Panel, 2010). Several in vivo PK approaches are 
possible to assess the oral bioavailability of veterinary drugs, the bolus model is the most used 
model for this purpose. The factors determining the outcome are presented in Figure 5.  
 
 
 
Figure 5: Factors determining the outcome of an in vivo pharmacokinetic oral bolus 
experiment in which pharmacokinetics can be described by a 1-compartmental model. 
Cp: Plasma concentration at time t, Ka: absorption rate constant, Ke: elimination rate 
constant, Xa: drug available for absorption, X0: dose of drug administered, F: fraction 
available for absorption. Factors in green: controlled for by the experimental setup. 
Factors in red: depend on the binder and veterinary medicinal product and test animal, 
cannot be controlled for. 
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Similarities can be seen with the factors determining the in vitro outcome, nevertheless, also 
differences are noted. They include the kinetic nature of the system, namely dynamic and 
static. In the animals, drugs are usually constantly removed from the system, i.e. a dynamic 
system, whereas in the in vitro model, the total amount of drug remains constant throughout 
the experiment. Another discrepancy is the presence of microbiota in live animals. The effect 
of mycotoxin binders on the microbiota is poorly understood. It is expected that direct effects 
of mycotoxin binders on bacteria will depend on the dose, type of binder and time of 
exposure. Indirect effects may arise by alleviation of negative effects of mycotoxins on 
bacteria. In case the drug is subject to microbial degradation, alterations in gut microbiota 
may have an influence. Finally, mycotoxin binders can have an influence on the morphology 
and physiology of the gut wall (Osselaere et al., 2013c; Pinton and Oswald, 2014; Antonissen 
et al., 2015), possibly resulting in alterations of the rate and extent of absorption of the drug. 
Long term effects on the microbiota and gut wall are most described for yeast derived 
mycotoxin binders (Newman, 1994; de los Santos et al., 2007; Goossens et al., 2012), 
whereas no data is available for mineral binders.  
The in vitro model described in Chapter 5 is a refinement of the model described in Chapter 1 
and 2. It is basically the same setup, but with an important alteration, namely the presence of 
feed in the system. The results should be interpreted with the same prudence as with the first 
model, but they are better aligned with the in vivo results obtained in this thesis and 
previously reported by other authors. To illustrate this, an overview of these studies are 
presented in Table 1. These results indicate that the presence of feed and the inclusion rate are 
decisive for interaction. For tylosin, (clinical) interactions were seen when including a high 
dose in the feed (estimated 5%) (Canadian Bureau of Veterinary Drugs, 1992) or when using 
a low dose (0.1%) in fasted chickens. However, no interactions were seen when using fed 
chickens and using a dose of 0.2% binder. The in vitro model, with inclusion of feed, 
indicated that an interaction can be expected as from an inclusion rate of 1% binder. This 
finding is in accordance with the results of the in vivo experiment in fed chickens using a dose 
of 0.2% binder, since no interaction was noted. It is also in accordance with the reported in 
vivo interaction, which included a low dose (0.1%) but no feed was present. For doxycycline, 
the in vitro tests indicate an interaction as from 2% inclusion rate onwards, which is also in 
accordance with the in vivo experiments. Because mycotoxin binders are included in the feed, 
the latter is always present in the matrix of interactions between mycotoxin binders and oral 
medicinal products. Therefore, it is advised to always include feed in safety testing models 
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and experiments, both in vitro and in vivo. For the combinations tested in this thesis, the risk 
for interaction is low when using doses of 0.2%, which is generally recommended by the 
manufacturer. When using higher doses, interaction cannot be excluded. 
Indications for specific (stereochemical) interactions, i.e. having a high capacity/affinity to 
that extent they can overcome the challenges raised by the presence of feed or other matrix 
components, were not seen in the combinations studied in this thesis.  
Table 6: Overview of the available results obtained from literature and the presented 
doctoral thesis for interactions between veterinary medicinal products and mycotoxin 
binders.  
Medicinal 
product 
Species/ 
in vitro 
Mycotoxin 
binder type 
Presence 
of feed 
Inclusion 
rate or 
equivalent 
Outcome Reference 
Tylosin Cattle ? Yes ? ( >5%) Clinical interaction 
(Canadian Bureau of 
Veterinary Drugs, 
1992) 
Tilmicosin Broiler Clay Yes ≥ 2%  Clinical interaction (Shryock et al., 1994) 
Monensin Chicken Clay Yes 0,5% Clinical interaction  
(if dose drugs < 
recommended) 
(Gray et al., 1998) 
Salinomycin Chicken Clay Yes 0,5% 
Salinomycin Chicken Clay Yes 0,5% Clinical interaction (Nesic et al., 2003) 
Lincomycin Broiler ? ? ? Interaction (Amer, 2005) 
Sulfadiazine Broiler Clay Yes 0.2% 
No interaction 
(De Mil et al, non- 
published results) Trimethoprim Broiler Clay Yes 0.2% 
Doxycycline In vitro Clay No 1% Adsorption 
(De Mil et al., 2015a) 
Doxycycline Broiler Clay No 1% PK interaction 
Tylosin Broiler Clay No 0.1% PK interaction 
(Devreese et al., 
2012) 
Doxycycline Broiler Clay and yeast Yes 0.2% 
No significant PK 
interaction 
(De Mil et al., 2016c) 
Tylosin Broiler Clay and yeast Yes 0.2% caution is advised  
Diclazuril Broiler Clay and yeast Yes 0.2% No interaction 
Diclazuril Broiler Clay and yeast Yes 0.2% No interaction 
Doxycycline Pig Clay and yeast No 0.2% Not significant 
(De Mil et al., 2016b) Doxycycline Pig Clay No 1% PK interaction 
Doxycycline Pig Clay and yeast Yes (SS) 0.2% No interaction 
Tylosin In vitro Clay and yeast Yes 0 – 10% Adsorption as from 
2% 
(De Mil et al., 2016a) 
Doxycyline In vitro Clay and yeast Yes 0 – 10% 
PK: Pharmacokinetic; SS: Steady State 
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Conclusion and future perspectives 
For the veterinary medicinal products and the mycotoxin binders included in this thesis, no 
interactions are expected provided they are used at the recommended level of 0.2% feed. 
Caution is needed to ensure this inclusion rate is respected because the clays, registered as 
mycotoxin binders, can also be added for other purposes. No indications were noted of highly 
specific (stereochemical) interactions. This does not exclude the possibility for these kind of 
interactions for other combinations of oral veterinary drugs and/or mycotoxin binders. 
Although it is advisable to evaluate interaction with veterinary medicinal products on an 
individual basis, extrapolation of the results can probably be done to veterinary medicinal 
products belonging to the same class and having with similar physicochemical properties (e.g. 
doxycycline to other tetracyclines). 
Therefore, screening for potential interactions should be carried out in the context of 
registration of new mycotoxin binders. In case a highly specific interaction is suspected, the 
binding mechanism is essential to assess the risks and benefits of the mycotoxin binder. The 
models used for this screening, in vitro or in vivo, should include feed as an important 
constituent of the matrix in which the screening is executed. Furthermore, they should be 
standardized to enable comparison between independently conducted research. Exploration of 
in silico models such as the physiologically based pharmacokinetic (PBPK) modeling, might 
contribute to this field. 
A topic that was not covered in this thesis but which is highly relevant to the field are the long 
term effects of feeding mycotoxin binders to farm animals, in relation to absorption of 
xenobiotics such as antimicrobials, coccidiostats, but also vitamins (Papaioannou et al., 2002; 
Afriyie-Gyawu et al., 2008), micronutrients or other contaminants. To date they are poorly 
investigated but could be significant. Direct long term effects may include morphological- 
(Gonzalez et al., 2004; Goossens et al., 2012), metabolic- (Newman, 1994), digestibility 
changes and/or effects on the integrity of the barrier function of the GIT (Osselaere et al., 
2013c). Indirect long term impact of mycotoxin binders may result from alterations in 
microbiota (Hu et al., 2004; Xia et al., 2004; Trckova et al., 2009), effects of nutrients in the 
mycotoxin binder (Reichardt et al., 2012), or scavenging low doses of (endo)toxins might also 
be important (Patterson and Staszak, 1977; Gilardi et al., 1999; Szajewska et al., 2006). For 
the latter, the long term effects of these (endo)toxins needs to be elucidated.  
General Discussion 
147 
 
Another valuable contribution to the field would be a cost-efficacy study of the deployment of 
mycotoxin binders compared to other measures to reduce the damage caused by mycotoxins, 
such as Good Agricultural Practices and diverse treatments of feedstuffs. This is a very 
challenging task, especially to include all the potential effects of these additives. Another 
threshold is to understand the total impact of mycotoxins, a scientific area still in 
development. Tools to conduct cost effectiveness assessments, such as the incremental cost 
effectiveness ratio (ICER) (Russell et al., 1996), are available and frequently used in human 
medicine. Barring appropriate adaptations of these frameworks, they should yield valuable 
information to assess these additives compared to other measures to reduce damage caused by 
mycotoxins. 
Finally, the effect of mycotoxin binders on the extractability of mycotoxins or veterinary 
medicinal products should be investigated in the context of analysis of these compounds in 
feed. It is important that these compounds can be quantified accurately, however, this may not 
be the case if mycotoxin binders e.g. alter the efficacy of sample clean-up and preparation.  
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Mycotoxins are secondary metabolites of fungi and contamination of food and animal feed 
with these compounds is a well-known problem in the agricultural sector. Many mycotoxins 
can impair human and animal health when they are ingested. European legislation and 
guidelines aim to prevent that highly contaminated feed enters the market. Therefore, the 
number of cases of clinical intoxication in animals (mycotoxicosis) is low in the European 
Union. Nevertheless, chronic exposure to low concentrations of mycotoxins can cause 
significant economic losses by reducing the zootechnical performance of food producing 
animals. To counteract the effects of low concentrations of mycotoxins, various strategies are 
being used. A frequently used method is the inclusion of special additives in the feed, called 
mycotoxin binders and - modifiers. Mycotoxin binders aim to adsorb mycotoxins to their 
surface in the gastro-intestinal tract and subsequently remove them with the excreta. In case 
veterinary medicinal products are adsorbed instead of mycotoxins, less is available to be 
absorbed by the target animal with a reduced pharmacological action as a consequence, and 
therefore the therapeutic efficacy may be in jeopardy.  
The European Food Safety Authority (EFSA) recommends investigating the safety of 
mycotoxin binders regarding non-specific binding of other compounds such as orally 
administered veterinary drugs. To date, only a limited number of studies have been conducted 
with respect to this safety assessment. The approach and design of these studies are not 
aligned, for example, the inclusion rates of binders range from 0.1% up to 6%. This results in 
a pool of fragmented information from which no general conclusions can be deducted.  
The General Introduction gives an overview of the various aspects of the risks associated 
with mycotoxins in animal feed. Both the toxicological properties and exposure are discussed 
for the main mycotoxins. Furthermore, an overview of the legislation and pre- and post-
harvest measures against the deleterious effects of mycotoxins on animals is presented. The 
second part of the introduction is dedicated to the mycotoxin binders. An overview of the 
molecular structure of the registered binders is presented. Specific attention is drawn to the 
diversity and physicochemical properties of clays. Next, the European legislation of 
mycotoxin binders is discussed. Finally, an overview of the hitherto available in vitro and in 
vivo models for the efficacy and safety assessment of binders is discussed, including their 
advantages and weaknesses in light of this research.  
The General Objective of this thesis is to investigate the influence of mycotoxin binders on 
the pharmacokinetics of orally administered veterinary medicinal products in broiler chickens 
and pigs using appropriate models. These species were selected because veterinary medicinal 
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products, such as antimicrobials and coccidiostats, are mainly administered through feed or 
drinking water in these species. 
In Chapter 1, the physicochemical properties of 27 commercially available mycotoxin 
binders were determined. An in vitro screening model was validated for binding with 
zearalenone (ZEN), a mycotoxin which has – based on the available literature –shown a large 
diversity in terms of binding to mycotoxin binders. The model comprised mixing ZEN and 
mycotoxin binder in a buffer system, representative for the various pH values found in the 
gastro-intestinal tract. After 4 h of incubation, the free concentration of ZEN was determined. 
Finally, the physicochemical properties were correlated to the extent of binding of ZEN. 
There was a significant inverse correlation with the percentage of mineral fraction of the 
mycotoxin binders. A positive correlation between binding and the ‘d-spacing’ of clays, a 
measure of the distance between two successive layers of a clay, was also established. 
Chapter 2 describes the use of the in vitro model, developed in Chapter 1, to evaluate the 
binding of doxycycline (DOX), a widely used antimicrobial agent, to a selection of mycotoxin 
binders. Based on the results, three mycotoxin binders were selected and tested in vivo in 
broiler chickens, using an oral bolus model with fasted broilers and an inclusion rate of binder 
equivalent to the expected daily intake when 10 g/kg is included in the feed. The results 
demonstrated a significant decrease in systemic exposure to DOX for the chickens in the test 
groups compared to the control group, which received no binder. The relative oral 
bioavailability in the test groups amounted 40% or less. This indicates a strong interaction 
between the tested mycotoxin binders and DOX in fasted broiler chickens. 
In Chapter 3, the effects of four different mycotoxin binders were studied on the oral 
absorption of two antimicrobials (DOX and tylosin, TYL) and two coccidiostats (salinomycin, 
SAL, and diclazuril, DIC) in broiler chickens. A similar bolus design was used as in Chapter 
2, however, the animals were non-fasted and were given an oral bolus with a lower dose of 
mycotoxin binder, equivalent to the daily dose for an inclusion rate of 2 g/kg, which is the 
recommended dose according to most manufacturers of binders. Pharmacokinetic analysis 
revealed a trend to lower plasma concentrations of DOX and TYL in the test groups in 
comparison with the control group. However, the observed interactions were not significant 
and not as pronounced as observed in Chapter 2 for DOX. It can be concluded that the feeding 
status and/or inclusion rate of mycotoxin binder are major factors influencing possible 
interactions. 
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In Chapter 4, two experiments in pigs were conducted. In the first experiment, the influence 
of four mycotoxin binders on the oral bioavailability of DOX was determined. For this, the 
bolus model was applied as described in Chapter 2 using fasted animals. In order to verify the 
effect of the inclusion rate of mycotoxin binder, two different dosages were tested, 
corresponding to 2 and 10 g/kg feed. Again, there was a clear effect of the inclusion rate 
noted, with a relative oral bioavailability of DOX of only 20% in the group that received the 
high dose, compared to a relative oral bioavailability of 100% in the group that received the 
low dose. 
In the second experiment, the mycotoxin binder was added to a rate of 2 g/kg feed, and DOX 
was also mixed in the feed at the recommended dose. The conditions in this study were thus 
the same as those in the field situation. However, no difference in oral bioavailability of DOX 
was recorded between the test groups and the control group. These in vivo experiments 
demonstrate that also in pigs, both the inclusion rate and the feeding status are two decisive 
variables for interaction between binders and veterinary drugs. 
The goal of Chapter 5 was to examine as from which inclusion rate onwards there is a 
potential risk of interaction in an in vitro setup. The experimental design showed some 
important differences compared to the setup in Chapter 1. Mycotoxin binders and DOX or 
TYL were incubated in buffer in which also feed was present and wherein the amount of 
mycotoxin binder ranged from 1 g/kg to 100 g/kg feed. 
For most of the mycotoxin binders, both for DOX as for TYL, a no interaction could be 
detected up to an inclusion rate of 20 g/kg. For one bentonite-based binder, an interaction was 
observed with TYL at an inclusion rate of 5 (pH 6.5) or 10 g/kg (pH 8.0) feed. The European 
guideline advises a maximum inclusion rate for bentonite of 20 g/kg. These findings further 
demonstrate that interaction between these antimicrobials and mycotoxin binders is inter alia 
dependent on the inclusion rate. 
In the General Discussion and Conclusions of this doctoral thesis, the used models are 
related to each other and attention is paid to the practical applicability and relevance to the 
field situation. 
For the veterinary medicinal products and mycotoxin binders studied in this thesis, no 
interaction is expected when used at the recommended inclusion rate of 2 g/kg feed in fed 
pigs or broiler chickens. At higher inclusion rates, interactions cannot be excluded. Although 
it is possible that this type of interaction may occur with other combinations of oral veterinary 
medicinal products and mycotoxin binders. Therefore, it is necessary to screen for possible 
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interactions in the registration process of new mycotoxin binders. The models developed in 
this thesis, both in vitro and in vivo, may contribute to this purpose and should include feed as 
an important factor.  
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Mycotoxinen zijn secundaire metabolieten van schimmels en contaminatie van voedsel en 
diervoeder met deze verbindingen is een gekend probleem in de landbouw. Diverse 
mycotoxinen kunnen de gezondheid van mens en dier aantasten wanneer ze worden 
opgenomen. De Europese wetgeving en richtlijnen hebben als doel te voorkomen dat sterk 
gecontamineerde voeders op de markt gebracht worden. Het aantal gevallen van acute 
intoxicatie bij dieren (mycotoxicose) is bijgevolg beperkt in de Europese Unie. 
Desalniettemin kan chronische blootstelling aan lage concentraties van mycotoxinen 
aanzienlijke economische schade veroorzaken door de zoötechnische prestaties van 
voedselproducerende dieren te verminderen. Om de effecten van lage concentraties van 
mycotoxines tegen te gaan worden diverse strategieën toegepast. Een veel gebruikte methode 
is de toevoeging van speciale additieven in voeder, genoemd mycotoxinebinders en - 
modifiers. Mycotoxinebinders hebben als doel mycotoxinen te adsorberen aan hun oppervlak 
in het gastro-intestinaal kanaal om ze vervolgens met de uitwerpselen te verwijderen. Indien 
echter diergeneeskundige geneesmiddelen geadsorbeerd worden in plaats van mycotoxinen, is 
er minder geneesmiddel beschikbaar om te worden geabsorbeerd door het doeldier met een 
daling van de farmacologische werking tot gevolg, waardoor de therapeutische werkzaamheid 
van het geneesmiddel in het gedrang komt. 
Het Europees Agentschap voor Voedselveiligheid (EFSA) adviseert om onderzoek te 
verrichten naar de veiligheid van mycotoxinebinders betreffende de niet-specifieke binding 
van andere componenten, zoals o.a. oraal toegediende diergeneesmiddelen. Tot op heden 
werden slechts een beperkt aantal studies uitgevoerd met betrekking tot dit aspect. De aanpak 
en opzet van de beschikbare studies zijn bovendien niet op elkaar afgestemd, bijvoorbeeld de 
gebruikte inclusieratio van binder varieert van 0,1% tot 6%. Dit resulteert in gefragmenteerde 
informatie waaruit geen algemene conclusies kunnen worden getrokken. 
In de Algemene Inleiding wordt een overzicht gegeven van de verschillende aspecten van de 
risico's verbonden aan contaminatie van diervoeders met mycotoxinen. Zowel de 
toxicologische eigenschappen als de blootstelling worden besproken voor de belangrijkste 
mycotoxinen. Verder wordt een overzicht gegeven van de wetgeving en de mogelijke 
maatregelen, zowel voor als na de oogst, tegen de schadelijke effecten van mycotoxinen. Het 
tweede deel van de inleiding is gewijd aan de mycotoxinebinders zelf. Een overzicht van de 
moleculaire structuur van de geregistreerde mycotoxinebinders wordt gegeven. Specifieke 
aandacht wordt gevestigd op de diversiteit en de fysicochemische eigenschappen van kleien. 
Vervolgens wordt de Europese wetgeving van mycotoxinebinders besproken. Tenslotte wordt 
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een overzicht gegeven van de bestaande in vitro en in vivo modellen om de efficaciteit en 
veiligheid ervan te onderzoeken, en hun voordelen en tekortkomingen worden besproken in 
het licht van dit onderzoek.  
De Algemene Doelstelling van dit proefschrift is om de invloed van mycotoxinebinders op de 
farmacokinetiek van oraal toegediende geneesmiddelen voor diergeneeskundig gebruik te 
onderzoeken bij vleeskippen en varkens aan de hand van geschikte modellen. Deze 
diersoorten werden geselecteerd omdat geneesmiddelen zoals antimicrobiële middelen en 
coccidiostatica, vooral worden toegediend via voeder of drinkwater bij deze diersoorten. 
In Hoofdstuk 1 werden de fysicochemische eigenschappen van 27 commercieel beschikbare 
mycotoxinebinders bepaald. Een in vitro screening model werd gevalideerd voor binding met 
zearalenone (ZEN), een mycotoxine dat - op basis van de beschikbare literatuur - een grote 
diversiteit in binding aan verschillende mycotoxinebinders vertoont. Het model omvat het 
mengen ZEN en de mycotoxinebinders in een buffersysteem, representatief voor de 
verschillende pH-waarden in het gastro-intestinaal kanaal. Na 4 uur incubatie werd de vrije 
concentratie van ZEN bepaald. Tenslotte werden de fysicochemische eigenschappen 
gecorreleerd met de mate van binding van ZEN. Er was een significante omgekeerde 
correlatie met het percentage minerale fractie van mycotoxinebinders. Een positieve correlatie 
tussen mate van binding en de ‘d-spacing’ van kleien, een maat voor de afstand tussen twee 
opeenvolgende lagen van een klei, kon eveneens worden vastgesteld. 
Hoofdstuk 2 beschrijft het gebruik van het in vitro model, ontwikkeld in Hoofdstuk 1, 
teneinde de binding van doxycycline (DOX) te evalueren bij een aantal mycotoxinebinders. 
Op basis van de resultaten werden drie mycotoxinebinders geselecteerd en in vivo getest aan 
de hand van een oraal bolus model bij uitgevaste vleeskippen, met een inclusieratio van 
binder overeenkomstig met 10 g/kg voeder. De resultaten toonden een significante daling in 
systemische blootstelling van DOX bij de kippen in de testgroepen in vergelijking met de 
controlegroep, die geen binder verstrekt kreeg. De relatieve orale biologische beschikbaarheid 
bedroeg 40% of minder. Dit duidt op een sterke interactie tussen de geteste 
mycotoxinebinders en DOX bij nuchtere vleeskippen. 
In Hoofdstuk 3 werden de effecten van vier verschillende mycotoxinebinders bestudeerd op 
de orale opname van twee antimicrobiële middelen (DOX en tylosine, TYL) en twee 
coccidiostatica (salinomycine, SAL, en diclazuril, DIC) bij vleeskippen. Een gelijkaardige 
orale bolus proefopzet werd gebruikt als in Hoofdstuk 2, maar de dieren waren in gevoede 
toestand en kregen een bolus met een lagere inclusieratio aan mycotoxinebinder, 
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overeenkomend met de dagelijkse dosis bij een inclusie van 2 g/kg voeder, hetgeen de 
aanbevolen dosering is volgens de meeste fabrikanten van mycotoxinebinders. 
Farmacokinetische analyse toonde een trend tot lagere plasmaconcentraties van DOX en TYL 
bij de testgroepen in vergelijking met de controlegroep. Echter, de waargenomen interacties 
waren niet significant en niet zo uitgesproken als deze gezien in Hoofdstuk 2 voor DOX. Er 
kan geconcludeerd worden dat de prandiale status en/of dosering van mycotoxinebinders 
bepalende factoren zijn voor mogelijke interacties. 
In Hoofdstuk 4 werden twee experimenten bij varkens uitgevoerd. In het eerste experiment 
werd de invloed van vier mycotoxinebinders op de biologische beschikbaarheid van DOX 
bepaald. Hiervoor werd opnieuw het bolus model toegepast zoals beschreven in Hoofdstuk 2 
bij uitgevaste dieren. Om het effect van de inclusieratio mycotoxinebinder te verifiëren, 
werden twee verschillende doseringen getest, overeenkomend met 2 en 10 g/kg voeder. 
Opnieuw werd er een significante daling in de relatieve orale biologische beschikbaarheid van 
DOX vastgesteld. Deze bedroeg slechts 20% in de groep die de hoge dosis kreeg, vergeleken 
met een relatieve orale biologische beschikbaarheid van 100% in de groep die de lagere dosis 
toegediend kreeg. 
In het tweede experiment werden de mycotoxinebinders toegevoegd aan een inclusieratio van 
2 g/kg voeder, en werd DOX eveneens gemengd in het voeder aan de aanbevolen dosering. 
De omstandigheden in deze studie zijn bijgevolg dezelfde als deze in de veldsituatie. Er kon 
geen verschil in orale biologische beschikbaarheid van DOX waargenomen worden tussen de 
testgroepen en de controlegroep. Deze in vivo experimenten tonen aan dat ook bij varkens 
zowel de inclusieratio als prandiale status twee beslissende variabelen zijn voor het optreden 
van interacties tussen binders en geneesmiddelen. 
Het doel van Hoofdstuk 5 was om te onderzoeken vanaf welke inclusieratio er een potentieel 
risico is tot interactie, dit in een in vitro model. De experimentele opzet vertoonde enkele 
belangrijke verschillen met deze in Hoofdstuk 1. Mycotoxinebinders en DOX of TYL werden 
in een buffer gebracht waarin ook voeder aanwezig was. De hoeveelheid mycotoxinebinder 
varieerde van 1 g/kg tot 100 g/kg voeder. 
Voor de meeste mycotoxinebinders, zowel voor DOX als voor TYL kon geen interactie 
waargenomen tot en met een inclusieratio van 20 g/kg voeder. Voor één bentoniet-gebaseerde 
mycotoxinebinder werd een interactie waargenomen met TYL vanaf een inclusieratio van 10 
(pH 6,5) of 20 g/kg (pH 8,0) voeder. De Europese richtlijn voor het gebruik van bentoniet 
adviseert een maximum inclusieratio van 20 g/kg. Deze bevindingen tonen eveneens aan dat 
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de interactie tussen mycotoxinebinders en antimicrobiële middelen onder meer afhankelijk is 
van de inclusieratio. 
In de Algemene Discussie en Conclusie van dit proefschrift worden de gebruikte in vitro en 
in vivo modellen aan elkaar gerelateerd en wordt aandacht besteed aan de praktische 
toepasbaarheid en de relevantie van de resultaten voor de veldsituatie. 
Voor de antimicrobiële middelen, coccidiostatica en mycotoxinebinders bestudeerd in dit 
proefschrift, worden er geen interacties verwacht bij gebruik aan de aanbevolen inclusieratio 
van 2 g/kg voeder in niet-gevaste varkens en vleeskippen. Bij gebruik van hogere 
inclusieratios kunnen interacties niet worden uitgesloten. Het is evenwel mogelijk dit soort 
interactie kan optreden met andere combinaties van orale geneesmiddelen voor 
diergeneeskundig gebruik en mycotoxinebinders. Daarom is het steeds noodzakelijk om te 
screenen op mogelijke interacties in de registratieprocedure van nieuwe mycotoxinebinders. 
De ontwikkelde modellen in dit proefschrift, zowel in vitro als in vivo, kunnen bijdragen aan 
dit doel en dienen bij voorkeur voeder in te sluiten als een belangrijke factor. 
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